EP2854057B1 - Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung - Google Patents

Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung Download PDF

Info

Publication number
EP2854057B1
EP2854057B1 EP14198470.8A EP14198470A EP2854057B1 EP 2854057 B1 EP2854057 B1 EP 2854057B1 EP 14198470 A EP14198470 A EP 14198470A EP 2854057 B1 EP2854057 B1 EP 2854057B1
Authority
EP
European Patent Office
Prior art keywords
dna
chromosome
allele
sample
ploidy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14198470.8A
Other languages
English (en)
French (fr)
Other versions
EP2854057A3 (de
EP2854057A2 (de
Inventor
Matthew Rabinowitz
George Gemelos
Milena Banjevic
Allison Ryan
Zachary Demko
Matthew Hill
Bernhard Zimmermann
Johan Baner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natera Inc
Original Assignee
Natera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natera Inc filed Critical Natera Inc
Publication of EP2854057A2 publication Critical patent/EP2854057A2/de
Publication of EP2854057A3 publication Critical patent/EP2854057A3/de
Application granted granted Critical
Publication of EP2854057B1 publication Critical patent/EP2854057B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/155—Modifications characterised by incorporating/generating a new priming site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/149—Sequential reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/161—A competitive reaction step
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • the present disclosure relates generally to methods for non-invasive prenatal ploidy calling.
  • NPD Non-Invasive Prenatal Genetic Diagnosis
  • chromosomes normal humans have two sets of 23 chromosomes in every diploid cell, with one copy coming from each parent.
  • Aneuploidy a condition in a nuclear cell where the cell contains too many and/or too few chromosomes is believed to be responsible for a large percentage of failed implantations, miscarriages, and genetic diseases.
  • Detection of chromosomal abnormalities can identify individuals or embryos with conditions such as Down syndrome, Klinefelter's syndrome, and Turner syndrome, among others, in addition to increasing the chances of a successful pregnancy. Testing for chromosomal abnormalities is especially important as the mother's age: between the ages of 35 and 40 it is estimated that at least 40% of the embryos are abnormal, and above the age of 40, more than half of the embryos are abnormal.
  • Low levels of pregnancy-associated plasma protein A (PAPP-A) as measured in maternal serum during the first trimester may be associated with fetal chromosomal anomalies including trisomies 13, 18, and 21.
  • low PAPP-A levels in the first trimester may predict an adverse pregnancy outcome, including a small for gestational age (SGA) baby or stillbirth.
  • Pregnant women often undergo the first trimester serum screen, which commonly involves testing women for blood levels of the hormones PAPP-A and beta human chorionic gonadotropin (beta-hCG). In some cases women are also given an ultrasound to look for possible physiological defects.
  • the nuchal translucency (NT) measurement can indicate risk of aneuploidy in a fetus.
  • the standard of treatment for prenatal screening includes the first trimester serum screen combined with an NT test.
  • triple test also called triple screen, the Kettering test or the Bart's test
  • Kettering test is an investigation performed during pregnancy in the second trimester to classify a patient as either high-risk or low-risk for chromosomal abnormalities (and neural tube defects).
  • multiple-marker screening test is sometimes used instead.
  • triple test can encompass the terms “double test,” “quadruple test,” “quad test” and "penta test.”
  • the triple test measures serum levels of alpha-fetoprotein (AFP), unconjugated estriol (UE 3 ), beta human chorionic gonadotropin (beta-hCG), Invasive Trophoblast Antigen (ITA) and/or inhibin.
  • AFP alpha-fetoprotein
  • UE 3 unconjugated estriol
  • beta-hCG beta human chorionic gonadotropin
  • ITA Invasive Trophoblast Antigen
  • a positive test means having a high risk of chromosomal abnormalities (and neural tube defects), and such patients are then referred for more sensitive and specific procedures to receive a definitive diagnosis, mostly invasive procedures like amniocentesis.
  • the triple test can be used to screen for a number of conditions, including trisomy 21 (Down syndrome).
  • the triple and quadruple tests screen for fetal trisomy 18 also known as Edward's syndrome, open neural tube defects, and may also detect an increased risk of Turner syndrome, triploidy, trisomy 16 mosaicism, fetal death, Smith-Lemli-Opitz syndrome, and steroid sulfatase deficiency.
  • methods for non-invasive prenatal ploidy calling are disclosed herein.
  • methods for determining a ploidy status of a chromosome in a gestating fetus including obtaining a first sample that contains DNA from the mother of the fetus and DNA from the fetus; obtaining genotypic data from one or both parents of the fetus; processing the first sample by purifying the DNA so as to obtain a second sample; measuring the DNA in the second sample at a set of polymorphic alleles; calculating, on a computer, allele ratios at the set of polymorphic alleles from the DNA measurements made on the second sample; creating, on a computer, a plurality of ploidy hypotheses concerning expected allele ratios at the set of polymorphic alleles on the chromosome for different possible ploidy states of the chromosome; building, on a computer, a joint distribution model for
  • processing the first sample further comprises preferentially enriching the DNA at the plurality of polymorphic loci.
  • the preferentially enriching the DNA at a plurality of polymorphic loci comprises obtaining a pre-circularized probe such that the 3' and 5' ends are designed to hybridize to a region of DNA that is separated from the polymorphic region of the allele by a small number of bases, where the small number is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or a combination thereof; hybridizing the pre-circularized probe to purified DNA from the first sample; circularizing the pre-circularized probe; and amplifying some or all of the circularized probe.
  • the preferentially enriching the DNA at a plurality of polymorphic loci comprises obtaining a forward probe such that the 3' end of the forward probe is designed to hybridize to the region of DNA immediately upstream from the polymorphic region, and separated from the polymorphic region by a small number of bases, where the small number is selected from the group consisting of 1, 2, 3, 4, 5, 6 to 10, and 11 to 20; obtaining a reverse probe such that the 3' end of the reverse probe is designed to hybridize to the region of DNA immediately downstream from the polymorphic region, and separated from the polymorphic region by a small number of bases, where the small number is selected from the group consisting of 1, 2, 3, 4, 5, 6 to 10, and 11 to 20; hybridizing the two probes to DNA in the first sample of DNA; and amplifying the DNA using the polymerase chain reaction.
  • the preferentially enriching the DNA at a plurality of polymorphic loci comprises obtaining a set of hybrid capture probes; hybridizing the hybrid capture probes to the DNA in the first sample; and physically separating the hybridized DNA from the first sample of DNA from the unhybridized DNA from the first sample.
  • the set of hybrid capture probes are designed to hybridize to a region that is flanking but not crossing the polymorphic allele.
  • the set of hybrid capture probes are designed to hybridize to a region that is flanking but not crossing the polymorphic allele, and wherein the length of the flanking capture probe may be selected from the group consisting of as low as about 120 bases, as low as about 110 bases, as low as about 100 bases, as low as about 90 bases, as low as about 80 bases, as low as about 70 bases, as low as about 60 bases, as low as about 50 bases, as low as about 40 bases, as low as about 30 bases, and as low as about 25 bases.
  • the preferential enrichment results in average degree of allelic bias between the second sample and the first sample of a factor selected from the group consisting of no more than a factor of 2, no more than a factor of 1.5, no more than a factor of 1.2, no more than a factor of 1.1, no more than a factor of 1.05, no more than a factor of 1.02, no more than a factor of 1.01, no more than a factor of 1.005, no more than a factor of 1.002, no more than a factor of 1.001 and no more than a factor of 1.0001.
  • the set of polymorphic alleles are SNPs.
  • measuring the DNA in the second sample is done by sequencing.
  • the method is executed for a plurality of gestating fetuses, the method further comprising determining the percent of DNA that is fetal in each of the second fractions; and wherein measuring the DNA in the second sample is done by sequencing a number of DNA molecules in each of the second samples, where more molecules of DNA are sequenced from those second samples that have a smaller fraction of fetal DNA than those second samples that have a larger fraction of fetal DNA.
  • the method is executed for a plurality of gestating fetuses, and where the measuring the DNA in the second sample is done, for each of the fetuses, by sequencing a fraction of the second sample of DNA to give a first set of measurements, the method further comprising making a first relative probability determination for each of the ploidy hypotheses for each of the fetuses, given the first set of DNA measurements; re-sequencing a second fraction of the second sample from those fetuses where the first relative probability determination for each of the ploidy hypotheses indicates that a ploidy hypothesis corresponding to an aneuploid fetus has a significant probability, to give a second set of measurements; making a second relative probability determination for ploidy hypotheses for the fetuses using the second set of measurements and optionally also the first set of measurements; and calling the ploidy states of the fetuses whose second sample was re-se
  • building a joint distribution model is done by using data about the probability of chromosomes crossing over at different crossover locations in a chromosome to model dependence between polymorphic alleles on the chromosome.
  • building a joint distribution model and determining the relative probability of each hypothesis are done using a method that does not require the use of a reference chromosome.
  • determining the relative probability of each hypothesis makes use of an estimated fraction of fetal DNA in the measured sample.
  • the DNA measurements from the second sample used in calculating allele ratios and determining the relative probability of each hypothesis comprise primary genetic data.
  • selecting the ploidy state corresponding to the hypothesis with the greatest probability is carried out using maximum likelihood estimates.
  • calling the ploidy state of the fetus further comprises combining the relative probabilities of each of the ploidy hypotheses determined using the joint distribution model and the allele ratios with relative probabilities of each of the ploidy hypotheses that are calculated using statistical techniques taken from a group consisting of a read count analysis, comparing heterozygosity rates, a statistic that is only available when parental genetic information is used, the probability of normalized genotype signals for certain parent contexts, a statistic that is calculated using an estimated fetal fraction of the first or second mixture, and combinations thereof.
  • a confidence estimate is calculated for the called ploidy state.
  • the method further comprises producing a report stating the called ploidy state of the fetus.
  • the method can be performed at between 4 and 5 weeks gestation; between 5 and 6 weeks gestation; between 6 and 7 weeks gestation; between 7 and 8 weeks gestation; between 8 and 9 weeks gestation; between 9 and 10 weeks gestation; between 10 and 12 weeks gestation; between 12 and 14 weeks gestation; between 14 and 20 weeks gestation; between 20 and 40 weeks gestation; in the first trimester; in the second trimester; or in the third trimester.
  • a composition comprising a sample of preferentially enriched DNA, wherein the sample of preferentially enriched DNA has been preferentially enriched at a plurality of polymorphic loci from a first sample of DNA, wherein the degree of enrichment is selected from the group consisting of at least 10, at least 100, at least 1,000, at least 10,000, at least 100,000, or at least 1,000,000, and wherein the allelic bias between the first sample and the preferentially enriched sample is, on average, selected from the group consisting of less than 1000%, less than 500%, less than 200%, less than 100%, less than 50%, less than 20%, less than 10%, less than 5%, less than 2%, less than 1%, less than 0.5%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.02%, and less than 0.01%.
  • a method is to create such a sample of preferentially enriched DNA.
  • methods for determining a fetal aneuploidy by determining the number of copies of maternal and fetal target chromosomes, having target sequences in a mixture of maternal and fetal genetic material, comprising the steps of (a) obtaining maternal tissue comprising both maternal and fetal genetic material; (b) obtaining a mixture of maternal and fetal genetic material from said maternal tissue; (c) distributing the genetic material obtained in step b) into a plurality of reaction samples, to randomly provide individual reaction samples that contain a target sequence from a target chromosome and individual reaction samples that do not contain a target sequence from a target chromosome; (d) analyzing the target sequences of genetic material present or absent in said individual reaction samples to provide a first number of binary results representing presence or absence of a presumably euploid fetal chromosome in the reaction samples and a second number of binary results representing presence or absence of a possibly aneuploid fetal chromosome in the reaction samples; (
  • the present disclosure provides ex vivo methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a mixed sample of DNA (i.e., DNA from the mother of the fetus, and DNA from the fetus) and from genotypic data measured from a sample of genetic material from the mother and optionally also from the father, wherein the determining is done by using a joint distribution model to create a set of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern.
  • a mixed sample of DNA i.e., DNA from the mother of the fetus, and DNA from the fetus
  • genotypic data measured from a sample of genetic material from the mother and optionally also from the father
  • the determining
  • the mixed sample is derived from maternal blood.
  • the mixed sample of DNA is preferentially enriched at a plurality of polymorphic loci.
  • the preferential enrichment is done in a way that minimizes the allelic bias.
  • the present disclosure provides methods for non-invasive prenatal diagnosis (NPD), specifically, determining the aneuploidy status of a fetus by observing allele distributions at a set of polymorphic alleles in genotypic data measured on DNA mixtures, where certain allele distributions are indicative of an aneuploid fetus, while other allele distributions are indicative of a euploid fetus.
  • the genotypic data is measured by sequencing DNA mixtures that were derived from maternal plasma.
  • the DNA sample is preferentially enriched in molecules of DNA that correspond to the set of alleles whose allele distributions are being calculated.
  • the method involves determining whether the distribution of observed allele measurements is indicative of a euploid or an aneuploid fetus using a joint distribution model.
  • a joint distribution model is a significant improvement over methods that determine heterozygosity rates by treating polymorpic loci independently in that the resultant determinations are of significantly higher accuracy. Without being bound by any particular theory, it is believed that one reason they are of higher accuracy is that the joint distribution model takes into account the linkage between SNPs, and likelihood of crossovers occurring. Another reason it is believed that they are of higher accuracy is that they can take into account alleles where the total number of reads is low, and the allele ratio method would produce disproportionately weighted stochastic noise.
  • the method involves determining whether the distribution of observed allele measurements is indicative of a euploid or an aneuploid fetus using a maximum likelihood technique.
  • a maximum likelihood technique is a significant improvement over methods that use single hypothesis rejection technique in that the resultant determinations will be made with significantly higher accuracy.
  • single hypothesis rejection techniques set cut off thresholds based on only one measurement distribution rather than two, meaning that the thresholds are usually not optimal.
  • the maximum likelihood technique allows the optimization of the cut off threshold for each individual sample instead of determining a cut off threshold to be used for all samples regardless of the particular characteristics of each individual sample.
  • Another reason is that the use of a maximum likelihood technique allows the calculation of a confidence for each ploidy call.
  • the method involves determining whether the distribution of observed allele measurements is indicative of a euploid or an aneuploid fetus without comparing the distribution of observed allele measurements on a suspect chromosome to a distribution of observed allele measurements on a reference chromosome that is expected to be disomic. This is a significant improvement over methods that require the use of a reference chromosome to determine whether a suspect chromosome is euploid or aneuploid.
  • the method disclosed herein demonstrates how observing allele distributions at polymorphic alleles can be used to determine the ploidy state of a fetus with greater accuracy than methods in the prior art.
  • the method involves using algorithms that analyze the distribution of alleles found for alleles that have different parental contexts, and comparing the observed allele distributions to the expected allele distributions for different ploidy states for the different parental contexts (different parental genotypic patterns). This is an improvement over methods that do not utilize allele distribution patterns for alleles from a plurality of different parental contexts because it allows the use of significantly more genetic measurement data from a set of sequence data in the ploidy determination, resulting in a more accurate determination.
  • the method involves determining whether the distribution of observed allele measurements is indicative of a euploid or an aneuploid fetus using observed allelic distributions measured at loci where the mother is heterozygous. This is an improvement over methods that do not use observed allelic distributions are loci where the mother is heterozygous because it allows the use of about twice as much genetic measurement data from a set of sequence data in the ploidy determination, resulting in a more accurate determination.
  • the method disclosed herein uses selective enrichment techniques that preserve the allele distributions that are present in the original sample of DNA.
  • the amplification and/or selective enrichment technique may involve targeted amplification, hybrid capture, or circularizing probes.
  • methods for amplification or selective enrichment may involve using probes where the hybridizing region on the probe is separated from the variable region of the polymorphic allele by a small number of nucleotides. This separation results in lower amounts of allelic bias. This separation results in lower amounts of allelic bias. This is an improvement over methods that involve using probes where the hybridizing region on the probe is designed to hybridize at the base pair directly adjacent to the variable region of the polymorphic allele.
  • the methods described herein are particularly advantageous when used on samples where a small amount of DNA is available, or where the percent of fetal DNA is low. This is due to the correspondingly higher allele drop out rate that occurs when only a small amount of DNA is available, or the correspondingly higher fetal allele drop out rate when the percent of fetal DNA is low.
  • a high allele drop out rate meaning that a large percentage of the alleles were not measured for the target individual, results in poorly accurate fetal fractions calculations, and poorly accurate ploidy determinations. Since the method disclosed herein uses a joint distribution model that takes into account the linkage in inheritance patterns between SNPs, significantly more accurate ploidy determinations may be made.
  • the ploidy state of an individual based on measurements when that individual's DNA is mixed with DNA of a related individual.
  • the DNA from the mother with known karyotype and known genotype, is mixed with DNA of the fetus, with unknown karyotype and unknown genotype.
  • the known genotypic information from one or both parents to predict a plurality of potential compositions of the DNA in the mixed sample for different ploidy states, different chromosome contributions from each parent to the fetus, and optionally, different fetal DNA fractions in the mixture.
  • Each potential composition may be referred to as a hypothesis.
  • the ploidy state of the fetus can then be determined by looking at the actual measurements, and determining which potential compositions are most likely given the observed data.
  • NPD Non-Invasive Prenatal Diagnosis
  • the process of non-invasive prenatal diagnosis involves a number of steps. Some of the steps may include: (1) obtaining the genetic material from the fetus; (2) enriching the genetic material of the fetus, ex vivo; (3) amplifying the genetic material, ex vivo; (4) preferentially enriching specific loci in the genetic material, ex vivo; (5) genotyping the genetic material, ex vivo; and (6) analyzing the genotypic data, on a computer, and ex vivo. Methods to reduce to practice these six and other relevant steps are described herein. At least some of the method steps are not directly applied on the body. In an embodiment, the present disclosure relates to methods of treatment and diagnosis applied to tissue and other biological materials isolated and separated from the body. At least some of the method steps are executed on a computer.
  • Some embodiments of the present disclosure allow a clinician to determine the genetic state of a fetus that is gestating in a mother in a non-invasive manner such that the health of the baby is not put at risk by the collection of the genetic material of the fetus, and that the mother is not required to undergo an invasive procedure.
  • the present disclosure allows the fetal genetic state to be determined with high accuracy, significantly greater accuracy than, for example, the non-invasive maternal serum analyte based screens, such as the triple test, that are in wide use in prenatal care.
  • the accuracy of the methods disclosed herein is a result of an informatics approach to analysis of the genotype data, as described herein.
  • Modern technological advances have resulted in the ability to measure large amounts of genetic information from a genetic sample using such methods as high throughput sequencing and genotyping arrays.
  • the methods disclosed herein allow a clinician to take greater advantage of the large amounts of data available, and make a more accurate diagnosis of the fetal genetic state.
  • the details of a number of embodiments are given below. Different embodiments may involve different combinations of the aforementioned steps. Various combinations of the different embodiments of the different steps may be used interchangeably.
  • a blood sample is taken from a pregnant mother, and the free floating DNA in the plasma of the mother's blood, which contains a mixture of both DNA of maternal origin, and DNA of fetal origin, is used to determine the ploidy status of the fetus.
  • a key step of the method involves preferential enrichment of those DNA sequences in a mixture of DNA that correspond to polymorphic alleles in a way that the allele ratios and/or allele distributions remain mostly consistent upon enrichment.
  • the method involves sequencing a mixture of DNA that contains both DNA of maternal origin, and DNA of fetal origin.
  • a key step of the method involves using measured allele distributions to determine the ploidy state of a fetus that is gestating in a mother.
  • the methods described herein may be used to help determine the genotype of a child, fetus, or other target individual where the genetic material of the target is found in the presence of a quantity of other genetic material.
  • the discussion focuses on determining the genetic state of a fetus where the fetal DNA is found in maternal blood, but this example is not meant to limit to possible contexts that this method may be applied to.
  • the method may be applicable in cases where the amount of target DNA is in any proportion with the non-target DNA; for example, the target DNA could make up anywhere between 0.000001 and 99.999999% of the DNA present.
  • the non-target DNA does not necessarily need to be from one individual, or even from a related individual, as long as genetic data from non-target individual(s) is known.
  • the method can be used to determine genotypic data of a fetus from maternal blood that contains fetal DNA. In one embodiment, the method can be used in a case where there are multiple fetuses in the uterus of a pregnant woman, or where other contaminating DNA may be present in the sample, for example from other already born siblings.
  • the technique makes use of the phenomenon of fetal blood cells gaining access to maternal circulation through the placental villi. Ordinarily, only a very small number of fetal cells enter the maternal circulation in this fashion (not enough to produce a positive Kleihauer-Betke test for fetal-maternal hemorrhage). The fetal cells can be sorted out and analyzed by a variety of techniques to look for particular DNA sequences, but without the risks that these latter two invasive procedures inherently have.
  • the technique makes use of the phenomenon of free floating fetal DNA gaining access to maternal circulation by DNA release following apoptosis of placental tissue where the placental tissue in question contains DNA of the same genotype as the fetus. The free floating DNA found in maternal plasma has been shown to contain fetal DNA in proportions as high as 30-40% fetal DNA.
  • blood may be drawn from a pregnant woman.
  • maternal blood may contain a small amount of free floating DNA from the fetus, in addition to free floating DNA of maternal origin.
  • fetal blood cells comprising DNA of fetal origin, in addition to many blood cells of maternal origin, which typically do not contain nuclear DNA.
  • chromatography has been show to create certain fractions that are enriched in fetal DNA.
  • genotype the DNA found in said sample can be used to determine genotypic data of the fetus. For example, it can be used to determine the ploidy state at one or more chromosomes, it can be used to determine the identity of one or a set of SNPs, including insertions, deletions, and translocations. It can be used to determine one or more haplotypes, including the parent of origin of one or more genotypic features.
  • this method will work with any nucleic acids that can be used for any genotyping and/or sequencing methods, such as the ILLUMINA INFINIUM ARRAY platform, AFFYMETRIX GENECHIP, ILLUMINA GENOME ANALYZER, or LIFE TECHNOLGIES' SOLID SYSTEM.
  • This includes extracted free-floating DNA from plasma or amplifications (e.g. whole genome amplification, PCR) of the same; genomic DNA from other cell types (e.g. human lymphocytes from whole blood) or amplifications of the same.
  • genomic DNA from other cell types (e.g. human lymphocytes from whole blood) or amplifications of the same.
  • any extraction or purification method that generates genomic DNA suitable for the one of these platforms will work as well.
  • storage of the samples may be done in a way that will minimize degradation (e.g. at -20 C or lower).
  • PARENTAL SUPPORTTM is an informatics based approach that can be used to analyze genetic data.
  • the methods disclosed herein may be considered as part of the PARENTAL SUPPORTTM method.
  • the PARENTAL SUPPORTTM method is a collection of methods that may be used to determine the genetic data, with high accuracy, of one or a small number of cells, specifically to determine disease-related alleles, other alleles of interest, and/or the ploidy state of the cell(s). PARENTAL SUPPORTTM may refer to any of these methods. PARENTAL SUPPORTTM is an example of an informatics based method.
  • the PARENTAL SUPPORTTM method makes use of known parental genetic data, i.e. haplotypic and/or diploid genetic data of the mother and/or the father, together with the knowledge of the mechanism of meiosis and the imperfect measurement of the target DNA, and possible of one or more related individuals, in order to reconstruct, in silico, the genotype at a plurality of alleles, and/or the ploidy state of an embryo or of any target cell(s), and the target DNA at the location of key loci with a high degree of confidence.
  • the PARENTAL SUPPORTTM method can reconstruct not only single nucleotide polymorphisms (SNPs) that were measured poorly, but also insertions and deletions, and SNPs or whole regions of DNA that were not measured at all. Furthermore, the PARENTAL SUPPORTTM method can both measure multiple disease-linked loci as well as screen for aneuploidy, from a single cell. In some embodiments, the PARENTAL SUPPORTTM method may be used to characterize one or more cells from embryos biopsied during an IVF cycle to determine the genetic condition of the one or more cells.
  • the PARENTAL SUPPORTTM method allows the cleaning of noisy genetic data. This may be done by inferring the correct genetic alleles in the target genome (embryo) using the genotype of related individuals (parents) as a reference. PARENTAL SUPPORTTM may be particularly relevant where only a small quantity of genetic material is available (e.g. PGD) and where direct measurements of the genotypes are inherently noisy due to the limited amounts of genetic material.
  • the PARENTAL SUPPORTTM method is able to reconstruct highly accurate ordered diploid allele sequences on the embryo, together with copy number of chromosomes segments, even though the conventional, unordered diploid measurements may be characterized by high rates of allele dropouts, drop-ins, variable amplification biases and other errors.
  • the method may employ both an underlying genetic model and an underlying model of measurement error.
  • the genetic model may determine both allele probabilities at each SNP and crossover probabilities between SNPs. Allele probabilities may be modeled at each SNP based on data obtained from the parents and model crossover probabilities between SNPs based on data obtained from the HapMap database, as developed by the International HapMap Project. Given the proper underlying genetic model and measurement error model, maximum a posteriori (MAP) estimation may be used, with modifications for computationally efficiency, to estimate the correct, ordered allele values at each SNP in the embryo.
  • MAP maximum a posteriori
  • One aspect of the PARENTAL SUPPORTTM technology is a chromosome copy number calling algorithm that in some embodiments uses parental genotype contexts.
  • the algorithm may use the phenomenon of locus dropout (LDO) combined with distributions of expected embryonic genotypes. During whole genome amplification, LDO necessarily occurs. LDO rate is concordant with the copy number of the genetic material from which it is derived, i.e., fewer chromosome copies result in higher LDO, and vice versa. As such, it follows that loci with certain contexts of parental genotypes behave in a characteristic fashion in the embryo, related to the probability of allelic contributions to the embryo.
  • LDO locus dropout
  • the embryo should never have AB or AA states. In this case, measurements on the A detection channel are expected to have a distribution determined by background noise and various interference signals, but no valid genotypes. Conversely, if both parents have homozygous AA states, then the embryo should never have AB or BB states, and measurements on the A channel are expected to have the maximum intensity possible given the rate of LDO in a particular whole genome amplification.
  • loci corresponding to the specific parental contexts behave in a predictable fashion, based on the additional allelic content that is contributed by, or is missing from, one of the parents. This allows the ploidy state at each chromosome, or chromosome segment, to be determined. The details of one embodiment of this method are described elsewhere in this disclosure.
  • the techniques outlined above are able to determine the genotype of an individual given a very small amount of DNA originating from that individual. This could be the DNA from one or a small number of cells, or it could be from an even smaller amount of DNA, for example, DNA found in maternal blood.
  • the techniques described above may not be sufficient to determine the genotype and/or the ploidy state, or the partial genotype or partial ploidy state (meaning the genetic state of a subset of alleles or chromosomes) of an individual. This may be especially true when the DNA of the target individual is found in maternal blood, and the amount of maternal DNA present in the sample may be greater than the amount of DNA from the target individual. In other cases, the amount of maternal DNA present in the sample may be in a sufficiently great amount of DNA that it makes the determination of the genetic state of the target individual difficult.
  • Single Nucleotide Polymorphism refers to a single nucleotide that may differ between the genomes of two members of the same species. The usage of the term should not imply any limit on the frequency with which each variant occurs.
  • SNP refers to the act of making a decision about the true state of a particular base pair, taking into account the direct and indirect evidence.
  • Sequence refers to a DNA sequence or a genetic sequence. It refers to the primary, physical structure of the DNA molecule or strand in an individual. It refers to the sequence of nucleotides found in that DNA molecule, or the complementary strand to the DNA molecule.
  • Locus refers to a particular region of interest on the DNA of an individual, which may refer to a SNP, the site of a possible insertion or deletion, or the site of some other relevant genetic variation.
  • Disease-linked SNPs may also refer to disease-linked loci.
  • Polymorphic Allele also "Polymorphic Locus,” refers to an allele or locus where the genotype varies between individuals within a given species. Some examples of polymorphic alleles include single nucleotide polymorphisms, short tandem repeats, deletions, duplications, and inversions.
  • Allele refers to the genes that occupy a particular locus.
  • To Call an Allele refers to the act of determining the genetic state at a particular locus of DNA. This may involve calling a SNP, a plurality of SNPs, or determining whether or not an insertion or deletion is present at that locus, or determining the number of insertions that may be present at that locus, or determining whether some other genetic variant is present at that locus.
  • Correct Allele Call refers to an allele call that correctly reflects the true state of the actual genetic material of an individual.
  • To Clean Genetic Data refers to the act of taking imperfect genetic data and correcting some or all of the errors or fill in missing data at one or more loci. In the presently disclosed embodiments, this may involve using the genetic data of related individuals and the method described herein.
  • Genotypic Data refers to the data describing aspects of the genome of one or more individuals.
  • genotypic data refers to one or a set of loci, partial or entire sequences, partial or entire chromosomes, or the entire genome.
  • genotypic data refers to the identity of one or a plurality of nucleotides; it may refer to a set of sequential nucleotides, or nucleotides from different locations in the genome, or a combination thereof.
  • Genotypic data is typically in silico, however, it is also possible to consider physical nucleotides in a sequence as chemically encoded genetic data. Genotypic Data may be said to be “on,” “of,” “at,” “from” or “on” the individual(s). Genotypic Data may refer to output measurements from a genotyping platform where those measurements are made on genetic material.
  • Genetic Sample refers to physical matter, such as tissue or blood, from one or more individuals comprising DNA or RNA
  • Imperfect Genetic Data refers to genetic data with any of the following: allele dropouts, uncertain base pair measurements, incorrect base pair measurements, missing base pair measurements, uncertain measurements of insertions or deletions, uncertain measurements of chromosome segment copy numbers, spurious signals, missing measurements, other errors, or combinations thereof.
  • noisy Genetic Data also "Incomplete Genetic Data” refers to imperfect genetic data.
  • Uncleaned Genetic Data also “Crude Genetic Data,” refers to genetic data as measured, that is, where no method has been used to correct for the presence of noise or errors in the raw genetic data.
  • Confidence refers to the statistical likelihood that the called SNP, allele, set of alleles, ploidy call, or determined number of chromosome segment copies correctly represents the real genetic state of the individual.
  • CNC Chromosome Copy Number Calling
  • CNC Copy Number Calling
  • Aneuploidy refers to the state where the wrong number of chromosomes are present in a cell.
  • a somatic human cell it refers to the case where a cell does not contain 22 pairs of autosomal chromosomes and one pair of sex chromosomes.
  • a human gamete it refers to the case where a cell does not contain one of each of the 23 chromosomes.
  • a single chromosome it refers to the case where more or less than two homologous but non-identical chromosomes are present, and where each of the two chromosomes originate from a different parent.
  • Ploidy State refers to the quantity and chromosomal identity of one or more chromosomes in a cell.
  • Chromosomal Identity refers to the referent chromosome number. Normal humans have 22 types of numbered autosomal chromosomes, and two types of sex chromosomes. In an embodiment, chromosomal identity refers to the parental origin of the chromosome. In an embodiment, chromosomal identity refers to a specific chromosome inherited from the parent. In an embodiment, chromosomal identity refers to other identifying features of a chromosome.
  • the State of the Genetic Material or simply "Genetic State” refers to the identity of a set of SNPs on the DNA, to the phased haplotypes of the genetic material, and to the sequence of the DNA, including insertions, deletions, repeats and mutations.
  • the genetic state refers the ploidy state of one or more chromosomes, chromosomal segments, or set of chromosomal segments.
  • Allelic Data refers to a set of genotypic data concerning a set of one or more alleles.
  • allelic data refers to the phased, haplotypic data.
  • allelic data refers to SNP identities.
  • allelic data refers to the sequence data of the DNA, including insertions, deletions, repeats and mutations.
  • allelic data includes the parental origin of each allele.
  • allelic State refers to the actual state of the genes in a set of one or more alleles. In an embodiment, allelic state refers to the actual state of the genes described by the allelic data.
  • Allelic Distribution refers to the distribution of the set of alleles observed at a set of loci.
  • An allelic distribution for one locus is an allele ratio.
  • Allelic Distribution Pattern refers to a set of different allele distributions for different parental contexts. Certain allelic disribution patterns may be indicative of certain ploidy states.
  • Allelic Bias refers to the degree to which the measured ratio of alleles at a heterozygous locus is different to the ratio that was present in the original sample of DNA.
  • the degree of allelic bias at a particular locus is equal to the observed allelelic ratio at that locus, as measured, divided by the ratio of alleles in the original DNA sample at that locus.
  • Allelic bias may be defined to be greater than one, such that if the calculation of the degree of allelic bias returns a value, x, that is less than 1, then the degree of allelic bias may be restated as 1/x.
  • Matched Copy Error also "Matching Chromosome Aneuploidy" (MCA) refers to a state of aneuploidy where one cell contains two identical or nearly identical chromosomes. This type of aneuploidy may arise during the formation of the gametes in mitosis, and may be referred to as a mitotic non-disjunction error.
  • Matching trisomy may refer to the case where three copies of a given chromosome are present in an individual and two of the copies are identical.
  • Unmatched Copy Error also "Unique Chromosome Aneuploidy" (UCA) refers to a state of aneuploidy where one cell contains two chromosomes that are from the same parent, and that may be homologous but not identical. This type of aneuploidy may arise during meiosis, and may be referred to as a meiotic error. Unmatching trisomy may refer to the case where three copies of a given chromosome are present in an individual and two of
  • Homologous Chromosomes refers to chromosomes that contain the same set of genes that normally pair up during meiosis.
  • Identical Chromosomes refers to chromosomes that contain the same set of genes, and for each gene they have the same set of alleles that are identical, or nearly identical.
  • Allele Drop Out refers to the situation where one of the base pairs in a set of base pairs from homologous chromosomes at a given allele is not detected.
  • Locus Drop Out refers to the situation where both base pairs in a set of base pairs from homologous chromosomes at a given allele are not detected.
  • Homozygous refers to having similar alleles as corresponding chromosomal loci.
  • Heterozygous refers to having dissimilar alleles as corresponding chromosomal loci.
  • Heterozygosity Rate refers to the rate of individuals in the population having heterozygous alleles at a given locus.
  • heterozygosity rate refers to the expected or measured ratio of alleles, at a given locus in an individual, or a sample of DNA.
  • HISNP Highly Informative Single Nucleotide Polymorphism
  • Chromosomal Region refers to a segment of a chromosome, or a full chromosome.
  • Segment of a Chromosome refers to a section of a chromosome that can range in size from one base pair to the entire chromosome.
  • Chromosome refers to either a full chromosome, or also a segment or section of a chromosome.
  • Copies refers to the number of copies of a chromosome segment, to identical copies, or to non-identical, homologous copies of a chromosome segment wherein the different copies of the chromosome segment contain a substantially similar set of loci, and where one or more of the alleles are different. Note that in some cases of aneuploidy, such as the M2 copy error, it is possible to have some copies of the given chromosome segment that are identical as well as some copies of the same chromosome segment that are not identical.
  • Haplotype refers to a combination of alleles at multiple loci that are transmitted together on the same chromosome. Haplotype may refer to as few as two loci or to an entire chromosome depending on the number of recombination events that have occurred between a given set of loci. Haplotype can also refer to a set of single nucleotide polymorphisms (SNPs) on a single chromatid that are statistically associated.
  • SNPs single nucleotide polymorphisms
  • Haplotypic Data also "Phased Data” or “Ordered Genetic Data,” refers to data from a single chromosome in a diploid or polyploid genome, i.e., either the segregated maternal or paternal copy of a chromosome in a diploid genome.
  • Phasing refers to the act of determining the haplotypic genetic data of an individual given unordered, diploid (or polyploidy) genetic data. It may refer to the act of determining which of two genes at an allele, for a set of alleles found on one chromosome, are associated with each of the two homologous chromosomes in an individual.
  • Phased Data refers to genetic data where the haplotype has been determined.
  • Unordered Genetic Data refers to pooled data derived from measurements on two or more chromosomes in a diploid or polyploid genome, e.g., both the maternal and paternal copies of a particular chromosome in a diploid genome.
  • Hypothesis refers to a set of possible ploidy states at a given set of chromosomes, or a set of possible allelic states at a given set of loci.
  • the set of possibilities may contain one or more elements.
  • Copy Number Hypothesis also "Ploidy State Hypothesis,” refers to a hypothesis concerning the number of copies of a particular chromosome in an individual.
  • ploidy state hypothesis refers to a hypothesis concerning the identity of each of the chromosomes, including the parent of origin of each chromosome, and which of the parent's two chromosomes are present in the individual.
  • ploidy state hypothesis refers to a hypothesis concerning which chromosomes, or chromosome segments, if any, from a related individual correspond genetically to a given chromosome from an individual.
  • Allelic Hypothesis refers to a possible allelic state for a given set of alleles.
  • a set of allelic hypotheses may refer to a set of hypotheses that describe, together, all of the possible allelic states in the set of alleles.
  • allelic hypothesis refers to a hypothesis concerning which chromosomes, or chromosome segments, if any, from a related individual correspond genetically to a given chromosome from an individual.
  • Target Individual refers to the individual whose genetic data is being determined. In one context, only a limited amount of DNA is available from the target individual. In one context, the target individual is a fetus. In some embodiments, there may be more than one target individual. In some embodiments, each fetus that originated from a pair of parents may be considered to be target individuals.
  • the related individual refers to any individual who is genetically related to, and thus shares haplotype blocks with, the target individual.
  • the related individual may be a genetic parent of the target individual, or any genetic material derived from a parent, such as a sperm, a polar body, an embryo, a fetus, or a child. It may also refer to a sibling, parent or a grandparent.
  • Sibling refers to any individual whose parents are the same as the individual in question. In some embodiments, it may refer to a born child, an embryo, or a fetus, or one or more cells originating from a born child, an embryo, or a fetus. A sibling may also refer to a haploid individual that originates from one of the parents, such as a sperm, a polar body, or any other set of haplotypic genetic matter. An individual may be considered to be a sibling of itself.
  • Fetal refers to "of the fetus,” but it also may refer to "of the placenta".
  • some portion of the placenta is genetically similar to the fetus, and the free floating fetal DNA found in maternal blood may have originated from the portion of the placenta with a genotype that matches the fetus.
  • the genetic information in half of the chromosomes in a fetus were inherited from the mother of the fetus.
  • the DNA from these maternally inherited chromosomes that came from a fetal cell are considered to be "of fetal origin,” not "of maternal origin.”
  • DNA of Fetal Origin refers to DNA that was originally part of a cell whose genotype was essentially equivalent to that of the fetus.
  • DNA of Maternal Origin refers to DNA that was originally part of a cell whose genotype was essentially equivalent to that of the mother.
  • Child is used interchangeably with the terms embryo, blastomere, and fetus. Note that in the presently disclosed embodiments, the concepts described apply equally well to individuals who are a born child, a fetus, an embryo or a set of cells therefrom. The use of the term child may simply be meant to connote that the individual referred to as the child is the genetic offspring of the parents.
  • Parent refers to the genetic mother or father of an individual. An individual typically has two parents, a mother and a father. A parent may be considered to be an individual.
  • Parental Context refers to the genetic state of a given SNP, on each of the two relevant chromosomes for each of the two parents of the target.
  • develop Normally refers to a viable embryo implanting in a uterus and resulting in a pregnancy. In an embodiment, develop normally refers to the pregnancy continuing and resulting in a live birth. In an embodiment, develop normally refers to the born child being free of chromosomal abnormalities. In an embodiment, develop normally refers to the born child being free of other undesired genetic conditions such as disease-linked genes.
  • the term “develop as desired” encompasses anything that may be desired by parents or healthcare facilitators. In some cases, “develop as desired” may refer to an unviable or viable embryo that is useful for medical research or other purposes.
  • Insertion Into a Uterus refers to the process of transferring an embryo into the uterine cavity in the context of in vitro fertilization.
  • Clinical Decision refers to any decision to take or not take an action that has an outcome that affects the health or survival of an individual.
  • a clinical decision may refer to a decision to conduct further testing, to take actions to mitigate an undesireable phenotype, or to take actions to prepare for the birth of a child with abnormalities.
  • Platform Response refers to the mathematical characterization of the input/output characteristics of a genetic measurement platform, and may be used as a measure of the statistically predictable measurement differences.
  • the platform response may concern the mathematical characterization of expected possible error rates in a set of data measured from a genotyping platform.
  • Informatics Based Method refers to a method designed to determine the ploidy state at one or more chromosomes or the allelic state at one or more alleles by statistically inferring the most likely state, rather than by directly physically measuring the state.
  • the informatics based technique may be one disclosed in this patent. In one embodiment of the present disclosure it may be PARENTAL SUPPORTTM.
  • Primary Genetic Data refers to the analog intensity signals that are output by a genotyping platform. In the context of SNP arrays, primary genetic data refers to the intensity signals before any genotype calling has been done. In the context of sequencing, primary genetic data refers to the analog measurements, analogous to the chromatogram, that comes off the sequencer before the identity of any base pairs have been determined, and before the sequence has been mapped to the genome.
  • Secondary Genetic Data refers to processed genetic data that are output by a genotyping platform.
  • the secondary genetic data refers to the allele calls made by software associated with the SNP array reader, wherein the software has made a call whether a given allele is present or not present in the sample.
  • the secondary genetic data refers to the base pair identities of the sequences have been determined, and possibly also the sequences have been mapped to the genome.
  • Non-Invasive Prenatal Diagnosis or also “Non-Invasive Prenatal Screening” (NPS) refers to a method of determining the genetic state of a fetus that is gestating in a mother using genetic material found in the mother's blood, where the genetic material is obtained by drawing the mother's intravenous blood.
  • Preferential Enrichment of DNA that corresponds to a locus refers to any method that results in the percentage of molecules of DNA in a post-enrichment DNA mixture that correspond to the locus being higher than the percentage of molecules of DNA in the pre-enrichment DNA mixture that correspond to the locus.
  • the method involves selective amplification of DNA molecules that correspond to a locus.
  • the method involves removing DNA molecules that do not correspond to the locus.
  • the method involves a combination of methods.
  • the degree of enrichment is defined as the percentage of molecules of DNA in the post-enrichment mixture that correspond to the locus divided by the percentage of molecules of DNA in the pre-enrichment mixture that correspond to the locus.
  • Preferential enrichment may be carried out at a plurality of loci. In some embodiments of the present disclosure, the degree of enrichment is greater than 20. In some embodiments of the present disclosure, the degree of enrichment is greater than 200. When preferential enrichment is carried out at a plurality of loci, the degree of enrichment may refer to the average degree of enrichment of all of the loci.
  • Amplification refers to a method that increases the number of copies of a molecule of DNA.
  • Selective Amplification refers to a method that increases the number of copies of a particular molecule of DNA, or molecules of DNA that correspond to a particular region of DNA.
  • selective amplification refers to a method that increases the number of copies of a particular targeted molecule of DNA, or targeted region of DNA more than it increases non-targeted molecules or regions of DNA.
  • Selective amplification may be a method of preferential enrichment.
  • Targeting refers to a method used to preferentially enrich those molecules of DNA that correspond to a set of loci, in a mixture of DNA.
  • Joint Distribution Model refers to a model that defines the probability of events defined in terms of multiple random variables, given a plurality of random variables defined on the same probability space, where the probabilities of the variable are linked.
  • any of the embodiments disclosed herein may be implemented in digital electronic circuitry, integrated circuitry, specially designed ASICs (application-specific integrated circuits), computer hardware, firmware, software, or in combinations thereof.
  • Apparatus of the presently disclosed embodiments can be implemented in a computer program product tangibly embodied in a machine-readable storage device for execution by a programmable processor; and method steps of the presently disclosed embodiments can be performed by a programmable processor executing a program of instructions to perform functions of the presently disclosed embodiments by operating on input data and generating output.
  • the presently disclosed embodiments can be implemented advantageously in one or more computer programs that are executable and/or interpretable on a programmable system including at least one programmable processor, which may be special or general purpose, coupled to receive data and instructions from, and to transmit data and instructions to, a storage system, at least one input device, and at least one output device.
  • Each computer program can be implemented in a high-level procedural or object-oriented programming language, or in assembly or machine language if desired; and in any case, the language can be a compiled or interpreted language.
  • a computer program may be deployed in any form, including as a stand-alone program, or as a module, component, subroutine, or other unit suitable for use in a computing environment.
  • a computer program may be deployed to be executed or interpreted on one computer or on multiple computers at one site, or distributed across multiple sites and interconnected by a communication network.
  • Computer readable storage media refers to physical or tangible storage (as opposed to signals) and includes without limitation volatile and non-volatile, removable and non-removable media implemented in any method or technology for the tangible storage of information such as computer-readable instructions, data structures, program modules or other data.
  • Computer readable storage media includes, but is not limited to, RAM, ROM, EPROM, EEPROM, flash memory or other solid state memory technology, CD-ROM, DVD, or other optical storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other physical or material medium which can be used to tangibly store the desired information or data or instructions and which can be accessed by a computer or processor.
  • any of the methods described herein may include the output of data in a physical format, such as on a computer screen, or on a paper printout.
  • the described methods may be combined with the output of the actionable data in a format that can be acted upon by a physician.
  • the described methods may be combined with the actual execution of a clinical decision that results in a clinical treatment, or the execution of a clinical decision to make no action.
  • Some of the embodiments described in the document for determining genetic data pertaining to a target individual may be combined with the decision to select one or more embryos for transfer in the context of IVF, optionally combined with the process of transferring the embryo to the womb of the prospective mother.
  • Some of the embodiments described in the document for determining genetic data pertaining to a target individual may be combined with the notification of a potential chromosomal abnormality, or lack thereof, with a medical professional. Some of the embodiments described herein may be combined with the output of the actionable data, and the execution of a clinical decision that results in a clinical treatment, or the execution of a clinical decision to make no action.
  • a hypothesis refers to a possible genetic state.
  • a hypothesis refers to a possible ploidy state.
  • a hypothesis refers to a possible allelic state.
  • a set of hypotheses refers to a set of possible genetic states.
  • a set of hypotheses may be designed such that one hypothesis from the set will correspond to the actual genetic state of any given individual.
  • a set of hypotheses may be designed such that every possible genetic state may be described by at least one hypothesis from the set.
  • one aspect of the method is to determine which hypothesis corresponds to the actual genetic state of the individual in question.
  • one step involves creating a hypothesis.
  • the hypothesis is a copy number hypothesis.
  • the hypothesis involves a hypothesis concerning which segments of a chromosome from each of the related individuals correspond genetically to which segments, if any, of the other related individuals.
  • Creating a hypothesis may refer to the act of setting the limits of the variables such that the entire set of possible genetic states that are under consideration are encompassed by those variables.
  • a "copy number hypothesis,” also called a “ploidy hypothesis,” or a “ploidy state hypothesis,” refers to a hypothesis concerning a possible ploidy state for a given chromosome, or section of a chromosome, in the target individual.
  • a copy number hypothesis refers to the ploidy state at more than one of the chromosomes in the individual.
  • a set of copy number hypotheses refers to a set of hypotheses where each hypothesis corresponds to a different possible ploidy state in an individual.
  • a set of hypotheses concern to a set of possible ploidy states, a set of possible parental haplotype contributions, a set of possible fetal DNA percentages in the mixed sample, or combinations thereof.
  • a normal individual contains one of each chromosome from each parent. However, due to errors in meiosis and mitosis, it is possible for an individual to have 0, 1, 2, or more of a given chromosome from each parent. In practice, it is rare to see more that two of a given chromosomes from a parent. In this disclosure, the embodiments only consider the possible hypotheses where 0, 1, or 2 copies of a given chromosome come from a parent. In some embodiments, for a given chromosome, there are nine possible hypotheses: the three possible hypothesis concerning 0, 1, or 2 chromosomes of maternal origin, multiplied by the three possible hypotheses concerning 0, 1, or 2 chromosomes of paternal origin.
  • (m,f) refer to the hypothesis where m is the number of a given chromosome inherited from the mother, and f is the number of a given chromosome inherited from the father. Therefore, the nine hypotheses are (0,0), (0,1), (0,2), (1,0), (1,1), (1,2), (2,0), (2,1), and (2,2). These may also be written as H 00 , H 01 , H 02 , H 10 , H 12 , H 20 , H 21 , and H 22 . The different hypotheses correspond to different ploidy states.
  • (1,1) refers to a normal disomic chromosome
  • (2,1) refers to a maternal trisomy
  • (0,1) refers to a paternal monosomy.
  • the case where two chromosomes are inherited from one parent and one chromosome is inherited from the other parent may be further differentiated into two cases: one where the two chromosomes are identical (matched copy error), and one where the two chromosomes are homologous but not identical (unmatched copy error).
  • there are sixteen possible hypotheses there are sixteen possible hypotheses. It should be understood that it is possible to use other sets of hypotheses, and a different number of hypotheses.
  • the ploidy hypothesis may refer to a hypothesis concerning which chromosome from other related individuals correspond to a chromosome found in the target individual's genome.
  • a key to the method is the fact that related individuals can be expected to share haplotype blocks, and using measured genetic data from related individuals, along with a knowledge of which haplotype blocks match between the target individual and the related individual, it is possible to infer the correct genetic data for a target individual with higher confidence than using the target individual's genetic measurements alone.
  • the ploidy hypothesis may concern not only the number of chromosomes, but also which chromosomes in related individuals are identical, or nearly identical, with one or more chromosomes in the target individual.
  • an allelic hypothesis refers to a hypothesis concerning a possible allelic state of a set of alleles.
  • a key to this method is, as described above, related individuals may share haplotype blocks, which may help the reconstruction of genetic data that was not perfectly measured.
  • an allelic hypothesis refers to a hypothesis concerning which chromosomes, or chromosome segments, if any, from a related individual correspond genetically to a given chromosome from an individual. The theory of meiosis tells us that each chromosome in an individual is inherited from one of the two parents, and this is a nearly identical copy of a parental chromosome.
  • the haplotypes of the parents are known, that is, the phased genotype of the parents, then the genotype of the child may be inferred as well.
  • the term child, here, is meant to include any individual formed from two gametes, one from the mother and one from the father.
  • the allelic hypothesis describes a possible allelic state, at a set of alleles, including the haplotypes, as well as which chromosomes from related individuals may match the chromosome(s) which contain the set of alleles.
  • the algorithms when the algorithms operate on the input genetic data, they may output a determined statistical probability for each of the hypotheses under consideration.
  • the probabilities of the various hypotheses may be determined by mathematically calculating, for each of the various hypotheses, the value that the probability equals, as stated by one or more of the expert techniques, algorithms, and/or methods described elsewhere in this disclosure, using the relevant genetic data as input.
  • the probabilities of the different hypotheses may be combined. This may entail, for each hypothesis, multiplying the probabilities as determined by each technique. The product of the probabilities of the hypotheses may be normalized. Note that one ploidy hypothesis refers to one possible ploidy state for a chromosome.
  • a hypothesis may be determined to be the most likely, and the ploidy state, or other genetic state, may be called if the normalized probability is greater than a threshold. In one embodiment, this may mean that the number and identity of the chromosomes that are associated with that hypothesis may be called as the ploidy state. In one embodiment, this may mean that the identity of the alleles that are associated with that hypothesis may be called as the allelic state. In some embodiments, the threshold may be between about 50% and about 80%.
  • the threshold may be between about 80% and about 90%. In some embodiments the threshold may be between about 90% and about 95%. In some embodiments the threshold may be between about 95% and about 99%. In some embodiments the threshold may be between about 99% and about 99.9%. In some embodiments the threshold may be above about 99.9%.
  • the parental context may refer to the genetic state of a given SNP, on each of the two relevant chromosomes for each of the two parents of the target. Note that in one embodiment, the parental context does not refer to the allelic state of the target, rather, it refers to the allelic state of the parents.
  • the parental context for a given SNP may consist of four base pairs, two paternal and two maternal; they may be the same or different from one another. It is typically written as "m 1 m 2
  • the parental context may be written as "f 1 f 2
  • a and B are often used to generically represent base pair identities; A or B could equally well represent C (cytosine), G (guanine), A (adenine) or T (thymine).
  • C cytosine
  • G guanine
  • A adenine
  • T thymine
  • any of the four possible nucleotides could occur at a given allele, and thus it is possible, for example, for the mother to have a genotype of AT, and the father to have a genotype of GC at a given allele.
  • empirical data indicate that in most cases only two of the four possible base pairs are observed at a given allele.
  • the discussion assumes that only two possible base pairs will be observed at a given allele, although the embodiments disclosed herein could be modified to take into account the cases where this assumption does not hold.
  • a "parental context” may refer to a set or subset of target SNPs that have the same parental context. For example, if one were to measure 1000 alleles on a given chromosome on a target individual, then the context AA
  • AB BA
  • the set of SNPs wherein the parental context for one parent is heterozygous may be referred to as the heterozygous context.
  • Non-invasive prenatal diagnosis is an important technique that can be used to determine the genetic state of a fetus from genetic material that is obtained in a non-invasive manner, for example from a blood draw on the pregnant mother.
  • the blood could be separated and the plasma isolated, and size selection could also be used to isolate the DNA of the appropriate length.
  • This isolated DNA can then be measured by a number of means, such as by hybridizing to a genotyping array and measuring the fluorescence, or by sequencing on a high throughput sequencer.
  • sequence data When sequencing is used for ploidy calling of a fetus in the context of non-invasive prenatal diagnosis, there are a number of ways to use the sequence data. The most common way one could use the sequence data is to simply count the number of reads that map to a given chromosome. For example, imagine if you are trying to figure out the ploidy state of chromosome 21 on the fetus. Further imagine that the DNA in the sample is comprised of 10% DNA of fetal origin, and 90% DNA of maternal origin.
  • chromosome which can be expected to be disomic, for example chromosome 3, and compare that to the number of read on chromosome 21, where the reads are adjusted for the number of base pairs on that chromosome that are part of a unique sequence. If the fetus were euploid, one would expect the amount of DNA per unit of genome to be about equal at all locations (subject to stochastic variations). On the other hand, if the fetus were trisomic at chromosome 21, then one would expect there to be more slightly more DNA per genetic unit from chromosome 21 than the other locations on the genome.
  • AA are the most informative contexts, because the fetus is known to carry an allele that is different from the mother.
  • AA contexts may be referred to as AA
  • Another set of informative parental contexts are AA
  • AB contexts may be referred to as AA
  • a third set of informative parental contexts are AB
  • AA both AB
  • a fourth parental context is AB
  • the fifth parental context is AA
  • the method may involve amplifying DNA.
  • One method of amplifying DNA is polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • WGA whole genome amplification
  • LM-PCR ligation-mediated PCR
  • DOP-PCR degenerate oligonucleotide primer PCR
  • MDA multiple displacement amplification
  • LM-PCR short DNA sequences called adapters are ligated to blunt ends of DNA.
  • DOP-PCR degenerate oligonucleotide primer PCR
  • MDA multiple displacement amplification
  • LM-PCR short DNA sequences called adapters are ligated to blunt ends of DNA. These adapters contain universal amplification sequences, which are used to amplify the DNA by PCR.
  • DOP-PCR random primers that also contain universal amplification sequences are used in a first round of annealing and PCR.
  • MDA uses the phi-29 polymerase, which is a highly processive and non-specific enzyme that replicates DNA and has been used for single-cell analysis.
  • the major limitations to amplification of material from a single cell are (1) necessity of using extremely dilute DNA concentrations or extremely small volume of reaction mixture, and (2) difficulty of reliably dissociating DNA from proteins across the whole genome. Regardless, single-cell whole genome amplification has been used successfully for a variety of applications for a number of years. There are other method of amplifying DNA from a sample of DNA.
  • Amplification of single-cell DNA (or DNA from a small number of cells, or from smaller amounts of DNA) by PCR can fail completely, as reported in 5-10% of the cases. This is often due to contamination of the DNA, the loss of the cell, its DNA, or accessibility of the DNA during the PCR reaction.
  • Other sources of error that may arise in measuring the fetal DNA by amplification and microarray analysis include transcription errors introduced by the DNA polymerase where a particular nucleotide is incorrectly copied during PCR, and microarray reading errors due to imperfect hybridization on the array.
  • ADO allele drop-out
  • PCR Polymerase Chain Reaction
  • WGA whole genome amplification
  • MDA multiple displacement amplification
  • MIPS Molecular Inversion Probes
  • DNA may be targeted, or selectively enriched, include using circularizing probes, linked inverted probes (LIPs), capture by hybridization methods such as SURE SELECT, and targeted PCR amplification strategies.
  • LIPs linked inverted probes
  • LIPs Linked Inverted Probes
  • LIPs are a generic term meant to encompass technologies that involve the creation of a circular molecule of DNA, where the probes are designed to hybridize to targeted region of DNA on either side of a targeted allele, such that addition of appropriate polymerases and/or ligases, and the appropriate conditions, buffers and other reagents, will complete the complementary, inverted region of DNA across the targeted allele to create a circular loop of DNA that captures the information found in the targeted allele.
  • LIPs may also be called pre-circularized probes, pre-circularizing probes, or the circularizing probes.
  • the LIPs probe may be a linear DNA molecule between 50 and 500 nucleotides in length, and in a preferred embodiment between 70 and 100 nucleotides in length; in some embodiments, the LIPs probe is longer or shorter than described herein.
  • Others embodiments of the present disclosure involve different incarnations, of the LIPs technology, such as Padlock Probes and Molecular Inversion Probes (MIPs).
  • the method involves measuring genetic data for use with an informatics based method, such as PARENTAL SUPPORTTM (PS).
  • PARENTAL SUPPORTTM is an informatics based approach to manipulating genetic data, aspects of which are described herein.
  • the ultimate outcome of some of the embodiments is the actionable genetic data of an embryo or a fetus.
  • the algorithms behind the PS method take the measured genetic data of the target individual, often an embryo or fetus, and the measured genetic data from related individuals, and are able to increase the accuracy with which the genetic state of the target individual is known.
  • the measured genetic data is used in the context of making ploidy determinations during prenatal genetic diagnosis.
  • the measured genetic data is used in the context of making ploidy determinations or allele calls on embryos during in vitro fertilization.
  • the different methods comprise a number of steps, those steps often involving amplification of genetic material, addition of olgionucleotide probes, ligation of specified DNA strands, isolation of sets of desired DNA, removal of unwanted components of a reaction, detection of certain sequences of DNA by hybridization, detection of the sequence of one or a plurality of strands of DNA by DNA sequencing methods.
  • DNA strands may refer to target genetic material, in some cases they may refer to primers, in some cases they may refer to synthesized sequences, or combinations thereof. These steps may be carried out in a number of different orders. Given the highly variable nature of molecular biology, it is generally not obvious which methods, and which combinations of steps, will perform poorly, well, or best in various situations.
  • the percentage of the alleles that are read by the sequencer will be enriched with respect to their natural abundance in the sample.
  • the degree of enrichment can be anywhere from one percent (or even less) to tens fold, hundred fold, thousand fold or even many million fold.
  • the human genome there are roughly 3 billion base pairs, and nucleotides, comprising approximately 75 million polymorphic loci. The more loci that are targeted, the smaller the degree of enrichment is possible. The fewer the number of loci that are targeted, the greater degree of enrichment is possible, and the greater depth of read may be achieved at those loci for a given number of sequence reads.
  • the targeting may focus entirely on SNPs.
  • a number of commercial targeting products are available to enrich exons.
  • targeting exclusively SNPs is particularly advantageous when using a method for NPD that relies on allele distributions.
  • published methods for NPD using sequencing for example U.S. Patent 7,888,017 , a type of read count analysis where the read counting focuses on counting the number of reads that map to a given chromosome, where the analyzed sequence reads do not focused on regions of the genome that are polymorphic.
  • a small number of SNPs for example between 1 and 100 SNPs, or a larger number, for example, between 100 and 1,000, between 1,000 and 10,000, between 10,000 and 100,000 or more than 100,000 SNPs.
  • a targeting method to create a sample of DNA that is preferentially enriched in polymorphic regions of the genome.
  • a mixture of DNA that contains maternal DNA and fetal DNA, and that is preferentially enriched in 200 SNPs, all of which are located on either chromosome 18 or 21, and which are enriched an average of 1000 fold.
  • the method may further comprise measuring the DNA contained in the mixed fraction using a DNA sequencer, and the DNA contained in the mixed fraction contains a disproportionate number of sequences from one or more chromosomes, wherein the one or more chromosomes are taken from the group comprising chromosome 13, chromosome 18, chromosome 21, chromosome X, chromosome Y and combinations thereof.
  • the method can be used to determine genotypes (base composition of the DNA at specific loci) and relative proportions of those genotypes from a mixture of DNA molecules, where those DNA molecules may have originated from one or a number of genetically distinct individuals.
  • the method can be used to determine the genotypes at a set of polymorphic loci, and the relative ratios of the amount of different alleles present at those loci.
  • the polymorphic loci may consist entirely of SNPs.
  • the polymorphic loci can comprise SNPs, single tandem repeats, and other polymorphic regions.
  • the method can be used to determine the relative rations of different alleles at a set of polymorphic loci in a mixture of DNA, where the mixture of DNA is comprised of DNA that originates from a mother, and DNA that originates from a fetus.
  • the relative ratios of different alleles can be determined on a mixture of DNA isolated from blood from a pregnant woman.
  • the relative ratios of alleles at a set of loci can be used to determine the ploidy state of one or more chromosomes on a fetus that is gestating in the mother.
  • the mixture of DNA molecules could be derived from DNA extracted from multiple cells of one individual.
  • the original collection of cells from which the DNA is derived may contain a mixture of diploid or haploid cells of the same or of different genotypes, if that individual is mosaic (germline or somatic).
  • the mixture of DNA molecules could also be derived from DNA extracted from single cells.
  • the mixture of DNA molecules could also be derived form DNA extracted from mixture of two or more cells of the same individual, or of different individuals.
  • the mixture of DNA molecules could be derived from DNA isolated from biological material that has already liberated from cells such as blood plasma, which is known to contain cell free DNA.
  • the this biological material may be a mixture of DNA from one or more individuals, as is the case during pregnancy where it has been shown that fetal DNA is present in the mixture.
  • the originating source of DNA is cells.
  • the mixture may contain zero or more copies of a given chromosome.
  • Normal healthy human cells typically contain two copies of each chromosome that were inherited from the two unrelated parents. These copies typically vary at many different locations (loci).
  • the variations may be single nucleotide differences (SNPs), two or more nucleotide differences, insertions or deletions of one or more nucleotides, one or more exact copies of segments of DNA, which are often positioned adjacent to one another but can be located anywhere.
  • Common ancestral relationships may also result in segments within the normal two copies of the DNA being identical or near identical.
  • Germline or somatic mosacism may result in the cells derived form one individual being different in one or more chromosomal locations.
  • the method can be used to determine the relative ratios of two or more different haplotypes that contain the same set of loci in a sample of DNA.
  • the different haplotypes could represent two different homologous chromosomes from one individual, three different homologous chromosomes from a trisomic individual, three different homologous haplotypes from a mother and a fetus where one of the haplotypes is shared between the mother and the fetus, three or four haplotypes from a mother and fetus where one or two of the haplotypes are shared between the mother and the fetus, or other combinations.
  • haplotypes are known, or the diploid genotypes of one or more of the individuals are known, then a set of alleles that are polymorphic between the haplotypes can be chosen, and average allele ratios can be determined based on the set of alleles that uniquely originate from each of the haplotypes.
  • Direct sequencing of such a sample is extremely inefficient as it results in many sequences for regions that are not polymorphic between the different haplotypes in the sample and therefore reveal no information about the proportion of the two haplotypes.
  • Described herein is a method that specifically targets and enriches segments of DNA in the sample that are more likely to be polymorphic in the genome to increase the yield of allelic information obtained by sequencing. Note that for the allele ratios measured in an enriched sample to be truly representative of the actual haplotype ratios it is critical that there is little or no preferential enrichment of one allele as compared to the other allele at a given loci in the targeted segments.
  • On embodiment of the method described herein allows a plurality of alleles found in a mixture of DNA that correspond to a given locus in the genome to be amplified, or preferentially enriched in a way that the degree of enrichment of each of the alleles is nearly the same. Another way to say this is that the method allows the relative quantity of the alleles present in the mixture as a whole to be increased, while the ratio between the alleles that correspond to each locus remains essentially the same as they were in the original mixture of DNA.
  • the ratio of the alleles in the orginal mixture divided by the ratio of the alleles in the resulting mixture is between 0.5 and 1.5, between 0.8 and 1.2, between 0.9 and 1.1, between 0.95 and 1.05, between 0.98 and 1.02, between 0.99 and 1.01, between 0.995 and 1.005, between 0.998 and 1.002, between 0.999 and 1.001, or between 0.9999 and 1.0001.
  • a mixture may be sequenced using any one of the previous, current, or next generation of sequencing instruments that sequences a clonal sample (a sample generated from a single molecule; examples include ILLUMINA GAllx, ILLUMINA HISEQ, LIFE TECHNOLOGIES SOLiD, 5500XL).
  • the ratios can be evaluated by sequencing through the specific alleles within the targeted region. These sequencing reads can be analyzed and counted according the allele type and the rations of different alleles determined accordingly.
  • detection of the alleles will be performed by sequencing and it is essential that the sequencing read span the allele in question in order to evaluate the allelic composition of that captured molecule.
  • the total number of captured molecules assayed for the genotype can be increased by increasing the length of the sequencing read. Full sequencing of all molecules would guarantee collection of the maximum amount of data available in the enriched pool.
  • sequencing is currently expensive, and a method that can measure a certain number of allele ratios using a lower number of sequence reads will have great value.
  • there are technical limitations to the maximum possible length of read as well as accuracy limitations as read lengths increase.
  • allelic rations The alleles of greatest utility will be of one to a few bases in length, but theoretically any allele shorter than the length of the sequencing read can be used. While allele variations come in all types, the examples provided herein focus on SNPs or variants comprised of just a few neighboring base pairs. Larger variants such as segmental copy number variants can be detected by aggregations of these smaller variations in many cases as whole collections of SNP internal to the segment are duplicated. Variants larger than a few bases, such as STRs require special consideration and some targeting approaches work while others will not. The evaluation of the allelic rations is herein determined
  • the method involves using targeting probes that focus exclusively or almost exclusively on polymorphic regions. In one embodiment of the present disclosure, the method involves using targeting probes that focus exclusively or almost exclusively on SNPs.
  • the targeted polymorphic regions consist of at least 10% SNPs, at least 20% SNPs, at least 30% SNPs, at least 40% SNPs, at least 50% SNPs, at least 60% SNPs, at least 70% SNPs, at least 80% SNPs, at least 90% SNPs, at least 95% SNPs, at least 98% SNPs, at least 99% SNPs, at least 99.9% SNPs, exclusively SNPs.
  • One method of measuring genetic data involves the use of circularizing probes.
  • Two papers that discuss a method involving circularizing probes that can be used to measure the genomic data of the target individual include: Porreca et al., Nature Methods, 2007 4(11), pp. 931-936 .; and also Turner et al., Nature Methods, 2009, 6(5), pp. 315-316 .
  • the methods described in these papers may be used in combination with other methods described herein.
  • Certain steps of the method from these two papers may be used in combination with other steps from other methods described herein.
  • the genetic material of the target individual is amplified, and then the desired allelic genetic information is captured by circularizing appropriately designed oligonucleic probes, such as in the LIPs system. This may be followed by the genetic sequence of the circularized probes being measured to give the desired sequence data.
  • the appropriately designed oligonucleotides probes may be circularized directly on unamplified genetic material of the target individual, and amplified afterwards. Note that a number of amplification procedures may be used to amplify the original genetic material, or the circularized LIPs, including rolling circle amplification, MDA, or other amplification protocols. Different methods may be used to measure the genetic information on the target genome, for example using high throughput sequencing, Sanger sequencing, other sequencing methods, capture-by-hybridization, capture-by-circularization, multiplex PCR, other hybridization methods, and combinations thereof.
  • an informatics based method such as the PARENTAL SUPPORTTM method, along with the appropriate genetic measurements, can then be used to determination the ploidy state of one or more chromosomes on the individual, and/or the genetic state of one or a set of alleles, specifically those alleles that are correlated with a disease or genetic state of interest.
  • an informatics based method such as the PARENTAL SUPPORTTM method
  • LIPs has been reported for multiplexed capture of genetic sequences, followed by genotyping with sequencing.
  • a pregnant mother would like to determine if her fetus is afflicted with any gross chromosomal abnormalities. She goes to her doctor, and gives a sample of her blood, and she and her husband gives samples of their own DNA from cheek swabs.
  • a laboratory researcher genotypes the parental DNA using the MDA protocol to amplify the parental DNA, and ILLUMINA INFINIUM arrays to measure the genetic data of the parents at a large number of SNPs. The researcher then spins down the blood, takes the plasma, and isolates a sample of free-floating DNA using size exclusion chromatography.
  • the researcher uses one or more fluorescent antibodies, such as one that is specific to fetal hemoglobin to isolate a nucleated fetal red blood cell.
  • the researcher then takes the isolated or enriched fetal genetic material and amplifies it using a library of 70-mer oligonucleotides appropriately designed such that two ends of each oligonucleotide corresponded to the flanking sequences on either side of a target allele.
  • the oligonucleotides underwent gap-filling circularization, capturing the desired allele.
  • LIPs may be used as a method for targeting specific loci in a sample of DNA for genotyping by methods other than sequencing.
  • LIPs may be used to target DNA for genotyping using SNP arrays or other DNA or RNA based microarrays.
  • inverted probes may be used to genotype a wide variety of loci, for example, not just SNPs, but also large repeats such as triple repeats and tandem repeats, or large deletions. There are a number of diseases that are characterized by such repeats and/or deletions. Methods of amplification and genotyping that have been described in the literature have a number of problems that preclude their use in a large scale multiplexed fashion.
  • the LIPs technologies of which MIPs and PADLOCK PROBES are a subset, share a common feature in that they involve a synthesized DNA fragment in which the ends are specifically constructed to form complementary base-pairing to a target DNA under suitable reaction conditions, herein called the “probe,” or the “pre-circularized probe,” or the “pre-circularizing probe,” or the “circularizing probe.” Furthermore the ends of said probe are designed in a manner such that the 5-prime (5') and 3-prime (3') ends of the probe are oriented towards one another annealing of the probe, herein generally called “inverted-linked probes," to the target DNA, herein called “the template.” Consequently, addition of dNTPs, polymerase, ligase, and suitable buffers, results in polymerization from the 3' end of the probe, herein referred to as "the extension,” filling in the gap between the 3' and 5' ends of the probe with nucleotides complementary to the template DNA.
  • ligase catalyzes the formation of a covalent phosphodiester bond between the now adjacent 3' and 5' ends of the probe creating a complete circular molecule of DNA.
  • a practical upper limit may be determined by the reaction conditions, the processivity of the polymerase, and the ability to amplify the fragment by subsequent PCR based methods.
  • the region of interest between the original 3' and 5' ends of the fragment may be amplified by various techniques after the circle, now intertwined with the template, has been released from the target DNA Release may be achieved by breakage of the template molecule or by breakage of the now circular probe. This may be done along the backbone of the probe as not to disturb the newly polymerized target sequence. Amplification of the target region, herein referred to as "probe amplification,” may then be accomplished by various PCR techniques or by rolling circle amplification (if the probe remains a circle).
  • this technique may be used to accomplish specific targeting and amplification of sequences in the genome.
  • this technique enables efficient multiplexing, i.e. mixing in the same reaction vessel, of probes to distinct template targets.
  • the physical linking of the two complementary sequences into a single probe backbone has the effect of limiting cross-reactions between unintended combinations of target sequences, as typically occurs with multiplex PCR.
  • All of the newly extended probes may be amplified simultaneously using amplification primers or techniques common to all the probes.
  • the resulting amplified sequences may be analyzed for size, size distribution, allele constitution, or specific sequence by various methods. Gel separation can reveal size and size distribution.
  • Microarrays and quantitative PCR can reveal allele constitution using either target specific hybridization or probe specific hybridization, where probes are individually tagged with distinct sequences. Sequencing by methods, such as the Sanger dideoxy method, could also reveal sequence in certain circumstances. Sequencing using other methods, such as the clonal (e.g. polony, bridge) or single molecule sequencing methods, can reveal the sequence as well as counts of individual molecules in the amplified pool. Furthermore, sequencing enables mixing and sequencing multiple probe amplification pools from different individuals. One way to accomplish this would be for each initial probe pool applied to a sample to either contain a different synthesized sequence that could be used differentiate different samples, or a specific distinguishing sequence could be added and covalently linked to the products of the probe amplification.
  • sample specific sequences could then be detected during the sequence process allowing disambiguation as to from which sample each particular sequence instance was derived.
  • LIPs may be used to detect certain disease alleles that are not easily detected using other PCR based techniques. Alleles of certain diseases are not amenable to PCR based amplification.
  • the disease Fragile X an X-linked disorder, is caused by tandem expansion of a tri-nucleotide repeat of the DNA nucleotides CGG. When the number of repeats is greater than 45 repeats become unstable and become prone to further expansion. A chromosome with greater than 200 repeats is considered to have the full mutation. Both males, who only have one X chromosome, and heterozygous females, will show characteristics of the disease at repeats greater than about 200 triplets in size.
  • PCR while usually capable of amplifying the normal size range of alleles, will often fail to amplify expanded alleles due the highly repetitive nature of the DNA. Consequently, PCR based tests used on heterozygous individuals may yield a false negative test result when only the normal allele is detected.
  • this problem may be solved by using at least two, but also possibly three or more distinct linked inverted probes.
  • the first probe may be designed so that both ends are complementary to the DNA sequence flanking the repetitive sequence prone to expansion, herein called the "spanning probe.” Upon binding, this probe would straddle the entire repeat region, enabling detection and amplification of the normal allele and some size range of expanded alleles.
  • a second probe herein called the “non-spanning probe” may be designed such that one end of the probe is complementary to the non-repetitive sequence upstream of the repeat and the other end complementary to the repeat itself.
  • another non-spanning probe may also be designed with one end complementary to the downstream non-repetitive DNA sequence and the other end complementary to the repetitive sequence.
  • the spanning probe would be expected to extend and amplify in the presence of the normal allele as well as some size range of expanded alleles. However, for the same reasons that PCR fails at the largest size ranges of these repeat alleles, this probe may fail at the larger size ranges of the expanded allele.
  • the non-spanning probes allow detection of these alleles. These probes bind to one side of the repeat, anchoring the probe while the other end of the probe is free to find to bind to numerous places within the repeat. Extension and amplification of these probes then yields a distribution of differently sized fragments. The size distribution can be detected through various methods including DNA separation techniques (e.g. agarose gel), or by direct sequencing of the amplified probes any clonal sequencing method. Collectively, the spanning and one or both of the non-spanning probes may be used to detect the presence of all possible genotypes, by sequencing, for example.
  • the size of the allele may be readily observed upon analysis. If in a normal individual there are two different size normal alleles, both may be detectable by the spanning probe. If the size of one or both alleles is abnormal, but still within the limits of detection of the spanning probe, then again both alleles may be detectable. If the one or both of the alleles is so large such that it cannot be extended or amplified with the spanning probe, then the data from one or both of the non-spanning probes may be used to determine or estimate the repeat length, as both an internal positive control and as a means to demonstrate the presence of an allele that is larger than normal size rage.
  • LIPs may be used to detect large deletions with defined or potentially poorly defined end points.
  • Large deletions are responsible for a number of important human disorders.
  • Hemophilia A can be caused by large deletions of varying size in the Factor VIII gene on the X chromosome;
  • Duchenne and Becker Muscular Dystrophy can be caused by large deletions of varying size in the DMD gene, also on the X chromosome).
  • Two PCR based approaches for detecting large deletions are (a) to design multiple PCR within and flanking the region of the deletion and (b) design a set of PCR assay including ones that spans the entire deletion (both endpoints) as well as each endpoint individually.
  • the PCR assays within the mutation may fail to amplify while the ones flanking the mutation may amplify.
  • this method cannot be used to detect a heterozygote as all PCR assays will amplify.
  • one may design a collection of linked inverted probes that spanning various distances from one or both of the farthest known endpoints, in addition to a small number of probes spaced at various intervals to detect the normal allele.
  • Each of the spanning probes may have one end complementary to the non-deleted region.
  • the other end of each distinct probe may be complementary to some region at some variable large distance from non-deleted end. The distance between the probe ends could be too large to extend and amplify using typical approaches, but in the presence of a large deletion, a previously distant binding site for one or more of the probes could be brought to within distance that could be amplified and extended.
  • the resulting product may be detected by an array (detecting presence absence only of an amplified probe) or by sequencing as previously described. Sequencing of the probe may reveal a chimeric fragment of DNA with the two previously flanking DNA sequences now flanking one another. The number of probes required could be determined by the length of the gap that could be extended, amplified, and extended as well as the maximum possible length of the deletion.
  • the method involves measuring genetic data for use with an informatics based method, such as PARENTAL SUPPORTTM (PS).
  • PS PARENTAL SUPPORTTM
  • the ultimate outcome of some of the embodiments is the actionable genetic data of an embryo or a fetus.
  • the algorithms behind the PS method take the measured genetic data of the target individual, often an embryo or fetus, and the measured genetic data from related individuals, and are able to increase the accuracy with which the genetic state of the target individual is known.
  • the measured genetic data is used in the context of making ploidy determinations during prenatal genetic diagnosis.
  • the measured genetic data is used in the context of making ploidy determinations or allele calls on embryos during in vitro fertilization.
  • the different methods comprise a number of steps, those steps often involving amplification of genetic material, addition of oligonucleotide probes, ligation of specified DNA strands, isolation of sets of desired DNA, removal of unwanted components of a reaction, detection of certain sequences of DNA by hybridization, detection of the sequence of one or a plurality of strands of DNA by DNA sequencing methods.
  • DNA strands may refer to target genetic material, in some cases they may refer to primers, in some cases they may refer to synthesized sequences, or combinations thereof. These steps may be carried out in a number of different orders. Given the highly variable nature of molecular biology, it is generally not obvious which methods, and which combinations of steps, will perform poorly, well, or best in various situations.
  • the genetic material of the target individual is amplified before circularizing probes are added.
  • the small amount of genetic material may be amplified using a wide variety of techniques, for example, multiple displacement amplification or polymerase chain reaction. Other methods of amplification are outlined herein.
  • methods described in the literature that use circularizing probes. Note that the methods known in the art for using circularizing probes involve adding the probes to unamplified, genomic DNA.
  • the amplified the nucleic acid sequence may be mixed with a probe that can hybridize with two neighboring regions of the target sequence, one on either side.
  • the ends of the probe may be connected by adding a polymerase, a means for ligation, and any necessary reagents to allow the circularization of the probe.
  • an exonuclease may be added to digest to non-circularized genetic material, followed by detection of the circularized probe.
  • the detection of the circularized probe may be done in a number of ways, as described in the literature. For example, it may be isolated, for example by chromatography, it may be amplified, for example by rolling circle amplification, and it may be detected by hybridization, for example using ILLUMINA BEAD ARRAYS or AFFYMETRIX GENECHIP, or it may be sequenced using Sanger sequencing, or a high throughput sequencing platform such as the ILLUMINA SOLEXA GENOME ANALYZER.
  • the detection of the target genetic material may be done in a multiplexed fashion.
  • the number of genetic target sequences that may be run in parallel can range from one to ten, ten to one hundred, one hundred to one thousand, one thousand to ten thousand, ten thousand to one hundred thousand, one hundred thousand to one million, or one million to ten million.
  • this method may be used to genotype a single cell, a small number of cells, two to five cells, six to ten cells, ten to twenty cells, twenty to fifty cell, fifty to one hundred cells, one hundred to one thousand cells, or a small amount of extracellular DNA, for example from one to ten picograms, from ten to one hundred pictograms, from one hundred pictograms to one nanogram, from one to ten nanograms, from ten to one hundred nanograms, or from one hundred nanograms to one microgram.
  • the method may be used in the context of in vitro fertilization, where it may be desirable to genotype a single cell blastomere biopsied from a cleavage stage embryo for the purposes of determining the genetic state of the embryo. Or, it may be used to genotype a small number of cells biopsied from the trophectoderm, or from the inner cell mass, of a day 5 embryo, also for the purposes of determining the genetic state of the embryo. In another embodiment, it may be used in the context of non-invasive prenatal diagnosis to genotype isolated single fetal cells found in maternal blood. In another embodiment, in the context of prenatal diagnosis, it may be used to genotype free floating DNA found in maternal blood. In all of these embodiments, the target genetic data that is measured is expected to be actionable, and may be used to make clinical decisions.
  • One method to target specific locations for sequencing is to synthesize probes in which the 3' and 5' ends of the probes anneal to target DNA at locations adjacent to and on either side of the targeted region, in an inverted manner, such that the addition of DNA polymerase and DNA ligase results in extension from the 3' end, adding bases to single stranded probe that are complementary to the target molecule (gap-fill), followed by ligation of the new 3' end to the 5' end of the original probe resulting in a circular DNA molecule that can be subsequently isolated from background DNA.
  • the probe ends are designed to flank the targeted region of interest.
  • MIPS has been used in conjunction with array technologies to determine the nature of the sequence filled in.
  • this approach has been modified to be easily amenable to sequencing as a means of interrogating the filled in sequence.
  • allelic proportions of the original sample at least one key consideration must be taken into account.
  • the variable positions among different alleles in the gap-fill region must not be too close to the probe binding sites as there can be initiation bias by the DNA polymerase resulting in differential of the variants.
  • Another consideration is that additional variations may be present in the probe binding sites that are correlated to the variants in the gap-fill region which can result unequal amplification from different alleles.
  • the 3' ends and 5' ends of the pre-circularized probe are designed to hybridize to bases that are one or a few positions away from the variant positions (polymorphic regions) of the targeted allele.
  • the number of bases between the polymorphic region (SNP or otherwise) and the base to which the 3' end and/or 5' of the pre-circularized probe is designed to hybridize may be one base, it may be two bases, it may be three bases, it may be four bases, it may be five bases, it may be six bases, it may be seven to ten bases, it may be eleven to fifteen bases, or it may be sixteen to twenty bases.
  • the forward and reverse primers may be designed to hybridize a different number of bases away from the polymorphic region. Circularizing probes can be generated in large numbers with current DNA synthesis technology allowing very large numbers of probes to be generated and potentially pooled, enabling interrogation of many loci simultaneously. It has been reported to work with more than 300,000 probes.
  • the variable positions among different alleles in the region adjacent to the probe binding site must not be too close to the probe binding sites as there can be initiation bias by the DNA polymerase resulting in differential of the variants.
  • the 3' end of the PCR probe is designed to hybridize to bases that are one or a few positions away from the variant positions (polymorphic regions) of the targeted allele.
  • the number of bases between the polymorphic region (SNP or otherwise) and the base to which the 3 end of the PCR probe is designed to hybridize may be one base, it may be two bases; it may be three bases, it may be four bases, it may be five bases, it may be six bases, it may be seven to ten bases, it may be eleven to fifteen bases, or it may be sixteen to twenty bases.
  • the forward and reverse primers may be designed to hybridize a different number of bases away from the polymorphic region.
  • Targeting of a specific set of sequences in a target genome can be accomplished in a number of ways. Elsewhere in this document is a description of how LIPs can be used to target a specific set of sequences, but in all of those applications, other targeting methods can be used equally well for the same ends.
  • One example of another targeting method is the capture by hybridization approach. Some examples of commercial capture by hybridization technologies include AGILENT's SURE SELECT and ILLUMINA's TRUSEQ. In capture by hybridization, a set of oligonucleotides that is complimentary or mostly complimentary to the desired targeted sequences is allowed to hybridize to a mixture of DNA, and then physically separated from the mixture.
  • the effect of physically removing the targeting oligonucleotides is to also remove the targeted sequences.
  • the hybridized oligos Once the hybridized oligos are removed, they can be heated to above their melting temperature and they can be amplified.
  • Some ways to physically remove the targeting oligonucleotides is by covalently bonding the targeting oligos to a solid support, for example a magnetic bead, or a chip.
  • Another way to physically remove the targeting oligonucleotides is by covalently bonding them to a molecular moiety with a strong affinity for another molecular moiety.
  • biotin and streptavidin such as is used in SURE SELECT.
  • streptavidin such as is used in SURE SELECT.
  • targeted sequences could be covalently attached to a biotin molecule, and after hybridization, a solid support with streptavidin affixed can be used to pull down the biotinylated oligos, to which are hybridized the targeted sequences.
  • hybrid capture Another method of targeting is hybrid capture.
  • probes that are complementary to the targets of interest are synthesized and then used to hybridize to the target molecules.
  • the hybridized molecules can be separated by various published techniques from the non-hybridized (untargeted) molecules.
  • This probe was originally developed to target and enrich large fractions of the genome with relative uniformity between targets. In this application, it is important that all targets be amplified with enough uniformity that all regions could be detected by sequencing, however, no regard was paid to retaining the proportion of alleles in original sample.
  • the alleles present in the sample can be determined by direct sequencing of the captured molecules. The ratios can be evaluated by sequencing through the specific alleles within the targeted region. These sequencing reads can be analyzed and counted according the allele type.
  • the measured allele ratios of the captured sequences at a given loci are typically not representative of the original allele ratios.
  • Probe length, target molecule length, and sequencing read length can all be adjusted to improve the amount of useful enrichment and the uniformly of the enrichment of the different alleles in the original sample
  • detection of the alleles is performed by sequencing.
  • sequencing In order to capture the allele identity at the polymorphic site, it is essential that the sequencing read span the allele in question in order to evaluate the allelic composition of that captured molecule. Since the capture molecules are often of variable lengths upon sequencing cannot be guaranteed to overlap the variant positions unless the entire molecule is sequenced. However, cost considerations as well as technical limitations as to the maximum possible length and accuracy of sequencing reads make sequencing the entire molecule unfeasible.
  • the read length can be increased from about 30 to about 50 or about 70 bases can greatly increase the number of reads that overlap the variant positions within the targeted sequences.
  • Another way to increase the number of reads that interrogate the position of interest is to decrease the length of the probe, as long as it does not result in bias in the underlying enriched alleles.
  • the length of the synthesized probe should be long enough such that two probes designed to hybridize to two different alleles found at one locus will hybridize with near equal affinity to the various alleles in the original sample.
  • methods known in the art describe probes that are longer than 90 bases. However, if the allele is one or a few bases, a probe between 25 and 90 bases is sufficient to ensure equal enrichment from all alleles.
  • the mixture of DNA that is to be enriched using the hybrid capture technology is a mixture comprising free floating DNA isolated from blood, for example maternal blood
  • the average length of DNA is quite short, typically less than 200 bases. Using shorter probes results in a greater chance that the hybrid capture probes will capture desired DNA fragments. Larger variations may require longer probes.
  • the variations of interest are one (a SNP) to a few bases in length.
  • targeted regions in the genome can be preferentially enriched using hybrid capture probes wherein the hybrid capture probes are of a length below 90 bases, and can be as low as 80 bases, as low as 70 bases, as low as 60 bases, as low as 50 bases, as low as 40 bases, as low as 30 bases, or as low as 25 bases.
  • the length of the probe that is designed to hybridize to the regions flanking the polymorphic allele location can be decreased from above 90 bases, to about 80 bases, or to about 70 bases, or to about 60 bases, or to about 50 bases, or to about 40 bases, or to about 30 bases, or to about 25 bases.
  • the hybridization conditions can be adjusted to maximize uniformity in the capture of different alleles present in the original sample.
  • hybridization temperatures are decreased to minimize differences in hybridization bias between alleles. Methods known in the art avoid using lower temperatures for hybridization because lowering the temperature has the effect of increasing hybridization of probes to unintended targets. However, when the goal is to preserve allele ratios with maximum fidelity, the approach of using lower hybridization temperatures provides optimally accurate allele ratios, despite the fact that the current art teaches away from this approach.
  • Hybridization temperature can also be increased to require greater overlap between the target and the synthesized probe so that only targets with substantial overlap of the targeted region are captured. In some embodiments of the present disclosure, the hybridization temperature is lowered from the normal hybridization temperature to about 40°C, to about 45°C, to about 50°C, to about 55°C, to about 60°C, to about 65, or to about 70°C.
  • the hybrid capture probes can be designed such that the region of the capture probe with DNA that is complementary to the DNA found in regions flanking the polymorphic allele is not immediately adjacent to the DNA that is immediately adjacent to the polymorphic region.
  • the capture probe can be designed such that the region of the capture probe that is designed to hybridize to the DNA flanking the polymorphic region of the target is separated from the portion of the capture probe that will be in van der Waals contact with the polymorphic region by a small molecular moiety that is equivalent in length to one or a small number of bases, and which has a binding energy that is roughly independent of the sequence to which is in contact.
  • the hybrid capture probe is designed to hybridize to a region that is flanking the polymorphic allele but does not cross it; this may be termed a flanking capture probe.
  • the length of the flanking capture probe may be as low as about 120 bases, as low as about 110 bases, as low as about 100 bases, as low as about 90 bases, and can be as low as about 80 bases, as low as about 70 bases, as low as about 60 bases, as low as about 50 bases, as low as about 40 bases, as low as about 30 bases, or as low as about 25 bases.
  • PCR can be used to target specific locations of the genome.
  • the original DNA is highly fragmented (-100-200 bp, 150 peak).
  • both forward and reverse primers must anneal to the same fragment to enable amplification. Therefore, if the fragments are short, the PCR assays must amplify relatively short regions as well.
  • the polymorphic positions are too close the polymerase binding site, it could result in biases in the amplification from different alleles.
  • PCR primers that target polymorphic regions such as SNPs, are typically designed such that the 3' end of the primer will hybridize to the base immediately adjacent to the polymorphic base or bases.
  • the 3' ends of both the forward and reverse PCR primers are designed to hybridize to bases that are one or a few positions away from the variant positions (polymorphic regions) of the targeted allele.
  • the number of bases between the polymorphic region (SNP or otherwise) and the base to which the 3' end of the primer is designed to hybridize may be one base, it may be two bases, it may be three bases, it may be four bases, it may be five bases, it may be six bases, it may be seven to ten bases, it may be eleven to fifteen bases, or it may be sixteen to twenty bases.
  • the forward and reverse primers may be designed to hybridize a different number of bases away from the polymorphic region.
  • PCR assay can be generated in large numbers, however, the interactions between different PCR assays makes it difficult to multiplex them beyond about one hundred assays.
  • Various complex molecular approaches can be used to increase the level of multiplexing, but it may still be limited to fewer than 1000 assays per reaction.
  • Samples with large quantities of DNA can be split among multiple sub-reactions and then recombined before sequencing. For samples where either the overall sample or some subpopulation of DNA molecules is limited, splitting the sample would introduce statistical noise.
  • a small or limited quantity of DNA may refer to an amount below 10 pg, between 10 and 100 pg, between 100 pg and 1 ng, between 1 and 10 ng, or between 10 and 100 ng.
  • this method is particularly useful on small amounts of DNA where other methods that involve splitting into multiple pools can cause significant problems related to introduced stochastic noise, this method still provides the benefit of minimizing bias when it is run on samples of any quantity of DNA.
  • a pre-amplification step may be used to increase the overall sample quantity.
  • this pre-amplification step should not appreciably alter the allelic ratios.
  • the method can generate hundreds to thousands of PCR products (can be 10,000 and more), e.g. for genotyping by sequencing or some other genotyping method, from limited samples such as single cells or DNA from body fluids.
  • PCR products can be 10,000 and more
  • performing multiplex PCR reactions of more than 5 to 10 targets presents a major challenge and is often hindered by primer side products, such as primer dimers, and other artifacts.
  • primer side products such as primer dimers, and other artifacts.
  • next generation sequencing the vast majority of the sequencing reads would sequence such artifacts and not the desired target sequences in a sample.
  • to perform targeted sequencing of multiple (n) targets of a sample greater than 10, 50 or 1000's
  • one can split the sample into n parallel reactions that amplify one individual target, which is problematic for samples with a limited amount of DNA.
  • PCR multiwell plates This has been performed in PCR multiwell plates or can be done in commercial platforms such as the Fluidigm Access Array (48 reactions per sample in microfluidic chips) or droplet PCR by Rain Dance Technologies (100s to a few thousands of targets). Described here is a method to effectively amplify many PCR reactions, that is applicable to cases where only a limited amount of DNA is available. In one embodiment, the method may be applied for analysis of single cells, body fluids, biopsies, environmental and/or forensic samples.
  • the allelic ratio information can be used to determine the genetic state of an individual. In some embodiments of the present disclosure, this information can be used to determine the genetic state of a plurality of individuals from one DNA sample, wherein the DNA sample contains DNA from each of the plurality of individuals. In one embodiment, the allelic ratio information can be used to determine copy number of whole chromosomes from individual cells, or bulk samples. In one embodiment, the allelic ratio information can be used to determine copy number of parts, regions, or segments of chromosomes individual cells, or bulk samples.
  • the allelic ratio information can be used to determine the relative contribution of different cell types in mosaic samples. In one embodiment, the allelic ratio information can be used to determine the fraction of fetal DNA in maternal plasma samples as well as the chromosome copy number of the fetal chromosomes.
  • the amplified sample should be free of primer dimer products and be preferably unbiased between alleles and target loci. If during or after amplification the products are appended with sequencing compatible adaptors, analysis of these products can be performed by next-gen sequencing.
  • the initial solution to the problem of amplifying e.g. 5000 SNPs is to perform one 5000-plex PCR amplification of the total plasma DNA sample.
  • primer dimer products that are far in excess of the desired amplification products.
  • These can be reduced empirically by eliminating primers that form these mischief products and by performing in silico selection of primers.
  • the larger the number of assays the more insurmountable this problem becomes.
  • One solution is to split the 5000-plex reaction into several lower-plexed amplifications, e.g. one hundred 50-plex or fifty 100-plex reactions.
  • the sample DNA is limited, such as in non-invasive prenatal diagnostics from pregnancy plasma, dividing the sample between multiple reactions should be avoided. Note that this approach could be used to perform targeted amplification in a manner that would result in low amounts of allelic bias for 50-500 loci, for 500 to 5,000 loci, for 5,000 to 50,000 loci, or even for 50,000 to 500,000 loci.
  • Described herein is a method to first globally amplify the plasma DNA of a sample and then divide the sample up into multiple multiplexed target enrichment reactions with moderate target sequences per reaction.
  • the method can be used for preferentially enriching a DNA mixture at a plurality of loci, the method comprising generating and amplifying a library from a mixture of DNA where the molecules in the library have adaptor sequences ligated on both ends of the DNA fragments, dividing the amplified library into multiple reactions, performing a first round of multiplex amplification of selected targets using one target specific "forward" primer per target and one or a plurality of adaptor specific universal "reverse" primers.
  • the method may further comprise performing a second amplification using "reverse" target specific primers and one or a plurality of primers specific to a universal tag that was introduced as part of the target specific forward primers in the first round.
  • the method may be used for preferentially enriching a DNA mixture at a plurality of loci, the method comprising performing a multiplex preamplification of selected targets for a limited number of cycles, dividing the product into multiple aliquots and amplifying subpools of targets in individual reactions, and pooling products of parallel subpools reactions.
  • the primers carry partial or full length sequencing compatible tags.
  • the workflow may contain multiple sub-steps that comprise one of the listed steps (e.g. step 2.
  • Library preparation may comprise 3 enzymatic steps (blunt ending, dA tailing and adaptor ligation) and 3 purification steps).
  • Steps of the workflow may be combined, divided up or performed in different order (e.g. bar coding and pooling of samples).
  • amplification of a library can be performed in such away that it is biased to amplify short fragments more efficiently. In this manner it is possible to preferentially amplify shorter sequences, e.g. mono-nucleosomal DNA fragments as the cell free fetal DNA (of placental origin) found in the circulation of pregnant women.
  • a number of methods are described herein that may be used to preferentially enrich a sample of DNA at a plurality of loci in a way that minimizes allelic bias.
  • Some examples are using circularizing probes to target a plurality of loci where the 3' ends and 5' ends of the pre-circularized probe are designed to hybridize to bases that are one or a few positions away from the polymorphic regions of the targeted allele.
  • Another is to use PCR probes where the 3' end PCR probe is designed to hybridize to bases that are one or a few positions away from the polymorphic regions of the targeted allele.
  • Another is to use a split and pool approach to create mixtures of DNA where the preferentially enriched loci are enriched with low allelic bias without the drawbacks of direct multiplexing.
  • Another is to use a hybrid capture approach where the capture probes are designed such that the region of the capture probe that is designed to hybridize to the DNA flanking the polymorphic region of the target is separated from the polymorphic region by one or
  • allelic ratio measurements at polymorphic loci are used to determine the ploidy state of an individual, it is desirable to preserve the ratio of alleles in a sample of DNA as it is prepared for genetic measurements.
  • This preparation may involve WGA amplification, targeted amplification, selective enrichment techniques, hybrid capture techniques, circularizing probes or other methods meant to amplify the amount of DNA and/or selectively enhance the presence of molecules of DNA that correspond to certain alleles.
  • the loci are targeted using a method that could include circularizing probes, MIPs, capture by hybridization probes, probes on a SNP array, or combinations thereof.
  • the probes are used as circularizing probes, MIPs, capture by hybridization probes, probes on a SNP array, or combinations thereof.
  • the loci are sequenced for the purpose of non-invasive prenatal diagnosis.
  • the relative informativeness of a sequence is greater when combined with relevant parent contexts, it follows that maximizing the number of sequence reads that contain a SNP for which the parental context is known may maximize the informativeness of the set of sequencing reads on the mixed sample.
  • the number of sequence reads that contain a SNP for which the parent contexts are known may be enhanced by using qPCR to preferentially amplify specific sequences.
  • the number of sequence reads that contain a SNP for which the parent contexts are known may be enhanced by using circularizing probes (for example, MIPs) to preferentially amplify specific sequences.
  • the number of sequence reads that contain a SNP for which the parent contexts are known may be enhanced by using a capture by hybridization method (for example SURESELECT) to preferentially amplify specific sequences. Different methods may be used to enhance the number of sequence reads that contain a SNP for which the parent contexts are known.
  • the targeting may be accomplished by extension ligation, ligation without extension, capture by hybridization, or PCR.
  • DNA found in plasma whether maternal or fetal in origin is typically fragmented, often at lengths under 500 bp.
  • targeting methods may be used to enhance the fraction of DNA in a sample of DNA that map to a given chromosome such that the fraction significantly exceeds the percentages listed above that are typical for genomic samples. In one embodiment of the present disclosure, targeting methods may be used to enhance the fraction of DNA in a sample of DNA such that the percentage of sequences that contain a SNP are significantly greater than what may be found in typical for genomic samples. In one embodiment of the present disclosure, targeting methods may be used to target DNA from a chromosome or from a set of SNPs in a mixture of maternal and fetal DNA for the purposes of prenatal diagnosis.
  • the accuracy may refer to sensitivity, it may refer to specificity, or it may refer to some combination thereof.
  • the desired level of accuracy may be between 90% and 95%; it may be between 95% and 98%; it may be between 98% and 99%; it may be between 99% and 99.5%; it may be between 99.5% and 99.9%; it may be between 99.9% and 99.99%; it may be between 99.99% and 99.999%, it may be between 99.999% and 100%.
  • Levels of accuracy above 95% may be referred to as high accuracy.
  • an accurate ploidy determination may be made by using targeted sequencing, using any method of targeting, for example qPCR, capture by hybridization, or circularizing probes, wherein the number of loci along a chromosome that need to be targeted may be between 1,000 and 500 loci; it may be between 500 and 300 loci; it may be between 300 and 200 loci, it may be between 200 and 150 loci, it may be between 150 and 100 loci; it may be between 100 and 50 loci; it may be between 50 and 20 loci; it may be between 20 and 10 loci. Optimally, it may be between 100 and 500 loci.
  • the high level of accuracy may be achieved by targeting a small number of loci and executing an unexpectedly small number of sequence reads.
  • the number of reads may be between 5 million and 2 million reads; the number of reads may be between 2 million and 1 million; the number of reads may be between 1 million and 500,000; the number of reads may be between 500,000 and 200,000; the number of reads may be between 200,000 and 100,000; the number of reads may be between 100,000 and 50,000; the number of reads may be between 50,000 and 20,000; the number of reads may be between 20,000 and 10,000; the number of reads may be below 10,000.
  • composition comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to chromosome 13 is greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%.
  • composition comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to chromosome 18 is greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%.
  • composition comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to chromosome 21 is greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%.
  • composition comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to chromosome X is greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%.
  • composition comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to chromosome Y is greater than 1%, greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, greater than 20%, greater than 25%, or greater than 30%.
  • compositions comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to a chromosome, that contains at least one single nucleotide polymorphism is greater than 0.2%, greater than 0.3%, greater than 0.4%, greater than 0.5%, greater than 0.6%, greater than 0.7%, greater than 0.8%, greater than 0.9%, greater than 1%, greater than 1.2%, greater than 1.4%, greater than 1.6%, greater than 1.8%, greater than 2%, greater than 2.5%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, or greater than 20%, and where the chromosome is taken from the group 13, 18, 21, X, or Y.
  • compositions comprising a mixture of DNA of fetal origin, and DNA of maternal origin, wherein the percent of sequences that uniquely map to a chromosome and that contain at least one single nucleotide polymorphism from a set of single nucleotide polymorphisms is greater than 0.15%, greater than 0.2%, greater than 0.3%, greater than 0.4%, greater than 0.5%, greater than 0.6%, greater than 0.7%, greater than 0.8%, greater than 0.9%, greater than 1%, greater than 1.2%, greater than 1.4%, greater than 1.6%, greater than 1.8%, greater than 2%, greater than 2.5%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 12%, greater than 15%, or greater than 20%, where the chromosome is taken from the set of chromosome 13, 18, 21, X and Y, and where the number of single nucleotide polymorph
  • each cycle in the amplification doubles the amount of DNA present, however, in reality, the degree of amplification is slightly lower than two. In theory, amplification, including targeted amplification, will result in bias free amplification of a DNA mixture.
  • the degree of allelic bias typically increases with the number of amplification steps.
  • the methods described herein involve amplifying DNA with a low level of allelic bias. Since the allelic bias compounds, one can determine the per cycle allelic bias by calculating the nth root of the overall bias where n is the base 2 logarithm of degree of enrichment.
  • compositions comprising a second mixture of DNA, where the second mixture of DNA has been preferentially enriched at a plurality of polymorphic loci from a first mixture of DNA where the degree of enrichment is at least 10, at least 100, at least 1,000, at least 10,000, at least 100,000 or at least 1,000,000, and where the ratio of the alleles in the second mixture of DNA at each locus differs from the ratio of the alleles at that locus in the first mixture of DNA by a factor that is, on average, less than 1,000%, 500%, 200%, 100%, 50%, 20%, 10%, 5%, 2%, 1%, 0.5%, 0.2%, 0.1%, 0.05%, 0.02%, or 0.01%.
  • composition comprising a second mixture of DNA, where the second mixture of DNA has been preferentially enriched at a plurality of polymorphic loci from a first mixture of DNA where the per cycle allelic bias for the plurality of polymorphic loci is, on average, less than 10%, 5%, 2%, 1%, 0.5%, 0.2%, 0.1%, 0.05%, or 0.02%.
  • the plurality of polymorphic loci comprises at least 10 loci, at least 20 loci, at least 50 loci, at least 100 loci, at least 200 loci, at least 500 loci, at least 1,000 loci, at least 2,000 loci, at least 5,000 loci, at least 10,000 loci, at least 20,000 loci, or at least 50,000 loci.
  • the goal of the method is to detect fetal copy number based on a maternal blood sample which contains some free-floating fetal DNA.
  • the fraction of fetal DNA compared to the mother's DNA is unknown.
  • the combination of a targeting method, such as LIPs, followed by sequencing results in a platform response that consists of the count of observed sequences associated with each allele at each SNP.
  • the set of possible alleles, either A/T or C/G, is known at each SNP. Without loss of generality, the first allele will be labeled A and the second allele will be labeled B.
  • the measurement at each SNP consists of the number of A sequences (N A ) and the number of B sequences (N B ).
  • Measurements will be initially aggregated over SNPs from the same parent context based on unordered parent genotypes.
  • Each context is defined by the mother genotype and the father genotype, for a total of 9 contexts.
  • all SNPs where the mother's genotype is AA and the father's genotype is BB are members of the AA
  • the A allele is defined as present at ratio r m in the mother genotype and ratio r f in the father genotype.
  • each context defines values for r m and r f .
  • the allele ratio averaged over a large number of SNPs can be predicted based on the assumption that a parent AB genotype will contribute A and B at equal rates.
  • the ratio r of the A allele in a given context is a linear combination of the mother ratio r m and the child ratio r c , which can be reduced to a linear combination of the mother ratio and father ratio using equation 1.
  • each hypothesis h results in a predicted allele ratio r i h for the SNP in parent context i.
  • the data likelihood is defined as the probability of a given hypothesis producing the observed data.
  • the likelihood of measurement r i h from context i under hypothesis h is a binomial distribution, which can be approximated for large N as a Gaussian distribution with the following mean and variance. The mean is determined by the context and the hypothesis as described in equation 2.
  • the data from a particular chromosome consists of the sequence measurements from contexts i ranging from 1 to 9.
  • Equation 2 predicts the allele ratio as a function of parent copy number hypothesis, but also includes the fraction of child DNA. Therefore, the data likelihood for each chromosome is a function of through its effect on r i h . This effect is highlighted through the notation p( r ⁇ ... , r ⁇ 9
  • a number of different approaches may be used for parameter estimation.
  • One method involves the measurement of chromosomes for which copy number errors are not viable at the stage of development where testing will be performed. The other method measures only chromosomes on which errors are expected to occur.
  • a straight forward approach for classification of a limited set of chromosomes t is to consider the joint chromosome hypothesis H, which consists of the joint set of hypotheses for all chromosomes being tested. If the chromosome hypotheses consist of disomy, maternal trisomy and paternal trisomy, the number of possible joint hypotheses is 3 T where T is the number of tested chromosomes.
  • H) can be calculated for each joint hypothesis H, and the maximum likelihood hypothesis is selected, with its corresponding estimate ⁇ * (H) of the child fraction.
  • Hypothesis 1 predicts allele ratio r 1 and hypothesis 2 predictions allele ratio r 2 , as a function of the mother allele ratio r m and father allele ratio r f for the context under consideration.
  • r 1 1 ⁇ ⁇ 2 r m + ⁇ 2 r f
  • r 2 1 ⁇ ⁇ 3 r m + ⁇ 3 r f
  • the measured allele ratio r ⁇ is predicted to be Gaussian distributed, either with mean r 1 or mean r 2 , depending on whether hypothesis 1 or 2 is true.
  • the standard deviation of the measured allele ratio depends similarly on the hypothesis, according to equation 3.
  • the means r 1 , r 2 and standard deviations ⁇ 1 , ⁇ 2 must satisfy a relationship such as the following, which guarantees that the means are far apart compared to the standard deviations. This criterion represents a 2 percent error rate, meaning a 2 percent chance of either false negative or false positive.
  • FIG. 1 shows the required number of measurements (number of SNPs multiplied by depth of read) versus child concentration required to satisfy the previous condition. Two different parent contexts are shown. In practice, measurements from multiple contexts may be combined, resulting in a smaller number of required measurements per context.
  • the parent contexts, and chromosomes known to be euploid it is possible to estimate, by a set of simultaneous equations, the proportion of DNA in the maternal blood from the mother and the proportion of DNA in the maternal blood from the fetus.
  • simultaneous equations are made possible by the knowledge of the alleles present on the father.
  • alleles present on the father and not present on the mother provide a direct measurement of fetal DNA.
  • H mp where m represents the number of maternal chromosomes and p represents the number of paternal chromosomes e.g. H 11 representing euploid, H 21 and H 12 representing maternal and paternal trisomy respectively.
  • this method does not use a reference chromosome as a basis by which to compare observed allelic ratios on the chromosome of interest.
  • This disclosure presents a method by which one may determine the ploidy state of a gestating fetus, at one or more chromosome, in a non-invasive manner, using genetic information determined from fetal DNA found in maternal blood.
  • the fetal DNA may be purified, partially purified, or not purified; genetic measurements may be made on DNA that originated from more than one individual.
  • Informatics type methods can infer genetic information of the target individual, such as the ploidy state, from the bulk genotypic measurements at a set of alleles.
  • the set of alleles may contain various subsets of alleles, wherein one or more subsets may correspond to alleles that are found on the target individual but not found on the non-target individuals, and one or more other subsets may correspond to alleles that are found on the non-target individual and are not found on the target individual.
  • the method may involve using comparing ratios of measured output intensities for various subsets of alleles to expected ratios given various potential ploidy states.
  • the platform response may be determined, and a correction for the bias of the system may be incorporated into the method.
  • j 1...23 denotes chromosome number
  • i 1...N denotes the locus number on the chromosome
  • g ijk is platform response for particular locus and allele ijk
  • v ijk is independent noise on the measurement for that locus and allele.
  • x ijk am ijk + ⁇ c ijk
  • a is the amplification factor (or net effect of leakage, diffusion, amplification etc.) of the genetic material present on each of the maternal chromosomes
  • m ijk is the copy number of the particular allele on the maternal chromosomes
  • ⁇ is the amplification factor of the genetic material present on each of the child chromosomes
  • c ijk is the copy number (either 0,1,2,3) of the particular allele on the child chromosomes.
  • y ijk g ijk am ijk + ⁇ c i jk + ⁇ ijk
  • the goal is to estimate a and ⁇ .
  • the parent contexts are represented in terms of alleles A and B, where the first two alleles represent the mother and the second two alleles represent the father: T ⁇ ⁇ AA
  • T there is a set of loci i,j where the parent DNA conforms to that context, represented i,j ⁇ T.
  • m k,T , c k,T and v k,T represent the means of the respective values over all the loci conforming to the parent context T, or over all i, j ⁇ T.
  • the mean or expected values c k,T will depend on the ploidy status of the child.
  • hypotheses are denoted by the notation H mf , where m refers to the number of chromosomes from the mother and f refers to the number of chromosomes from the father e.g. H 11 is euploid, H 21 is maternal trisomy.
  • a H 11 2.0 1.0 0 1.0 1.0 1.0 2.0 2.0 0 0 2.0 1.5 1.0 1.5 1.0 0.5 0 0.5 0 1.0 2.0 1.0 1.0 1.0 0 0 2.0 2.0 0 0.5 1.0 0.5 1.0 1.5 2.0 1.5
  • a H 21 2.0 2.0 0 1.0 1.0 1.5 2.0 3.0 0 0 2.0 2.5 1.0 2.0 1.0 1.0 0 0.5 0 1.0 2.0 2.0 1.0 1.5 0 0 2.0 3.0 0 0.5 1.0 1.0 1.0 2.0 2.0 2.5
  • N T ' refers to the number of loci used on the chromosomes known to be euploid
  • C' denote the covariance matrix for mean measurements on the chromosomes known to be euploid.
  • C' the covariance matrix for mean measurements on the chromosomes known to be euploid.
  • P ⁇ argmi n P ⁇ C ' ⁇ 1 / 2 Y ' ⁇ B ⁇
  • a H 11 P ⁇ 2 A H 11 ⁇ C ' ⁇ 1 A H 11 ⁇ 1 A H 11 T C ' ⁇ 1 Y ⁇
  • H * argmi n H ⁇ C " ⁇ 1 / 2 Y " ⁇ B ⁇ A H P ⁇ ⁇ 2
  • H 11 euploid
  • H 21 eternal trisomy
  • One may then compute the probabilities of each hypothesis by adding the equation p H11 + p H21 1. The confidence that the chromosome is in fact euploid is given by p H11 .
  • Determining the ploidy status of a fetus by measuring the free floating DNA contained in maternal serum, or by measuring the genotypic data contained in any mixed sample, is a non-trivial exercise. There are a number of methods, for example, performing a read count analysis where the presumption is that if the fetus is trisomic at a particular chromosome, then the overall amount of DNA from that chromosome found in the maternal blood will be elevated with respect to a reference chromosome.
  • One way to detect trisomy in such fetuses is to normalize the amount of DNA expected for each chromosome, for example, according to the number of SNPs in the analysis set that correspond to a given chromosome, or according to the number of uniquely mappable portions of the chromosome. Once the measurements have been normalized, any chromosomes for which the amount of DNA measured exceeds a certain threshold are determined to be trisomic. This approach is described in Fan, et al. PNAS, 2008; 105(42); pp. 16266-16271 , and also in Chiu et al. BMJ 2011;342:c7401 . In the Chiu et al.
  • Z score for percentage chromosome 21 in test case percentage chromosome 21 in test case ⁇ mean percentage chromosome 21 in reference controls / standard deviation of percentage chromosome 21 in reference controls
  • the method used to determine the ploidy state of the fetus involves taking into account the fraction of fetal DNA in the sample. In another embodiment of the present disclosure, the method involves the use of maximum likelihood estimations. In one embodiment of the present disclosure, the method involves calculating the percent of DNA in a sample that is fetal or placental in origin. In one embodiment of the present disclosure, the threshold for calling aneuploidy is adaptively adjusted based on the calculated percent fetal DNA.
  • the method for estimating the percentage of DNA that is of fetal origin in a mixture of DNA comprises obtaining a mixed sample that contains genetic material from the mother, and genetic material from the fetus, obtaining a genetic sample from the father of the fetus, measuring the DNA in the mixed sample, measuring the DNA in the father sample, and calculating the percentage of DNA that is of fetal origin in the mixed sample using the DNA measurements of the mixed sample, and of the father sample.
  • the fraction of fetal DNA, or the percentage of fetal DNA in the mixture can be measured.
  • the fraction can be calculated using only the genotyping measurements made on the maternal plasma sample itself, which is a mixture of fetal and maternal DNA.
  • the fraction may be calculated also using the measured or otherwise known genotype of the mother and/or the measured or otherwise known genotype of the father.
  • the percent fetal DNA may be calculated using the measurements made on the mixture of maternal and fetal DNA along with the knowledge of the parental contexts.
  • the fraction of fetal DNA may be calculated using population frequencies to adjust the model on the probability on particular allele measurements.
  • a confidence may be calculated on the accuracy of the determination of the ploidy state of the fetus.
  • the confidence of the hypothesis of greatest likelihood (H major ) may be calculated as (1- H major ) / ⁇ (all H). It is possible to determine the confidence of a hypothesis if the distributions of all of the hypotheses are known. It is possible to determine the distribution of all of the hypotheses if the parental genotype information is known. It is possible to calculate a confidence of the ploidy determination if the knowledge of the expected distribution of data for the euploid fetus and the expected distribution of data for the aneuploid fetus are known.
  • a test statistic around a normal hypothesis and around an abnormal hypothesis to determine both the reliability of the call as well as refine the threshold to make a more reliable call. This is particularly useful when the amount and/or percent of fetal DNA in the mixture is low. It will help to avoid the situation where a fetus that is actually aneuploid is found to be euploid because a test statistic, such as the Z statistic does not exceed a threshold that is made based on a threshold that is optimized for the case where there is a higher percent fetal DNA.
  • Described herein is a method for determining the ploidy state of a fetus given sequence data that was measured on free floating DNA isolated from maternal blood, wherein the free floating DNA contains some DNA of maternal origin, and some DNA of fetal / placental origin.
  • This section will describe one embodiment of the present invention in which the ploidy state of the fetus is determined using the calculated fraction of fetal DNA in the mixture that has been analyzed. It will also describe an embodiment in which the fraction of fetal DNA or the percentage of fetal DNA in the mixture can be measured. In some embodiments the fraction can be calculated using only the genotyping measurements made on the maternal blood sample itself, which is a mixture of fetal and maternal DNA. In some embodiments the fraction may be calculated also using the measured or otherwise known genotype of the mother and/or the measured or otherwise known genotype of the father.
  • N SNPs For a particular chromosome, suppose there are N SNPs, for which:
  • each trisomy whether the origin was mitotis, meiosis I, or meiosis II, would be one of the matched or unmatched trisomies. Due to crossovers, true trisomy is a combination of the two.
  • a method to derive hypothesis likelihoods for simple hypotheses is described.
  • a method to derive hypothesis likelihoods for composite hypotheses is described, combining individual SNP likelihood with crossovers.
  • m i true mother genotype
  • f i true father genotype
  • cf known or derived child fraction.
  • X i P(A
  • m i , f i , H , cf ⁇ c p c
  • m,f,H ) is the probability of getting true child genotype c, given parents m, f, and assuming hypothesis H, which can be easily calculated. For example, for H11, H21 matched and H21 unmatched, p(c
  • m , c , cf ) is the likelihood of getting derived probability x i on SNP i, assuming true mother m, true child c, defined as pdf x (x i ) of the distribution that x i should be following if hypothesis H were true.
  • pdf x (x i ) pdf x ( x i )
  • trisomy In the case of trisomy, if there were no crossovers, trisomy would be simply matched or unmatched trisomy. Matched trisomy is where child inherits two copies of the identical chromosome segment from one parent. Unmatched trisomy is where child inherits one copy of each homologous chromosome segment from the parent. Due to crossovers, some segments of a chromosome may have matched trisomy, and other parts may have unmatched trisomy. Described in this section is how to build a joint distribution model for the heterozygosity rates for a set of alleles.
  • LIK H ⁇ S , E LIK S , E ,1 : N
  • LIK(S, E, 1: N) is the likelihood starting with hypothesis S, ending in hypothesis E, for SNPs 1 :N.
  • S hypothesis of the first SNP
  • E hypothesis of the last SNP, S,E ⁇ ( Hm,Hu ) .
  • i N .
  • LIK(chr, H11, cf) log likelihood as described above, for the disomy hypothesis, and for child fraction cf on chromosome chr.
  • Cset usually 1:16.
  • m i , f i , H , cf ⁇ c p c
  • m i , H ⁇ f p c
  • mother dropout rate MDO
  • child dropout rate CDO
  • the mother dropout rate can be assumed to be zero, and child dropout rates are relatively low, so the results in practice are not severely affected by dropouts. Nonetheless, they have been incorporated into the algorithm here.
  • m i , c, cf) pdf x (x i ) has been defined as the likelihood of getting x i probability of A on SNP i, given sequence measurements S, assuming true mother m i , true child c. If there is a dropout in the mother or child, the input data is NOT true mother(m i ) or child(c), but mother after possible dropout (m d ) and child after a possible dropout (c d ).
  • m i , c , cf ⁇ m d , c d p m d
  • m i ) is the probability of new mother genotype m d , given true mother genotype m i , assuming dropout rate mdo
  • c ) is the probability of new child genotype c d , given true child genotype c, assuming dropout rate CDO.
  • nA T number of A alleles in true genotype c
  • nA D number of A alleles in 'drop' genotype c d
  • nB T number of B alleles in true genotype c
  • nB D number of B alleles in 'drop' genotype c d
  • nB T ⁇ nB D and d dropout rate
  • the parent genotypes have been measured, as well as the true child genotype, where the child has maternal trisomy on chromosomes 14 and 21. Sequencing measurements have been simulated for varying values of child fraction, N distinct SNPs, and total number of reads NR. From this data it is possible to derive the most likely child fraction, and derive copy number assuming known or derived child fraction.
  • An estimated versus true dropout rate is shown in FIG.
  • FIG. 8 shows hit rates versus child fraction when the method includes a dropout model, assuming 5% dropout rate.
  • the method disclosed herein can be used to determine a fetal aneuploidy by determining the number of copies of maternal and fetal target chromosomes, having target sequences in a mixture of maternal and fetal genetic material.
  • This method may entail obtaining maternal tissue comprising both maternal and fetal genetic material; in some embodiments this maternal tissue may be maternal plasma or a tissue isolated from maternal blood.
  • This method may also entail obtaining a mixture of maternal and fetal genetic material from said maternal tissue by processing the aforementioned maternal tissue.
  • This method may entail distributing the genetic material obtained into a plurality of reaction samples, to randomly provide individual reaction samples that contain a target sequence from a target chromosome and individual reaction samples that do not contain a target sequence from a target chromosome, for example, performing high throughput sequencing on the sample.
  • This method may entail analyzing the target sequences of genetic material present or absent in said individual reaction samples to provide a first number of binary results representing presence or absence of a presumably euploid fetal chromosome in the reaction samples and a second number of binary results representing presence or absence of a possibly aneuploid fetal chromosome in the reaction samples.
  • Either of the number of binary results may be calculated, for example, by way of an informatics technique that counts sequence reads that map to a particular chromosome, to a particular region of a chromosome, to a particular locus or set of loci.
  • This method may involve normalizing the number of binary events based on the chromosome length, the length of the region of the chromosome, or the number of loci in the set.
  • This method may entail calculating an expected distribution of the number of binary results for a presumably euploid fetal chromosome in the reaction samples using the first number.
  • This method may entail calculating an expected distribution of the number of binary results for a presumably aneuploid fetal chromosome in the reaction samples using the first number and an estimated fraction of fetal DNA found in the mixture, for example, by multiplying the expected read count distribution of the number of binary results for a presumably euploid fetal chromosome by (1 + n/2) where n is the estimated fetal fraction.
  • the fetal fraction may be estimated by a plurality of methods, some of which are described elsewhere in this disclosure. This method may involve using a maximum likelihood approach to determine whether the second number corresponds to the possibly aneuploid fetal chromosome being euploid or being aneuploid. This method may involve calling the ploidy status of the fetus to be the ploidy state that corresponds to the hypothesis with the maximum likelihood of being correct given the measured data.
  • the present disclosure relates to a method for determining ploidy state of an individual given the genotypic data as output from a sequencing platform, where the genomic data has been amplified using a massively multiplex amplification procedure involving LIPs followed by ultra-high throughput sequencing.
  • the data set consists of 16 individuals. -13,000 MIPs probes were selected. For each individual, 8 million reads were made, for a theoretical average read depth (number of reads / number of probes) of 615.
  • the 8 million reads must be mapped to locations on a reference genome in order to conduct analysis. This is done using the DNA Nexus web service.
  • the processed data from DNA nexus contains the 8 million reads, in order of genome position, along with their alignment and QC properties.
  • FIG. 9 is representative of the data for each of the first 22 chromosomes; note the log scale. The number of reads varies widely from one probe to another. The plot for the last subject in FIG. 10 looks different. Note that its percentile values look the same; 95th percentile depth of read is still about 1000.
  • FIGS. 11 and 12 show various percentiles of the sequence count distributions as a function of the chromosome.
  • the last chromosome shown is the X.
  • the sample on the top is male, so the copy number for X is half that of the other chromosomes, which is clearly observable in the data.
  • the sample on the bottom is female.
  • FIG. 13 considers two samples (na10851 and na12156), one chromosome at a time. The plot shows the correlation coefficient between the number of reads for the two samples. The high correlation coefficient suggests that variation in the number of reads is due largely to probe characteristics rather than variation between samples. (This data shows only forward reads.)
  • the disclosed method is used to detect fetal copy number by using genetic material found in a maternal blood sample, where the maternal blood sample contains some free-floating fetal DNA.
  • the fraction of fetal DNA compared to the mother's DNA may be unknown.
  • the ratio of the identity of alleles can be used to determine the ploidy state of a fetus, as that ratio is characteristic of a given ploidy state.
  • the ratio may be 1:0, if he is heterogeneous, it may be 1:1; and if he is trisomic it could be 1:0 in the case of a homogenous allele, and 2:1 in the case of a heterogeneous allele.
  • This ratio can be hard to detect if it is in the presence of a large quantity of genetic material from another individual whose ploidy state is different from the target individual.
  • the method described herein is one way to accomplish the ploidy determination of such an individual in such a situation.
  • the method may involve obtaining a maternal blood sample, and enriching the fetal DNA.
  • the method may involve amplifying and/or genotyping or sequencing the genetic material in the sample. It may involve using the method described herein to determine said ploidy state using data taken from the list comprising: the output of the genotyping, the sequence data, the determined allele identities, the allelic ratios, the intensities of the individual measurements, the separately measured haplotypic and/or diploid genetic data from the mother, the haploid and diploid genetic data from the father, genetic data from other related individuals, and combinations thereof.
  • the results of the ploidy determination may be used for the purpose of making a clinical decision in the context of prenatal diagnosis, where said decision may involve to conduct further testing, and/or to make a medical intervention.
  • the methods described herein could be used in other contexts as well, for example in archaeology, or forensics, where the goal is to determine ploidy information or other genetic information, where the genetic material from the target individual is in the presence of genetic material from other individuals.
  • the alleles of interest may be SNPs, or they may be larger regions of DNA.
  • the goal of the methods described herein is to determine genotypic data of the target individual in the presence of other, contaminating DNA, originating from other individuals.
  • the genotypic data that is desired involves the ploidy state of the target individual.
  • the target DNA is fetal DNA, and thus the target individual is a gestating fetus, and where the fetal DNA is isolated, preferentially enriched, or simply measured in maternal blood or plasma, and where the maternal DNA is the genetic material from other individuals.
  • the fetal DNA may be free floating, extracellular DNA, or it may be cellular DNA, for example, from enucleated fetal red blood cells as found in maternal blood or plasma samples.
  • the genetic measurements of the DNA may be done using a combination of amplification methods, and genotyping methods, such as those described in the patent applications listed in this document, and may also include other methods such as rolling circle amplification, bridge sequencing, and other DNA amplification, genotyping and sequencing methods known in the art.
  • the parental genetic data may be used to increase the accuracy with which the ploidy determination may be made.
  • the maternal genetic data may be used to increase the accuracy with which the ploidy determination may be made.
  • the knowledge of the maternal haplotypic genetic data may be used along with the genetic data measured from free floating DNA found in the blood to determine which haplotypes from the mother and father are present in the fetus. This knowledge may be used to determine the presence or absence of specific disease related genes, or other phenotypically correlated genes, in the genotype of the fetus. It may also be used to infer the more complete genotypic information of the fetus, specifically, allele calls, the presence of insertions, deletions, transpositions, and other genetic modifications that may correlate with diseases, conditions, or other phenotypes.
  • the ploidy state of a gestating fetus may be determined using a method that looks at allele ratios. Some methods determine fetal ploidy state by comparing numerical sequencing output DNA counts from a suspect chromosome to a reference euploid chromosome. In contrast to that concept, the allele ratio method determines fetal ploidy state by looking at allele ratios for different parental contexts on one chromosome. This method has no need to use a reference chromosome.
  • Parent context A:B Euploidy Child genotype A:B P-U tri* Child genotype A:B P-M tri* Child genotype AA
  • this table represents only a subset of the parental contexts and a subset of the possible ploidy states that this method is designed to differentiate.
  • the profile of A:B ratios among different contexts will be different for different ploidy states, and the profiles should be distinctive enough that it will be possible to determine the ploidy state for a chromosome with high accuracy.
  • the calculated value of r may be determined using a different method, or it can be determined using a maximum likelihood approach to this method.
  • the method requires the maternal genotypic knowledge.
  • the method requires paternal genotypic knowledge.
  • the method does not require paternal genotypic knowledge.
  • the percent fetal fraction and the ratio of maternal to fetal DNA are essentially equivalent, and can be used interchangeably after applying the appropriate linear algebraic transformation.
  • r [percent fetal fraction] / [1-percent fetal fraction].
  • the SNP130 database has been linked with Matlab in order to identify sequences that have SNPs in them.
  • the goal is to determine how well the observed allele ratio reflects expected allele ratio in genotype. These are healthy adult samples, so SNPs should either be homozygous, in which case they should have a 1:0 allele ration, or heterozygous, in which case they should have a 1:1 allele ratio.
  • FIGS. 14 and 15 show the allele ratios at all SNPs as a function of the number of sequences. All mapped sequences are included for which there is a base call at the SNP location (i.e., no minimum phred score is required). The dotted lines show 1-sigma bounds for the observed rate, modeling each sequence as an independent Bernoulli trial. Note that the x-axis varies between plots.
  • x in (0, 0.5, 1 ⁇ corresponds to ⁇ MM, RM, RR ⁇ .
  • z the allele observed in a sequence, z in ⁇ R, M ⁇ .
  • P(gc) and P(bc) are calculated from the phred score.
  • P(z R
  • bc,x) 1-x, assuming that probes are unbiased.
  • the likelihood of a set of measurements at the same SNP is simply the product of the individual likelihoods. This method accounts for varying phred scores. In another embodiment, it is possible to account for varying confidence in the sequence mapping. Given the set of n sequences for a single SNP, the combination of likelihoods results in a polynomial of order n that can be evaluated at the candidate allele ratios that represent the various hypotheses.
  • the polynomial likelihood function on the allele ratio becomes intractable.
  • a SNP can be classified as RR, RM, or MM by considering the allele ratios ⁇ 1, 0.5, 0 ⁇ , or a maximum likelihood estimate of the allele ratio can be calculated.
  • a SNP is classified as RM in two different samples, it is possible to compare the MLE estimates of the allele ratio to look for consistent "probe bias.”
  • SNPs were taken where exactly two samples are classified as RM, and plotted are the MLE allele ratios for those samples. If all probes were perfectly unbiased, the dots should be clustered at (0.5, 0.5). If the probes had perfectly consistent bias, the dots would lie along the 1:1 line, subject to some standard deviation.
  • FIG. 16 shows 159 SNPs that were classified RM on two samples. Note that some dots lie on the perimeter of the plot, showing that the MLE estimate of the allele ratio disagrees with the classification.
  • Phred scores range from 0 to 30 and are reported as integers; in this case integer bins are used. Count the number of bases in each bin, and the number of reference calls in each bin.
  • FIG. 17 (bottom) uses an alternative definition for the phred score which was used in older versions of this sequencing platform. This prediction more closely matches the data.
  • the DNA sequence can be classified as maternal, with P(x
  • maternal) P(x
  • fetal) P(x
  • a distributions of maternal and fetal sequence lengths can be determined that is specific for that sample by considering the sequences that can be assigned as maternal or fetal with high probability, and then that sample specific distribution can be used as the expected size distribution for that sample.
  • a protocol with a number of parameters is set, and then the same protocol is executed with the same parameters for each of the patients in the trial.
  • one pertinent parameter is the number of reads.
  • the number of reads may refer to the number of actual reads, the number of intended reads, fractional lanes, full lanes, or full flow cells on a sequencer. In these studies, the number of reads is typically set at a level that will ensure that all or nearly all of the samples achieve the desired level of accuracy.
  • Sequencing is currently an expensive technology, a cost of roughly $200 per 5 mappable million reads, and while the price is dropping, any method which allows a sequencing based diagnostic to operate at a similar level of accuracy but with fewer reads will necessarily save a considerable amount of money.
  • the accuracy of a ploidy determination is typically dependent on a number of factors, including the number of reads and the fraction of fetal DNA in the mixture.
  • the accuracy is typically higher when the fraction of fetal DNA in the mixture is higher.
  • the accuracy is typically higher if the number of reads is greater. It is possible to have a situation with two cases where the ploidy state is determined with comparable accuracies wherein the first case has a lower fraction of fetal DNA in the mixture than the second, and more reads were sequenced in the first case than the second. It is possible to use the estimated fraction of fetal DNA in the mixture as a guide in determining the number of reads necessary to achieve a given level of accuracy.
  • a set of samples can be run where different samples in the set are sequenced to different reads depths, wherein the number of reads run on each of the samples is chosen to achieve a given level of accuracy given the calculated fraction of fetal DNA in each mixture.
  • this may entail making a measurement of the mixed sample to determine the fraction of fetal DNA in the mixture; this estimation of the fetal fraction may be done with sequencing, it may be done with TaqMan, it may be done with qPCR, it may be done with SNP arrays, it may be done with any method that can distinguish different alleles at a given loci.
  • the need for a fetal fraction estimate may be eliminated by including hypotheses that cover all or a selected set of fetal fractions in the set of hypotheses that are considered when comparing to the actual measured data. After the fraction fetal DNA in the mixture has been determined, the number of sequences to be read for each sample may be determined.
  • 100 pregnant women visit their respective OB's, and their blood is drawn into blood tubes with an anti-lysant. They each take home a kit for the father of their gestating fetus who gives a saliva sample. Both sets of genetic materials for all 100 couples are sent back to the laboratory, where the mother blood is spun down and the buffy coat is isolated, as well as the serum.
  • the serum contains a mixture of maternal DNA as well as placentally derived DNA.
  • the maternal buffy coat and the paternal blood is genotyped using a SNP array, and the DNA in the maternal plasma samples are targeted with SURESELECT hybridization probes.
  • the DNA that was pulled down with the probes is used to generate 100 tagged libraries, one for each of the maternal samples, where each sample is tagged with a different tag.
  • a fraction from each library is withdrawn, each of those fractions are mixed together and added to two lanes of a ILLUMINA HISEQ DNA sequencer in a multiplexed fashion, wherein each lane resulted in approximately 50 million mappable reads, resulting in approximately 100 million mappable reads on the 100 multiplexed mixtures, or approximately 1 million reads per sample.
  • the sequence reads were used to determine the fraction of fetal DNA in each mixture. 50 of the samples had more than 15% fetal DNA in the mixture, and the 1 million reads were sufficient to determine the ploidy status of the fetuses with a 99.9% confidence.
  • 25 had between 10 and 15% fetal DNA; a fraction of each of the relevant libraries prepped from these mixtures were multiplexed and run down one lane of the HISEQ generating an additional 2 million reads for each sample.
  • the two sets of sequence data for each of the mixture with between 10 and 15% fetal DNA were added together, and the resulting 3 million reads per sample which were sufficient to determine the ploidy state of those fetuses with 99.9% confidence.
  • This method required six lanes of sequencing on a HISEQ machine to achieve 99.9% accuracy over 100 samples. If the same number of runs had been required for every sample, to ensure that every ploidy determination was made with a 99.9% accuracy, it would have taken 25 lanes of sequencing, and if a no-call rate or error rate of 4% was tolerated, it could have been achieved with 14 lanes of sequencing.
  • the congenital disorder is a malformation, neural tube defect, chromosome abnormality, Down syndrome (or trisomy 21), Trisomy 18, spina bifida, cleft palate, Tay Sachs disease, sickle cell anemia, thalassemia, cystic fibrosis, Huntington's disease, and/or fragile x syndrome.
  • Chromosome abnormalities include, but are not limited to, Down syndrome (extra chromosome 21), Turner Syndrome (45X0) and Klinefelter's syndrome (a male with 2 X chromosomes).
  • the malformation is a limb malformation.
  • Limb malformations include, but are not limited to, amelia, ectrodactyly, phocomelia, polymelia, polydactyly, syndactyly, polysyndactyly, oligodactyly, brachydactyly, achondroplasia, congenital aplasia or hypoplasia, amniotic band syndrome, and cleidocranial dysostosis.
  • the malformation is a congenital malformation of the heart.
  • Congenital malformations of the heart include, but are not limited to, patent ductus arteriosus, atrial septal defect, ventricular septal defect, and tetralogy of fallot.
  • the malformation is a congenital malformation of the nervous system.
  • Congenital malformations of the nervous system include, but are not limited to, neural tube defects (e.g., spina bifida, meningocele, meningomyelocele, encephalocele and anencephaly), Arnold-Chiari malformation, the Dandy-Walker malformation, hydrocephalus, microencephaly, megencephaly, lissencephaly, polymicrogyria, holoprosencephaly, and agenesis of the corpus callosum.
  • neural tube defects e.g., spina bifida, meningocele, meningomyelocele, encephalocele and anencephaly
  • Arnold-Chiari malformation e.g., the Dandy-Walker malformation
  • hydrocephalus e.g., microencephaly, megencephaly, lissencephaly, polymicrogyria
  • the malformation is a congenital malformation of the gastrointestinal system.
  • Congenital malformations of the gastrointestinal system include, but are not limited to, stenosis, atresia, and imperforate anus.
  • the systems, methods, and techniques of the present disclosure are used in methods to increase the probability of implanting an embryo obtained by in vitro fertilization that is at a reduced risk of carrying a predisposition for a genetic disease.
  • the genetic disease is either monogenic or multigenic.
  • Genetic diseases include, but are not limited to, Bloom Syndrome, Canavan Disease, Cystic fibrosis, Familial Dysautonomia, Riley-Day syndrome, Fanconi Anemia (Group C), Gaucher Disease, Glycogen storage disease 1a, Maple syrup urine disease, Mucolipidosis IV, Niemann-Pick Disease, Tay-Sachs disease, Beta thalessemia, Sickle cell anemia, Alpha thalessemia, Beta thalessemia, Factor XI Deficiency, Friedreich's Ataxia, MCAD, Parkinson disease- juvenile, Connexin26, SMA, Rett syndrome, Phenylketonuria, Becker Muscular Dystrophy, Duchennes Muscular Dystrophy, Fragile X syndrome, Hemophilia A, Alzheimer dementia- early onset, Breast/Ovarian cancer, Colon cancer, Diabetes/MODY, Huntington disease, Myotonic Muscular Dystrophy, Parkinson
  • the method may further comprise administering prenatal or post-natal treatments for the congenital disorder. In some embodiments, the method may further comprise determining whether the fetus is likely to be afflicted with a malformation. In some embodiments, the method may further comprise administering prenatal or post-natal treatments for the malformation. In some embodiments, the method may further comprise determining whether the fetus is likely to be afflicted with a genetic disease. In some embodiments, the method may further comprise administering prenatal or post-natal treatments for the genetic disease. In some embodiments, the prenatal or post-natal treatment is taken from the group comprising pharmaceutical based intervention, surgery, genetic therapy, nutritional therapy, or combinations thereof.
  • the method may further comprise generating a report comprising information pertaining to the determination.
  • the report may contain information pertaining to the determination as determined in any preceding or subsequent claim.
  • the method may further comprise generating a report comprising the likelihood of a fetus displaying a phenotype, wherein the likelihood of the fetus displaying the phenotype was estimated using the determination as determined in any preceding or subsequent claim.
  • DNA that originated from cancer that is living in a host can be found in the blood of the host.
  • genetic diagnoses can equally well be made from the measurement of mixed DNA found in host blood.
  • the genetic diagnoses may include aneuploidy states, or gene mutations. Any claim in that patent that reads on determining the ploidy state or genetic state of a fetus from the measurements made on maternal blood can equally well read on determining the ploidy state or genetic state of a cancer from the measurements on host blood.
  • the method may allow one to determine the ploidy status of a cancer, the method comprising obtaining a mixed sample that contains genetic material from the host, and genetic material from the cancer, measuring the DNA in the mixed sample, calculating the fraction of DNA that is of cancer origin in the mixed sample, and determining the ploidy status of the cancer using the measurements made on the mixed sample and the calculated fraction.
  • the method may further comprise administering a cancer therapeutic based on the determination of the ploidy state of the cancer.
  • the method may further comprise administering a cancer therapeutic based on the determination of the ploidy state of the cancer, wherein the cancer therapeutic is taken from the group comprising a pharmaceutical, a biologic therapeutic, and antibody based therapy and combination thereof.
  • a method which can provide more information for a given number of reads, or alternately, require a fewer number of reads for a given level of accuracy, is to focus on reads that cover SNPs, where the context of the parents are known at that SNP. Furthermore, there are a number of methods, such as circularizing probes or capture probes, for targeting specific SNPs that can enhance the number of reads that map to those SNPs. In a targeted approach to sequencing maternal plasma the question then becomes, which SNPs should one target? In general, the most informative context is AA
  • the second most informative context is AA
  • BB context there is a 100% chance that there is a fetal allele that is a HISNP.
  • AB context there is a 50% chance that there is a fetal allele that is a HISNP.
  • the remaining three contexts are of different levels of informativeness for given situations. Note, for reasons of symmetry, the nine contexts can be collapsed into five; e.g. AB
  • a method for selecting SNPs for targeting that maximizes the chance of obtaining maximally informative SNPs.
  • the set of SNPs with the highest minor allele frequency are selected for targeting.
  • the maximum minor allele frequency possible is 50%. From a set of SNPs with known minor allele frequencies, those with the highest minor allele frequency may be selected.
  • the SNPs are selected where the parent contexts maximize the chance that the fetus will have a HISNP at that locus. Note that when no apriori knowledge of the actual parental contexts is available, those loci with the highest minor allele frequency will result in the maximal likelihood of the fetus having a HISNP at that allele.
  • those loci may be chosen where the father's context is homozygous for allele that is the minor allele in the population. Alternately, those loci may be chosen where the paternal context is heterozygous. In the case where the parental genotypes are both known, those loci may be chosen that are from the AA
  • three alleles may have some frequency in the population, (e.g. A, T and G).
  • the set of SNPs where the sum of the minor allele frequencies are greatest are selected for targeting.
  • the set of SNPs for targeting is selected by selecting loci that maximize the chance that the fetus will have a HISNP at that locus. Note that a locus where the allele frequencies that are 60%/40% will not be as likely to result in a fetal allele that is a HISNP as a context that is, for example, 60%/30%/10%.
  • different populations may have different allele frequencies.
  • the parents are from different population groups where those two populations have different allele frequencies at some loci, then it is possible to choose loci to target that provide a greater likelihood of the fetus having a HISNP that by using one overall population allele frequency model.
  • one way to maximize the likelihood of a given SNP being from a highly informative parental context is to choose a set of SNPs where the heterozygosity is as low as possible but different from one another. For example, if the mother is Caucasian and the father is Asian, and within the Caucasian population the SNP has a frequency of 40% T and 60% G, and within the Asian population the SNP has a frequency of 60% T and 40% G, then the frequency of the parental context is AA
  • locus set #1 0.5 and 0.3
  • locus set #2 0.4 and 0.4.
  • the (0.5/0.3) locus set will contain, on average, 14.5% of SNPs with the AA
  • the (0.4/0.4) locus set will contain, on average, 11.52% of SNPs with the AA
  • the (0.5/0.3) locus set will contain, on average, 21.0% of SNPs with the AA
  • the (0.4/0.4) locus set will contain, on average, 25.0% of SNPs with the AA
  • the (0.5/0.3) locus set will contain, on average, 25.0% fetal HISNP, and the (0.4/0.4) locus set will contain, on average, 24.0% fetal HISNPS.
  • Some of these methods involve making measurements of the fetal DNA using SNP arrays, some methods involve untargeted sequencing, and some methods involve targeted sequencing.
  • the targeted sequencing may target SNPs, it may target STRs, it may target other loci, or is may target some combination of those loci.
  • the method may involve using a commercial or proprietary allele caller than calls the identity of the alleles from the intensity data that comes from the sensors in the machine doing the measuring.
  • the ILLUMINA INFINIUM system or the AFFYMETRIX GENECHIP microarray system involves beads or microchips with attached DNA sequences that can hybridize to complementary segments of DNA.
  • sequencing methods for example the ILLUMINA SOLEXA GENOME SEQUENCER or the ABI SOLID GENOME SEQUENCER, wherein the genetic sequence of fragments of DNA are sequenced.
  • genotypic or sequencing data is typically determined on the basis of fluorescent signals (or the lack thereof).
  • These systems typically are combined with low level software packages that make specific allele calls (secondary genetic data) from the analog output of the fluorescent or other detection device (primary genetic data).
  • the software will make a call, for example, that a certain SNP is present or not present if the fluorescent intensity is measure above or below a certain threshold.
  • the output of a sequencer is a chromatogram that indicates the level of fluorescence detected for each of the dyes, and the software will make a call that a certain base pair is A or T or C or G.
  • High throughput sequencers typically make a series of such measurements, called a read, that represents the most likely structure of the DNA sequence that was sequenced.
  • the direct analog output of the chromatogram is defined here to be the primary genetic data, and the base pair / SNP calls made by the software are considered here to be the secondary genetic data.
  • primary data refers to the raw intensity data that is the unprocessed output of a genotyping platform, where the genotyping platform may refer to a SNP array, or to a sequencing platform.
  • the secondary genetic data refers to the processed genetic data, where an allele call has been made, or the sequence data has been assigned base pairs, and/or the sequence reads have been mapped to the genome.
  • SNP calls and sequence reads that is, the secondary genetic data, that the genotyping software produces.
  • DNA NEXUS, ELAND or MAQ will take the sequencing reads and map them to the genome.
  • complex informatics such as PARENTAL SUPPORTTM
  • PARENTAL SUPPORTTM may leverage a large number of SNP calls to determine the genotype of an individual.
  • preimplantation genetic diagnosis it is possible to take a set of sequence reads that are mapped to the genome, and by taking a normalized count of the reads that are mapped to each chromosome, or section of a chromosome, it may be possible to determine the ploidy state of an individual.
  • non-invasive prenatal diagnosis it may be possible to take a set of sequence reads that have been measured on DNA present in maternal serum, and map them to the genome. One may then take a normalized count of the reads that are mapped to each chromosome, or section of a chromosome, and use that data to determine the ploidy state of an individual. For example, it may be possible to conclude that those chromosomes that have a disproportionately large number of reads are trisomic in the fetus that is gestating in the mother from which the blood was drawn.
  • the output of the measuring instruments is an analog signal.
  • the software may call the base pair a T
  • the call is the call that the software believes to be most likely.
  • the call may be of low confidence, for example, the analog signal may indicate that the particular base pair is only 90% likely to be a T, and 10% likely to be an A.
  • the genotype calling software that is associated with a SNP array reader may call a certain allele to be GG.
  • the underlying analog signal may indicate that it is only 90% likely that the allele is GG, and 10% likely that the allele is GT.
  • the higher level applications use the genotype calls and sequence calls made by the lower level software, they are losing some information. That is, the primary genetic data, as measured directly by the genotyping platform, may be messier than the secondary genetic data that is determined by the attached software packages, but it contains more information.
  • mapping the secondary genetic data sequences to the genome many reads are thrown out because some bases are not read with enough clarity and or mapping is not clear.
  • all or many of those reads that may have been thrown out when first converted to secondary genetic data sequence read can be used by treating the reads in a probabilistic manner.
  • the higher level software does not rely on the allele calls, SNP calls, or sequence reads that are determined by the lower level software. Instead, the higher level software bases its calculations on the analog signals directly measured from the genotyping platform.
  • an informatics based method such as PARENTAL SUPPORTTM is modified so that its ability to reconstruct the genetic data of the embryo / fetus / child is engineered to directly use the primary genetic data as measured by the genotyping platform.
  • an informatics based method such as PARENTAL SUPPORTTM is able to make allele calls, and/or chromosome copy number calls using primary genetic data, and not using the secondary genetic data.
  • all genetic calls, SNPs calls, sequence reads, sequence mapping is treated in a probabilistic manner by using the raw intensity data as measured directly by the genotyping platform, rather than converting the primary genetic data to secondary genetic calls.
  • the method can increase the accuracy of genetic data of a target individual which incorporates genetic data of at least one related individual, the method comprising obtaining primary genetic data specific to a target individual's genome and genetic data specific to the genome(s) of the related individual(s), creating a set of one or more hypotheses concerning which segments of which chromosomes from the related individual(s) correspond to those segments in the target individual's genome, determining the probability of each of the hypotheses given the target individual's primary genetic data and the related individual(s)'s genetic data, and using the probabilities associated with each hypothesis to determine the most likely state of the actual genetic material of the target individual.
  • the method can determining the number of copies of a segment of a chromosome in the genome of a target individual, the method comprising creating a set of copy number hypotheses about how many copies of the chromosome segment are present in the genome of a target individual, incorporating primary genetic data from the target individual and genetic information from one or more related individuals into a data set, estimating the characteristics of the platform response associated with the data set, where the platform response may vary from one experiment to another, computing the conditional probabilities of each copy number hypothesis, given the data set and the platform response characteristics, and determining the copy number of the chromosome segment based on the most probable copy number hypothesis.
  • the method can determine a ploidy state of at least one chromosome in a target individual, the method comprising obtaining primary genetic data from the target individual and from one or more related individuals, creating a set of at least one ploidy state hypothesis for each of the chromosomes of the target individual, using one or more expert techniques to determine a statistical probability for each ploidy state hypothesis in the set, for each expert technique used, given the obtained genetic data, combining, for each ploidy state hypothesis, the statistical probabilities as determined by the one or more expert techniques, and determining the ploidy state for each of the chromosomes in the target individual based on the combined statistical probabilities of each of the ploidy state hypotheses.
  • the method can determine an allelic state in a set of alleles, in a target individual, and from one or both parents of the target individual, and optionally from one or more related individuals, the method comprising obtaining primary genetic data from the target individual, and from the one or both parents, and from any related individuals, creating a set of at least one allelic hypothesis for the target individual, and for the one or both parents, and optionally for the one or more related individuals, where the hypotheses describe possible allelic states in the set of alleles, determining a statistical probability for each allelic hypothesis in the set of hypotheses given the obtained genetic data, and determining the allelic state for each of the alleles in the set of alleles for the target individual, and for the one or both parents, and optionally for the one or more related individuals, based on the statistical probabilities of each of the allelic hypotheses.
  • the genetic data of the mixed sample may comprise sequence data wherein the sequence data may not uniquely map to the human genome. In some embodiments, the genetic data of the mixed sample may comprise sequence data wherein the sequence data maps to a plurality of locations in the genome, wherein each possible mapping is associated with a probability that the given mapping is correct. In some embodiments, the sequence reads are not assumed to be associated with a particular position in the genome. In some embodiments, the sequence reads are associated with a plurality of positions in the genome, and an associated probability belonging to that position.
  • triple test a test wherein the levels of several (commonly two, three, four or five) different hormones are measured in maternal blood.
  • multiple methods are used to determine the likelihood of a given outcome, where none of the methods are definitive in and of themselves, it is possible to combine the information given by those methods to make a prediction that is more accurate than any of the individual methods.
  • combining the information given by the three different hormones can result in a prediction of genetic abnormalities that is more accurate than the individual hormone levels may predict.
  • a “more accurate” method may refer to a method for diagnosing an abnormality that has a lower false negative rate at a given false positive rate.
  • one or more of the predictions are made based on the genetic data known about the fetus, where the genetic knowledge was determined using the PARENTAL SUPPORTTM method, that is, using genetic data of individual related to the fetus to determine the genetic data of the fetus with greater accuracy.
  • the genetic data may include ploidy states of the fetus. In some embodiments, the genetic data may refer to a set of allele calls on the genome of the fetus. In some embodiments some of the predictions may have been made using the triple test. In some embodiments, some of the predictions may have been made using measurements of other hormone levels in maternal blood. In some embodiments, predictions made by methods considered diagnoses may be combined with predictions made by methods considered screening. In some embodiments, the method involves measuring maternal blood levels of alpha-fetoprotein (AFP). In some embodiments, the method involves measuring maternal blood levels of unconjugated estriol (UE 3 ).
  • AFP alpha-fetoprotein
  • UE 3 unconjugated estriol
  • the method involves measuring maternal blood levels of beta human chorionic gonadotropin (beta-hCG). In some embodiments, the method involves measuring maternal blood levels of invasive trophoblast antigen (ITA). In some embodiments, the method involves measuring maternal blood levels of inhibin. In some embodiments, the method involves measuring maternal blood levels of pregnancy-associated plasma protein A (PAPP-A). In some embodiments, the method involves measuring maternal blood levels of other hormones or maternal serum markers. In some embodiments, some of the predictions may have been made using other methods. In some embodiments, some of the predictions may have been made using a fully integrated test such as one that combines ultrasound and blood test at around 12 weeks of pregnancy and a second blood test at around 16 weeks. In some embodiments, the method involves measuring the fetal nuchal translucency (NT). In some embodiments, the method involves using the measured levels of the aforementioned hormones for making predictions. In some embodiments the method involves a combination of the aforementioned methods.
  • ITA invasive trophoblast antigen
  • Detection rates (DRs) and false-positive rates (FPRs) could be calculated by taking the proportions with risks above a given risk threshold.
  • Another method could involve a situation with four measured hormone levels, where the probability distribution around those hormones is known: p(x 1 , x 2 , x 3 , x 4
  • the ploidy state for the target individual is determined to be the ploidy state that is associated with the hypothesis whose probability is the greatest.
  • one hypothesis will have a normalized, combined probability greater than 90%.
  • Each hypothesis is associated with one, or a set of, ploidy states, and the ploidy state associated with the hypothesis whose normalized, combined probability is greater than 90%, or some other threshold value, such as 50%, 80%, 95%, 98%, 99%, or 99.9%, may be chosen as the threshold required for a hypothesis to be called as the determined ploidy state.
  • phased parental haplotypic data it is possible to use the phased parental haplotypic data to detect the presence of more than one homolog from the father, implying that the genetic material from more than one child is present in the blood.
  • chromosomes that are expected to be euploid in a fetus, one could rule out the possibility that the fetus was afflicted with a trisomy.
  • the methods described herein can be used for non-invasive gender determination at a very early gestational age, for example as early as four week, as early as five weeks, as early as six weeks, as early as seven weeks, as early as eight weeks, as early as nine weeks, as early as ten weeks, as early as eleven weeks, and as early as twelve weeks.
  • Non-invasive prenatal diagnosis involves the ability to determine the genetic state of a gestating fetus using non-invasive methods. Typically, this involves a blood draw from the mother, and the use of genetic material from the mother that may be found in the maternal blood, or some portion of the maternal blood. There may be other sources of fetal genetic material available via methods other than a blood draw. In the case of the fetal genetic material available in maternal blood, there are two main categories: (1) whole fetal cells, for example, nucleated fetal red blood cells, and (2) free floating fetal DNA.
  • fetal cells can persist in maternal blood for an extended period of time such that it is possible to isolate a cell from a pregnant woman that contains the DNA from a child or fetus from a prior pregnancy. There is also evidence that the free floating fetal DNA is cleared from the system in a matter of weeks.
  • One challenge is how to determine the identity of the individual whose genetic material is contained in the cell, namely to ensure that the measured genetic material is not from a fetus from a prior pregnancy.
  • the knowledge of the maternal genetic material can be used to ensure that the genetic material in question is not maternal genetic material.
  • informatics based methods such as PARENTAL SUPPORTTM, as described in this document or any of the patents referenced in this document.
  • the blood drawn from the pregnant mother may be separated into a fraction comprising free floating fetal DNA, and a fraction comprising nucleated red blood cells.
  • the free floating DNA may optionally be enriched, and the genotypic information of the DNA may be measured.
  • the knowledge of the maternal genotype may be used to determine aspects of the fetal genotype. These aspects may refer to ploidy state, and/or a set of allele identities.
  • individual nucleated red blood cells may be genotyped using methods described elsewhere in this document, and other referent patents, especially those mentioned in the first section of this document.
  • the knowledge of the maternal genome would allow one to determine whether or not any given single blood cell is genetically maternal.
  • this aspect of the present disclosure allows one to use the genetic knowledge of the mother, and possibly the genetic information from other related individuals, such as the father, along with the measured genetic information from the free floating DNA found in maternal blood to determine whether an isolated nucleated cell found in maternal blood is either (a) genetically maternal, (b) genetically from the fetus currently gestating, or (c) genetically from a fetus from a prior pregnancy.
  • a method for determining the ploidy state of one or more chromosome in a target individual may include any of the following steps, and combinations thereof: Amplification of the DNA, a process which transforms a small amount of genetic material to a larger amount of genetic material that contains a similar set of genetic data, can be done by a wide variety of methods, including, but not limited to, Polymerase Chain Reaction (PCR), ligand mediated PCR, degenerative oligonucleotide primer PCR, Multiple Displacement Amplification, allele-specific amplification techniques, Molecular Inversion Probes (MIP), padlock probes, other circularizing probes, and combination thereof.
  • PCR Polymerase Chain Reaction
  • ligand mediated PCR ligand mediated PCR
  • degenerative oligonucleotide primer PCR Multiple Displacement Amplification
  • MIP Molecular Inversion Probes
  • padlock probes other circularizing probes, and combination thereof.
  • the DNA amplification transforms the initial sample of DNA into a sample of DNA that is similar in the set of sequences, but of much greater quantity. In some cases, amplification may not be required.
  • the genetic data of the target individual and/or of the related individual can be transformed from a molecular state to an electronic state by measuring the appropriate genetic material using tools and or techniques taken from a group including, but not limited to: genotyping microarrays, and high throughput sequencing.
  • Some high throughput sequencing methods include Sanger DNA sequencing, pyrosequencing, the ILLUMINA SOLEXA platform, ILLUMINA's GENOME ANALYZER, or APPLIED BIOSYSTEM's 454 sequencing platform, HELICOS's TRUE SINGLE MOLECULE SEQUENCING platform, HALCYON MOLECULAR's electron microscope sequencing method, or any other sequencing method,. All of these methods physically transform the genetic data stored in a sample of DNA into a set of genetic data that is typically stored in a memory device en route to being processed.
  • Any relevant individual's genetic data can be measured by analyzing substances taken from a group including, but not limited to: the individual's bulk diploid tissue, one or more diploid cells from the individual, one or more haploid cells from the individual, one or more blastomeres from the target individual, extra-cellular genetic material found on the individual, extra-cellular genetic material from the individual found in maternal blood, cells from the individual found in maternal blood, one or more embryos created from (a) gamete(s) from the related individual, one or more blastomeres taken from such an embryo, extra-cellular genetic material found on the related individual, genetic material known to have originated from the related individual, and combinations thereof.
  • a set of at least one ploidy state hypothesis may be created for each of the chromosomes of interest of the target individual.
  • Each of the ploidy state hypotheses may refer to one possible ploidy state of the chromosome or chromosome segment of the target individual.
  • the set of hypotheses may include some or all of the possible ploidy states that the chromosome of the target individual may be expected to have.
  • Some of the possible ploidy states may include nullsomy, monosomy, disomy, uniparental disomy, euploidy, trisomy, matching trisomy, unmatching trisomy, maternal trisomy, paternal trisomy, tetrasomy, balanced (2:2) tetrasomy, unbalanced (3:1) tetrasomy, other aneuploidy, and they may additionally involve unbalanced translocations, balanced translocations, Robertsonian translocations, recombinations, deletions, insertions, crossovers, and combinations thereof.
  • the knowledge of the determined ploidy state may be used to make a clinical decision.
  • This knowledge typically stored as a physical arrangement of matter in a memory device, may then be transformed into a report. The report may then be acted upon.
  • the clinical decision may involve an intervention designed to decrease the severity of the phenotypic presentation of a genetic disorder, or a decision to take relevant steps to prepare for a special needs child.
  • any of the methods described herein may be modified to allow for multiple targets to come from same target individual, for example, multiple blood draws from the same pregnant mother. This may improve the accuracy of the model, as multiple genetic measurements may provide more data with which the target genotype may be determined.
  • one set of target genetic data served as the primary data which was reported, and the other served as data to double-check the primary target genetic data.
  • a plurality of sets of genetic data, each measured from genetic material taken from the target individual are considered in parallel, and thus both sets of target genetic data serve to help determine which sections of parental genetic data, measured with high accuracy, composes the fetal genome.
  • the source of the genetic material to be used in determining the genetic state of the fetus may be fetal cells, such as nucleated fetal red blood cells, isolated from the maternal blood.
  • the method may involve obtaining a blood sample from the pregnant mother.
  • the method may involve isolating a fetal red blood cell using visual techniques, based on the idea that a certain combination of colors are uniquely associated with nucleated red blood cell, and a similar combination of colors is not associated with any other present cell in the maternal blood.
  • the combination of colors associated with the nucleated red blood cells may include the red color of the hemoglobin around the nucleus, which color may be made more distinct by staining, and the color of the nuclear material which can be stained, for example, blue.
  • nucleated red blood cells By isolating the cells from maternal blood and spreading them over a slide, and then identifying those points at which one sees both red (from the Hemoglobin) and blue (from the nuclear material) one may be able to identify the location of nucleated red blood cells. One may then extract those nucleated red blood cells using a micromanipulator, use genotyping and/or sequencing techniques to measure aspects of the genotype of the genetic material in those cells.
  • one may stain the nucleated red blood cell with a die that only fluoresces in the presence of fetal hemoglobin and not maternal hemoglobin, and so remove the ambiguity between whether a nucleated red blood cell is derived from the mother or the fetus.
  • Some embodiments of the present disclosure may involve staining or otherwise marking nuclear material.
  • Some embodiments of the present disclosure may involve specifically marking fetal nuclear material using fetal cell specific antibodies.
  • the target individual is a fetus
  • the different genotype measurements are made on a plurality of DNA samples from the fetus.
  • the fetal DNA samples are from isolated fetal cells where the fetal cells may be mixed with maternal cells.
  • the fetal DNA samples are from free floating fetal DNA, where the fetal DNA may be mixed with free floating maternal DNA.
  • the fetal DNA may be mixed with maternal DNA in ratios ranging from 99.9:0.1% to 99:1%; 99:1% to 90:10%; 90:10% to 50:50%; 50:50% to 10:90%; or 10:90% to 1:99%; 1:99% to 0.1:99.9%.
  • the method may be used for the purpose of paternity testing. For example, given the SNP-based genotypic information from the mother, and from a man who may or may not be the genetic father, and the measured genotypic information from the mixed sample, it is possible to determine if the genotypic information of the male indeed represents that actual genetic father of the gestating fetus. A simple way to do this is to simply look at the contexts where the mother is AA, and the possible father is AB or BB. In these cases, one may expect to see the father contribution half (AA
  • One embodiment of the present disclosure could be as follows: a pregnant woman wants to know if her fetus is afflicted with Down Syndrome, and/or if it will suffer from Cystic Fibrosis, and she does not wish to bear a child that is afflicted with either of these conditions. A doctor takes her blood, and stains the hemoglobin with one marker so that it appears clearly red, and stains nuclear material with another marker so that it appears clearly blue. Knowing that maternal red blood cells are typically anuclear, while a high proportion of fetal cells contain a nucleus, he is able to visually isolate a number of nucleated red blood cells by identifying those cells that show both a red and blue color.
  • the PARENTAL SUPPORTTM method is able to determine that six of the ten cells are maternal blood cells, and four of the ten cells are fetal cells. If a child has already been born to a pregnant mother, PARENTAL SUPPORTTM can also be used to determine that the fetal cells are distinct from the cells of the born child by making reliable allele calls on the fetal cells and showing that they are dissimilar to those of the born child. Note that this method is similar in concept to the paternal testing embodiment of the present disclosure.
  • the genetic data measured from the fetal cells may be of very poor quality, comprising many allele drop outs, due to the difficulty of genotyping single cells.
  • the clinician is able to use the measured fetal DNA along with the reliable DNA measurements of the parents to infer aspects of the genome of the fetus with high accuracy using PARENTAL SUPPORTTM, thereby transforming the genetic data contained on genetic material from the fetus into the predicted genetic state of the fetus, stored on a computer.
  • the clinician is able to determine both the ploidy state of the fetus, and the presence or absence of a plurality of disease-linked genes of interest. It turns out that the fetus is euploidy, and is not a carrier for cystic fibrosis, and the mother decides to continue the pregnancy.
  • a couple where the mother, who is pregnant, and is of advanced maternal age wants to know whether the gestating fetus has Down syndrome, Turner Syndrome, Prader Willi syndrome, or some other chromosomal abnormality.
  • the obstetrician takes a blood draw from the mother and father.
  • the blood is sent to a laboratory, where a technician centrifuges the maternal sample to isolate the plasma and the buffy coat.
  • the DNA in the buffy coat and the paternal blood sample are transformed through amplification and the genetic data encoded in the amplified genetic material is further transformed from molecularly stored genetic data into electronically stored genetic data by running the genetic material on a SNP array to measure the parental genotypes.
  • the plasma sample is may be further processed by a method such as running a gel, or using a size exclusion column, to isolate specific size fractions of DNA; specifically, molecules of DNA that are shorter than 500 bases are isolated.
  • the mixture of short DNA fragments is prepared into a DNA library suitable for sequencing.
  • the preparation may involve preferential enrichment of certain polymorphic alleles.
  • the preferential enrichment may involve hybrid capture techniques, PCR based selective amplifications techniques, circularizing probe based targeting techniques, or other targeting techniques. Other methods may be used to enrich the fraction of fetal DNA in the sample.
  • the DNA may then be sequenced using a high throughput sequencing method, for example, using the ILLUMINA GAIIx GENOME ANALYZER.
  • the sequencing transforms the information that is encoded molecularly in the DNA into information that is encoded electronically in computer hardware.
  • An informatics based technique that includes the presently disclosed embodiments, such as PARENTAL SUPPORTTM, may be used to determine the ploidy state of the fetus. It is determined that the fetus has Down syndrome. A report is printed out, or sent electronically to the pregnant woman's obstetrician, who transmits the diagnosis to the woman. The woman, her husband, and the doctor sit down and discuss the options.
  • a pregnant woman hereafter referred to as "the mother” may decide that she wants to know whether or not her fetus(es) are carrying any genetic abnormalities or other conditions. She may want to ensure that there are not any gross abnormalities before she is confident to continue the pregnancy. She may go to her obstetrician, who may take a sample of her blood. He may also take a genetic sample, such as a buccal swab, from her cheek. He may also take a genetic sample from the father of the fetus, such as a buccal swab, a sperm sample, or a blood sample. He may send the samples to a clinician. The clinician may enrich the fraction of free floating fetal DNA in the maternal blood sample.
  • the mother may decide that she wants to know whether or not her fetus(es) are carrying any genetic abnormalities or other conditions. She may want to ensure that there are not any gross abnormalities before she is confident to continue the pregnancy. She may go to her obstetrician,
  • the clinician may enrich the fraction of enucleated fetal blood cells in the maternal blood sample.
  • the clinician may use various aspects of the method described herein to determine genotypic data of the fetus. That genotypic data may include the ploidy state of the fetus, and/or the identity of one or a number of alleles in the fetus.
  • a report may be generated summarizing the results of the prenatal diagnosis. The report may be transmitted or mailed to the doctor, who may tell the mother the genetic state of the fetus.
  • Another example may involve a pregnant woman who has been artificially inseminated by a sperm donor, and is pregnant. She is wants to minimize the risk that the fetus she is carrying has a genetic disease. She has blood drawn at a phlebotomist, and techniques described in this disclosure are used to isolate three nucleated fetal red blood cells, and a tissue sample is also collected from the mother and genetic father. The genetic material from the fetus and from the mother and father are amplified as appropriate and genotyped using the ILLUMINA INFINIUM BEADARRAY, and the methods described herein clean and phase the parental and fetal genotype with high accuracy, as well as to make ploidy calls for the fetus.
  • the fetus is found to be euploid, and phenotypic susceptibilities are predicted from the reconstructed fetal genotype, and a report is generated and sent to the mother's physician so that they can decide what clinical decisions may be best.
  • the raw genetic material of the mother and father is transformed by way of amplification to an amount of DNA that is similar in sequence, but larger in quantity. Then, by way of a genotyping method the genotypic data that is encoded by nucleic acids is transformed into genetic measurements that may be stored physically and/or electronically on a memory device, such as those described above.
  • the relevant algorithms that makeup the PARENTAL SUPPORTTM algorithm, relevant parts of which are discussed in detail herein, are translated into a computer program, using a programming language.
  • the computer program on the computer hardware instead of being physically encoded bits and bytes, arranged in a pattern that represents raw measurement data, they become transformed into a pattern that represents a high confidence determination of the ploidy state of the fetus.
  • the details of this transformation will rely on the data itself and the computer language and hardware system used to execute the method described herein, but is predictable if those contexts are known.
  • the data that is physically configured to represent a high quality ploidy determination of the fetus is transformed into a report which may be sent to a health care practitioner. This transformation may be carried out using a printer or a computer display.
  • the report may be a printed copy, on paper or other suitable medium, or else it may be electronic.
  • an electronic report it may be transmitted, it may be physically stored on a memory device at a location on the computer accessible by the health care practitioner; it also may be displayed on a screen so that it may be read.
  • the data may be transformed to a readable format by causing the physical transformation of pixels on the display device. The transformation may be accomplished by way of physically firing electrons at a phosphorescent screen, by way of altering an electric charge that physically changes the transparency of a specific set of pixels on a screen that may lie in front of a substrate that emits or absorbs photons.
  • This transformation may be accomplished by way of changing the nanoscale orientation of the molecules in a liquid crystal, for example, from nematic to cholesteric or smectic phase, at a specific set of pixels.
  • This transformation may be accomplished by way of an electric current causing photons to be emitted from a specific set of pixels made from a plurality of light emitting diodes arranged in a meaningful pattern.
  • This transformation may be accomplished by any other way used to display information, such as a computer screen, or some other output device or way of transmitting information.
  • the health care practitioner may then act on the report, such that the data in the report is transformed into an action.
  • transformations listed herein may be aggregated, such that, for example, one may transform the genetic material of a pregnant mother and the father, through a number of steps outlined in this disclosure, into a medical decision. Alternately, one may transform a set of genotypic measurements into a report that helps a physician treat his pregnant patient.
  • the method described herein can be used to determine the ploidy state of a fetus even when the host mother, i.e. the woman who is pregnant, is not the biological mother of the fetus she is carrying.
  • Some of the math in the presently disclosed embodiments makes hypotheses concerning a limited number of states of aneuploidy. In some cases, for example, only zero, one or two chromosomes are expected to originate from each parent. In some embodiments of the present disclosure, the mathematical derivations can be expanded to take into account other forms of aneuploidy, such as quadrosomy, where three chromosomes originate from one parent, pentasomy, hexasomy etc., without changing the fundamental concepts of the present disclosure. At the same time, it is possible to focus on a smaller number of ploidy states, for example, only trisomy and disomy. Note that ploidy determinations that indicate a non-whole number of chromosomes may indicate mosaicism in a sample of genetic material.
  • the genetic abnormality is a type of aneuploidy, such as Down syndrome (or trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner Syndrome (45X0) Klinefelter's syndrome (a male with 2 X chromosomes), Prader-Willi syndrome, and DiGeorge syndrome.
  • Congenital disorders such as those listed in the prior sentence, are commonly undesirable, and the knowledge that a fetus is afflicted with one or more phenotypic abnormalities may provide the basis for a decision to take necessary precautions to prepare for the birth of a special needs child, or to take some therapeutic approach meant to lessen the severity of a chromosomal abnormality.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Probability & Statistics with Applications (AREA)
  • Ecology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Algebra (AREA)
  • General Physics & Mathematics (AREA)
  • Mathematical Analysis (AREA)

Claims (11)

  1. Verfahren zur Bestimmung eines Ploidiegrades eines Chromosoms in einem heranreifenden Fötus, wobei das Verfahren für eine Vielzahl von heranreifenden Föten ausgeführt wird, das Verfahren umfassend:
    Verarbeiten einer ersten Probe, die DNA von der Mutter des Fötus und DNA von dem Fötus enthält, durch Aufreinigen der DNA, um eine zweite Probe zu erlangen;
    Bestimmen des Prozentsatzes der DNA, der fetal ist, in der zweiten Probe;
    Messen der DNA in der zweiten Probe durch Sequenzieren einer Reihe von polymorphen Allelen an dem Chromosom;
    Berechnen, auf einem Computer, von Allelverhältnissen bei der Reihe von polymorphen Allelen von den DNA-Messungen, die an der zweiten Probe durchgeführt werden;
    Erstellen, an einem Computer, einer Vielzahl von Ploidiehypothesen, die die erwarteten Allelverhältnisse an der Reihe von polymorphen Allelen an dem Chromosom betreffen, für unterschiedliche mögliche Ploidiezustände des Chromosoms;
    Bilden, an einem Computer, eines gemeinsamen Verteilungsmodells für Heterozygotieanteile von jedem polymorphen Allel an dem Chromosom für jede Ploidiehypothese unter Verwendung der DNA-Messungen, die an der zweiten Probe durchgeführt werden;
    Bestimmen, an einem Computer, einer relativen Wahrscheinlichkeit von jeder der Ploidiehypothesen unter Verwendung des gemeinsamen Verteilungsmodells and der Allelverhältnisse, die für die zweite Probe berechnet werden, wobei der Anteil der fetalen DNA in den Proben berücksichtigt wird, wobei die logarithmische Wahrscheinlichkeit der H-Hypothese für einen individuellen SNP i wie folgt definiert ist: LIK i , H = log lik x i | m i , f i , H , cf = ∑ c p c | m i , H * log lik x i | m i , c , H , cf
    Figure imgb0059
     wobei p c | m i , H = ∑ f p c | m i , f , H * p f | p A i
    Figure imgb0060
     wobei
    xi P(A|i,S) ist, was angesichts der Sequenzmessungen S die Wahrscheinlichkeit dessen ist, ein bestimmtes Allel an SNP i zu haben; und
    mi der Mutter-Genotyp ist; und
    cf der bestimmte fetale Anteil ist; und
    pAi die Populationsdichte des A-Allels an dieser SNP ist; und
    Benennen des Ploidiezustands des Fötus durch Auswählen des Ploidiezustands entsprechend der Hypothese mit der größten Wahrscheinlichkeit, und dadurch Bestimmen des Ploidiegrads eines Chromosoms in einem heranwachsenden Fötus; wobei die erste Probe von dem mütterlichen Blut isoliert wurde;
    wobei ein Verarbeiten der ersten Probe ferner ein Amplifizieren der DNA umfasst;
    wobei die Reihe von polymorphen Allelen SNPs sind.
  2. Verfahren nach Anspruch 1, wobei ein Bilden eines gemeinsamen Verteilungsmodells unter Verwendung von Daten über die Wahrscheinlichkeit davon erfolgt, dass sich Chromosomen an verschiedenen Kreuzungsstellen in einem Chromosom kreuzen, um eine Abhängigkeit zwischen polymorphen Allelen an dem Chromosom zu modellieren.
  3. Verfahren nach Anspruch 1, wobei ein Bilden eines gemeinsamen Verteilungsmodells und ein Bestimmen der relativen Wahrscheinlichkeit von jeder Hypothese unter Verwendung eines Verfahrens erfolgt, das die Verwendung eines Bezugschromosoms nicht benötigt.
  4. Verfahren nach Anspruch 1, wobei die DNA-Messungen von der zweiten Probe, die beim Berechnen von Allelverhältnissen und Bestimmen der relativen Wahrscheinlichkeit von jeder Hypothese verwendet werden, genetische Primärdaten umfassen.
  5. Verfahren nach Anspruch 1, wobei ein Auswählen des Ploidiezustands entsprechend der Hypothese mit der größten Wahrscheinlichkeit unter Verwendung von Schätzungen der maximalen Likelihood durchgeführt wird.
  6. Verfahren nach Anspruch 1, wobei ein Benennen des Ploidiezustands des Fötus ferner Folgendes umfasst:
    Kombinieren der relativen Wahrscheinlichkeiten von jeder der Ploidiehypothesen, die unter Verwendung des gemeinsamen Verteilungsmodells und der Allelverhältnisse bestimmt werden, mit relativen Wahrscheinlichkeiten von jeder der Ploidiehypothesen, die unter Verwendung von einer Zählerstandanalyse, Heterozygotieanteilen für Individuen in der Population, parentalen genetischen Informationen, der Wahrscheinlichkeit normalisierter Genotypsignale für bestimmte parentale Genotypen und Kombinationen davon berechnet werden, und
    Benennen des Ploidiezustands des Fötus durch Auswählen des Ploidiezustands entsprechend der Hypothese mit der größten kombinierten relativen Wahrscheinlichkeit.
  7. Verfahren nach Anspruch 1, wobei eine Vertrauensschätzung für den benannten Ploidiezustand berechnet wird.
  8. Verfahren nach Anspruch 1, ferner umfassend ein Erstellen eines Berichts, der den benannten Ploidiezustand des Fötus angibt.
  9. Verfahren nach Anspruch 1, wobei das Verfahren bei zwischen 4 und 5 Wochen Schwangerschaft; zwischen 5 und 6 Wochen Schwangerschaft; zwischen 6 und 7 Wochen Schwangerschaft; zwischen 7 und 8 Wochen Schwangerschaft; zwischen 8 und 9 Wochen Schwangerschaft; 15 zwischen 9 und 10 Wochen Schwangerschaft; zwischen 10 und 12 Wochen Schwangerschaft; zwischen 12 und 14 Wochen Schwangerschaft; zwischen 14 und 20 Wochen Schwangerschaft; zwischen 20 und 40 Wochen Schwangerschaft; im ersten Trimester; im zweiten Trimester; oder im dritten Trimester durchgeführt werden kann.
  10. Verfahren nach Anspruch 1, ferner umfassend ein Erfassen von genotypischen Daten von einem Elternteil oder beiden Elternteilen des Fötus.
  11. Verfahren nach Anspruch 1, wobei das Sequenzieren unter Verwendung von Hochdurchsatz-Sequenzierung durchgeführt wird.
EP14198470.8A 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung Active EP2854057B1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39585010P 2010-05-18 2010-05-18
US39815910P 2010-06-21 2010-06-21
US201161462972P 2011-02-09 2011-02-09
US201161448547P 2011-03-02 2011-03-02
US201161516996P 2011-04-12 2011-04-12
EP11784180.9A EP2572003A4 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen ploidiezuordnung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP11784180.9A Division EP2572003A4 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen ploidiezuordnung

Publications (3)

Publication Number Publication Date
EP2854057A2 EP2854057A2 (de) 2015-04-01
EP2854057A3 EP2854057A3 (de) 2015-08-26
EP2854057B1 true EP2854057B1 (de) 2018-03-07

Family

ID=44973174

Family Applications (3)

Application Number Title Priority Date Filing Date
EP14198470.8A Active EP2854057B1 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
EP14198478.1A Withdrawn EP2854058A3 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
EP11784180.9A Pending EP2572003A4 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen ploidiezuordnung

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP14198478.1A Withdrawn EP2854058A3 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
EP11784180.9A Pending EP2572003A4 (de) 2010-05-18 2011-05-18 Verfahren zur nichtinvasiven pränatalen ploidiezuordnung

Country Status (6)

Country Link
US (8) US8825412B2 (de)
EP (3) EP2854057B1 (de)
AU (1) AU2011255641A1 (de)
CA (3) CA3037126C (de)
HK (2) HK1208941A1 (de)
WO (1) WO2011146632A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8515679B2 (en) * 2005-12-06 2013-08-20 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US20070178501A1 (en) * 2005-12-06 2007-08-02 Matthew Rabinowitz System and method for integrating and validating genotypic, phenotypic and medical information into a database according to a standardized ontology
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US8532930B2 (en) * 2005-11-26 2013-09-10 Natera, Inc. Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US20070027636A1 (en) * 2005-07-29 2007-02-01 Matthew Rabinowitz System and method for using genetic, phentoypic and clinical data to make predictions for clinical or lifestyle decisions
US20110033862A1 (en) * 2008-02-19 2011-02-10 Gene Security Network, Inc. Methods for cell genotyping
AU2009223671B2 (en) 2008-03-11 2014-11-27 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
WO2009146335A1 (en) * 2008-05-27 2009-12-03 Gene Security Network, Inc. Methods for embryo characterization and comparison
WO2010017214A1 (en) 2008-08-04 2010-02-11 Gene Security Network, Inc. Methods for allele calling and ploidy calling
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
AU2010242073C1 (en) 2009-04-30 2015-12-24 Good Start Genetics, Inc. Methods and compositions for evaluating genetic markers
ES2640776T3 (es) 2009-09-30 2017-11-06 Natera, Inc. Métodos para denominar de forma no invasiva ploidía prenatal
HUE061110T2 (hu) 2009-11-05 2023-05-28 Univ Hong Kong Chinese Magzati genomelemzés anyai biológiai mintából
WO2011087760A2 (en) 2009-12-22 2011-07-21 Sequenom, Inc. Processes and kits for identifying aneuploidy
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
EP2854057B1 (de) 2010-05-18 2018-03-07 Natera, Inc. Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
CA2804293A1 (en) * 2010-06-20 2011-12-29 Univfy Inc. Method of delivering decision support systems (dss) and electronic health records (ehr) for reproductive care, pre-conceptive care, fertility treatments, and other health conditions
BR112013000879A2 (pt) 2010-07-13 2016-05-17 Univfy Inc método de avaliação do risco de nascimento múltiplos em travamentos para infertilidade
US20130261003A1 (en) 2010-08-06 2013-10-03 Ariosa Diagnostics, In. Ligation-based detection of genetic variants
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US10533223B2 (en) 2010-08-06 2020-01-14 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US11031095B2 (en) 2010-08-06 2021-06-08 Ariosa Diagnostics, Inc. Assay systems for determination of fetal copy number variation
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US10167508B2 (en) 2010-08-06 2019-01-01 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
US20140342940A1 (en) 2011-01-25 2014-11-20 Ariosa Diagnostics, Inc. Detection of Target Nucleic Acids using Hybridization
US11203786B2 (en) 2010-08-06 2021-12-21 Ariosa Diagnostics, Inc. Detection of target nucleic acids using hybridization
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
CA2821906C (en) 2010-12-22 2020-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
CN103459614B (zh) * 2011-01-05 2015-12-02 香港中文大学 胎儿性染色体的非侵入性产前基因分型
US11270781B2 (en) 2011-01-25 2022-03-08 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
US8756020B2 (en) 2011-01-25 2014-06-17 Ariosa Diagnostics, Inc. Enhanced risk probabilities using biomolecule estimations
US9994897B2 (en) 2013-03-08 2018-06-12 Ariosa Diagnostics, Inc. Non-invasive fetal sex determination
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
CA2834218C (en) 2011-04-29 2021-02-16 Sequenom, Inc. Quantification of a minority nucleic acid species using inhibitory oligonucleotides
US20140235474A1 (en) 2011-06-24 2014-08-21 Sequenom, Inc. Methods and processes for non invasive assessment of a genetic variation
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
US10196681B2 (en) 2011-10-06 2019-02-05 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20140242588A1 (en) 2011-10-06 2014-08-28 Sequenom, Inc Methods and processes for non-invasive assessment of genetic variations
US10424394B2 (en) 2011-10-06 2019-09-24 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US8688388B2 (en) 2011-10-11 2014-04-01 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
CA2852665A1 (en) 2011-10-17 2013-04-25 Good Start Genetics, Inc. Analysis methods
GB2497838A (en) 2011-10-19 2013-06-26 Nugen Technologies Inc Compositions and methods for directional nucleic acid amplification and sequencing
EP2805280B1 (de) 2012-01-20 2022-10-05 Sequenom, Inc. Diagnostische verfahren zur evaluierung von versuchsbedingungen
EP4372084A3 (de) 2012-01-26 2024-08-14 Tecan Genomics, Inc. Zusammensetzungen und verfahren zur gezielten nukleinsäuresequenzanreicherung und hocheffizienten erzeugung einer bibliothek
WO2013130848A1 (en) * 2012-02-29 2013-09-06 Natera, Inc. Informatics enhanced analysis of fetal samples subject to maternal contamination
ES2930180T3 (es) 2012-03-02 2022-12-07 Sequenom Inc Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
US9862995B2 (en) * 2012-03-13 2018-01-09 Abhijit Ajit Patel Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
CN107841543B (zh) * 2012-04-06 2021-12-31 香港中文大学 通过使用靶向大规模并行测序的等位基因比率分析进行的胎儿三体性的非侵入性产前诊断
US10227635B2 (en) 2012-04-16 2019-03-12 Molecular Loop Biosolutions, Llc Capture reactions
US10504613B2 (en) 2012-12-20 2019-12-10 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10289800B2 (en) 2012-05-21 2019-05-14 Ariosa Diagnostics, Inc. Processes for calculating phased fetal genomic sequences
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9193992B2 (en) * 2012-06-05 2015-11-24 Agilent Technologies, Inc. Method for determining ploidy of a cell
CN104619894B (zh) 2012-06-18 2017-06-06 纽亘技术公司 用于非期望核酸序列的阴性选择的组合物和方法
US10497461B2 (en) 2012-06-22 2019-12-03 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
CA2878979C (en) 2012-07-13 2021-09-14 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
CN104583421A (zh) 2012-07-19 2015-04-29 阿瑞奥萨诊断公司 遗传变体的基于多重的顺序连接的检测
KR101890466B1 (ko) 2012-07-24 2018-08-21 내테라, 인코포레이티드 고도의 다중 ｐｃｒ 방법 및 조성물
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US10482994B2 (en) 2012-10-04 2019-11-19 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014099979A2 (en) * 2012-12-17 2014-06-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
RU2529784C2 (ru) * 2012-12-26 2014-09-27 Закрытое акционерное общество "Геноаналитика" Технология определения анеуплоидии методом секвенирования
US20130309666A1 (en) 2013-01-25 2013-11-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2014168711A1 (en) 2013-03-13 2014-10-16 Sequenom, Inc. Primers for dna methylation analysis
JP2016518811A (ja) 2013-03-15 2016-06-30 ザ チャイニーズ ユニバーシティ オブ ホンコン 多胎妊娠における胎児ゲノムの決定
US20140274738A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
EP2978860B8 (de) * 2013-03-27 2019-12-11 BlueGnome Ltd Beurteilung des risikos von aneuploidie
HUE061261T2 (hu) 2013-04-03 2023-05-28 Sequenom Inc Eljárások és folyamatok genetikai variánsok nem invazív értékelésére
JP6561046B2 (ja) 2013-05-24 2019-08-14 セクエノム， インコーポレイテッド 遺伝子の変動の非侵襲性評価のための方法および処理
WO2014200579A1 (en) * 2013-06-13 2014-12-18 Ariosa Diagnostics, Inc. Statistical analysis for non-invasive sex chromosome aneuploidy determination
SI3011051T1 (sl) 2013-06-21 2019-05-31 Sequenom, Inc. Postopek za neinvazivno oceno genetskih variacij
GB201318369D0 (en) * 2013-10-17 2013-12-04 Univ Leuven Kath Methods using BAF
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US9499870B2 (en) 2013-09-27 2016-11-22 Natera, Inc. Cell free DNA diagnostic testing standards
IL289974B (en) 2013-10-04 2022-09-01 Sequenom Inc Methods and processes for non-invasive evaluation of genetic variations
JP6680680B2 (ja) 2013-10-07 2020-04-15 セクエノム， インコーポレイテッド 染色体変化の非侵襲性評価のための方法およびプロセス
US10851414B2 (en) 2013-10-18 2020-12-01 Good Start Genetics, Inc. Methods for determining carrier status
CA2929596C (en) 2013-11-13 2022-07-05 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
EP3736344A1 (de) 2014-03-13 2020-11-11 Sequenom, Inc. Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen
CN106460070B (zh) 2014-04-21 2021-10-08 纳特拉公司 检测染色体片段中的突变和倍性
RU2583830C2 (ru) * 2014-04-21 2016-05-10 Закрытое акционерное общество "Геноаналитика" Способ неинвазивной пренатальной диагностики анеуплоидий плода
US20180173845A1 (en) * 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
EP3940703A1 (de) 2014-07-18 2022-01-19 Illumina, Inc. Nichtinvasive pränatale diagnose fötaler genetischer leiden mittels zellulärer dna und zellfreier dna
KR20160010277A (ko) * 2014-07-18 2016-01-27 에스케이텔레콤 주식회사 산모의 무세포 dna의 차세대 서열분석을 통한 태아의 단일유전자 유전변이의 예측방법
EP3175000B1 (de) 2014-07-30 2020-07-29 Sequenom, Inc. Verfahren und prozesse zur nicht-invasiven beurteilung genetischer variationen
US11408024B2 (en) 2014-09-10 2022-08-09 Molecular Loop Biosciences, Inc. Methods for selectively suppressing non-target sequences
JP6802154B2 (ja) * 2014-09-18 2020-12-16 イラミーナ インコーポレーテッド 核酸シーケンシングデータを解析するための方法およびシステム
JP2017536087A (ja) 2014-09-24 2017-12-07 グッド スタート ジェネティクス， インコーポレイテッド 遺伝子アッセイのロバストネスを増大させるためのプロセス制御
EP3835429A1 (de) * 2014-10-17 2021-06-16 Good Start Genetics, Inc. Genetisches screening und nachweis von aneuploidie im vorfeld einer implantation
CA3010579A1 (en) 2015-01-06 2016-07-14 Good Start Genetics, Inc. Screening for structural variants
EP4428863A2 (de) 2015-05-11 2024-09-11 Natera, Inc. Verfahren und zusammensetzungen zur bestimmung der ploidie
WO2016189388A1 (en) 2015-05-22 2016-12-01 Nipd Genetics Ltd Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing
WO2017210603A1 (en) * 2016-06-03 2017-12-07 Illumina, Inc. Genotyping polyploid loci
US11200963B2 (en) 2016-07-27 2021-12-14 Sequenom, Inc. Genetic copy number alteration classifications
CA3037366A1 (en) 2016-09-29 2018-04-05 Myriad Women's Health, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
JP7237003B2 (ja) 2017-01-24 2023-03-10 セクエノム， インコーポレイテッド 遺伝子片の評価のための方法およびプロセス
AU2018225348A1 (en) 2017-02-21 2019-07-18 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
WO2018174821A1 (en) * 2017-03-20 2018-09-27 Nanyang Technological University A sequencing method for detecting dna mutation
CN110446787A (zh) 2017-03-24 2019-11-12 生物辐射实验室股份有限公司 通用发夹引物
CN107012226A (zh) * 2017-04-20 2017-08-04 司法部司法鉴定科学技术研究所 一种基于高通量测序的snp位点的检测试剂盒及其检测方法
US10176296B2 (en) 2017-05-17 2019-01-08 International Business Machines Corporation Algebraic phasing of polyploids
EP3655954A1 (de) * 2017-07-18 2020-05-27 Congenica Ltd. Screeningsystem und -verfahren
US12020779B1 (en) 2017-09-06 2024-06-25 Myriad Women's Health, Inc. Noninvasive prenatal screening using dynamic iterative depth optimization with depth-scaled variance determination
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
AU2018355575A1 (en) 2017-10-27 2020-05-21 Juno Diagnostics, Inc. Devices, systems and methods for ultra-low volume liquid biopsy
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
EP3830828A4 (de) * 2018-07-27 2022-05-04 Myriad Women's Health, Inc. Verfahren zum nachweis genetischer variationen in hochhomologen sequenzen durch unabhängige ausrichtung und paarung von sequenzauslesungen
CN112955960B (zh) * 2018-09-07 2024-08-16 Illumina公司 确定从怀孕母体分离的循环胎儿细胞来自当前妊娠或过往妊娠的方法
EP3899030A2 (de) 2018-12-17 2021-10-27 Natera, Inc. Verfahren zur analyse von zirkulierenden zellen
CA3126990A1 (en) 2019-02-14 2020-08-20 Maneesh Jain Methods and systems for determining a pregnancy-related state of a subject
US12059674B2 (en) 2020-02-03 2024-08-13 Tecan Genomics, Inc. Reagent storage system
US20230162814A1 (en) * 2020-03-12 2023-05-25 Vrije Universiteit Brussel Method for the analysis of genetic material
CN111951890B (zh) * 2020-08-13 2022-03-22 北京博昊云天科技有限公司 染色体和单基因病同步产前筛查的设备、试剂盒和分析系统
US20220246275A1 (en) * 2021-02-01 2022-08-04 Kpn Innovations, Llc. Systems and methods for generating a congenital nourishment program
AU2022323972A1 (en) 2021-08-02 2024-01-25 Natera, Inc. Methods for detecting neoplasm in pregnant women
WO2023034090A1 (en) 2021-09-01 2023-03-09 Natera, Inc. Methods for non-invasive prenatal testing
KR102704709B1 (ko) * 2021-11-24 2024-09-10 지놈케어 주식회사 가상 데이터에 기반한 태아의 염색체이수성을 검출하는 방법

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040785A (en) 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4935342A (en) 1986-12-01 1990-06-19 Syngene, Inc. Method of isolating and purifying nucleic acids from biological samples
US4942124A (en) 1987-08-11 1990-07-17 President And Fellows Of Harvard College Multiplex sequencing
US5153117A (en) 1990-03-27 1992-10-06 Genetype A.G. Fetal cell recovery method
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5262329A (en) 1991-06-13 1993-11-16 Carver Jr Edward L Method for improved multiple species blood analysis
IL103935A0 (en) 1991-12-04 1993-05-13 Du Pont Method for the identification of microorganisms by the utilization of directed and arbitrary dna amplification
US5965362A (en) 1992-03-04 1999-10-12 The Regents Of The University Of California Comparative genomic hybridization (CGH)
GB9305984D0 (en) 1993-03-23 1993-05-12 Royal Free Hosp School Med Predictive assay
CA2166729A1 (en) 1993-07-05 1995-01-19 Vivian Granger Preparation and stabilisation of cells
WO1995006137A1 (en) 1993-08-27 1995-03-02 Australian Red Cross Society Detection of genes
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
SE9400522D0 (sv) 1994-02-16 1994-02-16 Ulf Landegren Method and reagent for detecting specific nucleotide sequences
US5716776A (en) 1994-03-04 1998-02-10 Mark H. Bogart Enrichment by preferential mitosis of fetal lymphocytes from a maternal blood sample
US5891734A (en) 1994-08-01 1999-04-06 Abbott Laboratories Method for performing automated analysis
US6025128A (en) 1994-09-29 2000-02-15 The University Of Tulsa Prediction of prostate cancer progression by analysis of selected predictive parameters
US6479235B1 (en) 1994-09-30 2002-11-12 Promega Corporation Multiplex amplification of short tandem repeat loci
US5648220A (en) 1995-02-14 1997-07-15 New England Medical Center Hospitals, Inc. Methods for labeling intracytoplasmic molecules
EP0826069B1 (de) 1995-05-19 2002-04-10 Abbott Laboratories Nachweis von nukleinsäuren mit breitem dynamikbereich unter verwendung von aggregat-primer-reihen
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CA2248981C (en) 1996-03-15 2009-11-24 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6108635A (en) 1996-05-22 2000-08-22 Interleukin Genetics, Inc. Integrated disease information system
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6221654B1 (en) 1996-09-25 2001-04-24 California Institute Of Technology Method and apparatus for analysis and sorting of polynucleotides based on size
US5860917A (en) 1997-01-15 1999-01-19 Chiron Corporation Method and apparatus for predicting therapeutic outcomes
US5824467A (en) 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US20010051341A1 (en) 1997-03-04 2001-12-13 Isis Innovation Limited Non-invasive prenatal diagnosis
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
DK0866071T3 (da) 1997-03-20 2005-01-17 Hoffmann La Roche Modificerede primere
AU6846698A (en) 1997-04-01 1998-10-22 Glaxo Group Limited Method of nucleic acid amplification
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US20020119478A1 (en) 1997-05-30 2002-08-29 Diagen Corporation Methods for detection of nucleic acid sequences in urine
US5994148A (en) 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6833242B2 (en) 1997-09-23 2004-12-21 California Institute Of Technology Methods for detecting and sorting polynucleotides based on size
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
WO2000075306A2 (en) 1999-04-30 2000-12-14 Cyclops Genome Sciences Limited Method for producing double stranded polynucleotides
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US6964847B1 (en) * 1999-07-14 2005-11-15 Packard Biosciences Company Derivative nucleic acids and uses thereof
GB9917307D0 (en) 1999-07-23 1999-09-22 Sec Dep Of The Home Department Improvements in and relating to analysis of DNA
EP1196623B8 (de) 1999-07-23 2008-05-21 Forensic Science Service Ltd Verfahren zur Erkennung von Einzel-Nukleotid-Polymorphismen
US6440706B1 (en) 1999-08-02 2002-08-27 Johns Hopkins University Digital amplification
US6251604B1 (en) 1999-08-13 2001-06-26 Genopsys, Inc. Random mutagenesis and amplification of nucleic acid
EP1244811A1 (de) 1999-11-10 2002-10-02 Ligochem Inc. Verfahren zur isolierung von dna aus einem proteinhältigen medium und testsatz zur durchführung dieses verfahrens
US6221603B1 (en) 2000-02-04 2001-04-24 Molecular Dynamics, Inc. Rolling circle amplification assay for nucleic acid analysis
US20020006617A1 (en) 2000-02-07 2002-01-17 Jian-Bing Fan Nucleic acid detection methods using universal priming
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US7510834B2 (en) 2000-04-13 2009-03-31 Hidetoshi Inoko Gene mapping method using microsatellite genetic polymorphism markers
GB0009179D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Non-invasive prenatal diagnosis
EP1290225A4 (de) 2000-05-20 2004-09-15 Univ Michigan Methode zur herstellung einer dna-bank durch positionale vervielfältigung
JP2004511210A (ja) 2000-05-23 2004-04-15 バリアジェニックス　インコーポレーテッド 配列変動を検出する、ｄｎａを遺伝分析するための方法
US7087414B2 (en) 2000-06-06 2006-08-08 Applera Corporation Methods and devices for multiplexing amplification reactions
US6605451B1 (en) 2000-06-06 2003-08-12 Xtrana, Inc. Methods and devices for multiplexing amplification reactions
AU2001255518A1 (en) 2000-06-07 2001-12-17 Baylor College Of Medicine Compositions and methods for array-based nucleic acid hybridization
US7058616B1 (en) 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
GB0016742D0 (en) 2000-07-10 2000-08-30 Simeg Limited Diagnostic method
AU2002246612B2 (en) 2000-10-24 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Direct multiplex characterization of genomic DNA
US20020107640A1 (en) 2000-11-14 2002-08-08 Ideker Trey E. Methods for determining the true signal of an analyte
WO2002055985A2 (en) 2000-11-15 2002-07-18 Roche Diagnostics Corp Methods and reagents for identifying rare fetal cells in the material circulation
WO2002044411A1 (en) 2000-12-01 2002-06-06 Rosetta Inpharmatics, Inc. Use of profiling for detecting aneuploidy
US7218764B2 (en) 2000-12-04 2007-05-15 Cytokinetics, Inc. Ploidy classification method
AR031640A1 (es) 2000-12-08 2003-09-24 Applied Research Systems Amplificacion isotermica de acidos nucleicos en un soporte solido
US20020182622A1 (en) 2001-02-01 2002-12-05 Yusuke Nakamura Method for SNP (single nucleotide polymorphism) typing
JP2002300894A (ja) 2001-02-01 2002-10-15 Inst Of Physical & Chemical Res 一塩基多型タイピング方法
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
WO2002073504A1 (en) 2001-03-14 2002-09-19 Gene Logic, Inc. A system and method for retrieving and using gene expression data from multiple sources
US6489135B1 (en) 2001-04-17 2002-12-03 Atairgintechnologies, Inc. Determination of biological characteristics of embryos fertilized in vitro by assaying for bioactive lipids in culture media
FR2824144B1 (fr) 2001-04-30 2004-09-17 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US7392199B2 (en) 2001-05-01 2008-06-24 Quest Diagnostics Investments Incorporated Diagnosing inapparent diseases from common clinical tests using Bayesian analysis
US7262030B2 (en) 2001-05-09 2007-08-28 Virginia Commonwealth University Multiple sequencible and ligatible structures for genomic analysis
US20040126760A1 (en) 2001-05-17 2004-07-01 Natalia Broude Novel compositions and methods for carrying out multple pcr reactions on a single sample
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP2004531271A (ja) 2001-06-22 2004-10-14 ユニバーシティ オブ ジュネーブ 染色体不均衡により引き起こされる疾患を検出する方法
WO2003010537A1 (en) 2001-07-24 2003-02-06 Curagen Corporation Family based tests of association using pooled dna and snp markers
CA2455731C (en) 2001-07-25 2012-02-07 Oncomedx, Inc. Methods for evaluating pathologic conditions using extracellular rna
US7297778B2 (en) 2001-07-25 2007-11-20 Affymetrix, Inc. Complexity management of genomic DNA
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
IL160210A0 (en) 2001-08-23 2004-07-25 Immunivest Corp Stabilization of cells and biological specimens for analysis
US6807491B2 (en) 2001-08-30 2004-10-19 Hewlett-Packard Development Company, L.P. Method and apparatus for combining gene predictions using bayesian networks
US6927028B2 (en) 2001-08-31 2005-08-09 Chinese University Of Hong Kong Non-invasive methods for detecting non-host DNA in a host using epigenetic differences between the host and non-host DNA
AUPR749901A0 (en) 2001-09-06 2001-09-27 Monash University Method of identifying chromosomal abnormalities and prenatal diagnosis
US7153656B2 (en) 2001-09-11 2006-12-26 Los Alamos National Security, Llc Nucleic acid sequence detection using multiplexed oligonucleotide PCR
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
WO2003031646A1 (en) * 2001-10-12 2003-04-17 The University Of Queensland Multiple genetic marker selection and amplification
US6617137B2 (en) 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US7297485B2 (en) 2001-10-15 2007-11-20 Qiagen Gmbh Method for nucleic acid amplification that results in low amplification bias
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
AU2002357588B2 (en) 2001-12-11 2008-11-20 Netech Inc. Blood cell separation system
US7198897B2 (en) 2001-12-19 2007-04-03 Brandeis University Late-PCR
DE60123448T2 (de) 2001-12-24 2007-08-23 Prof. Wolfgang Holzgreve Verfahren zur nicht-invasiven Diagnose von Transplantationen und Transfusionen
US20040115629A1 (en) 2002-01-09 2004-06-17 Panzer Scott R Molecules for diagnostics and therapeutics
EP1468104A4 (de) 2002-01-18 2006-02-01 Genzyme Corp Verfahren zum nachweis fötaler dna und zur allelquantifizierung
US7035739B2 (en) 2002-02-01 2006-04-25 Rosetta Inpharmatics Llc Computer systems and methods for identifying genes and determining pathways associated with traits
WO2003074740A1 (en) 2002-03-01 2003-09-12 Ravgen, Inc. Rapid analysis of variations in a genome
US6977162B2 (en) 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
US20060229823A1 (en) 2002-03-28 2006-10-12 Affymetrix, Inc. Methods and computer software products for analyzing genotyping data
US20040096874A1 (en) 2002-04-11 2004-05-20 Third Wave Technologies, Inc. Characterization of CYP 2D6 genotypes
AU2003231244A1 (en) 2002-05-02 2003-11-17 University Of North Carolina At Chapel Hill In vitro mutagenesis, phenotyping, and gene mapping
US7442506B2 (en) 2002-05-08 2008-10-28 Ravgen, Inc. Methods for detection of genetic disorders
US7727720B2 (en) 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US20070178478A1 (en) 2002-05-08 2007-08-02 Dhallan Ravinder S Methods for detection of genetic disorders
US20040009518A1 (en) 2002-05-14 2004-01-15 The Chinese University Of Hong Kong Methods for evaluating a disease condition by nucleic acid detection and fractionation
US20040229231A1 (en) 2002-05-28 2004-11-18 Frudakis Tony N. Compositions and methods for inferring ancestry
EP1532453B1 (de) 2002-05-31 2013-08-21 Genetic Technologies Limited Maternale antikörper als marker für fötale zellen zur identifizierung und anreicherung fötaler zellen aus maternalem blut
AU2003243475A1 (en) 2002-06-13 2003-12-31 New York University Early noninvasive prenatal test for aneuploidies and heritable conditions
US7097976B2 (en) 2002-06-17 2006-08-29 Affymetrix, Inc. Methods of analysis of allelic imbalance
US7108976B2 (en) 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
US20050009069A1 (en) 2002-06-25 2005-01-13 Affymetrix, Inc. Computer software products for analyzing genotyping
CN100354298C (zh) 2002-06-28 2007-12-12 兰华生物科技公司 使用单核苷酸多态性组分析受损样品的方法和组合物
EP1388812A1 (de) 2002-07-04 2004-02-11 Ronald E. Dr. Kates Trainingsverfahren für lernfähiges System
UA53537C2 (en) 2002-07-15 2005-01-17 Amtech Ltd Ukrainian German Jo Injection syringe
US7459273B2 (en) 2002-10-04 2008-12-02 Affymetrix, Inc. Methods for genotyping selected polymorphism
AU2003285861A1 (en) 2002-10-07 2004-05-04 University Of Medicine And Dentistry Of New Jersey High throughput multiplex dna sequence amplifications
WO2004044225A2 (en) 2002-11-11 2004-05-27 Affymetrix, Inc. Methods for identifying dna copy number changes
AU2003298706A1 (en) 2002-12-04 2004-06-23 Applera Corporation Multiplex amplification of polynucleotides
DK1583904T3 (da) 2003-01-02 2013-12-16 Wobben Properties Gmbh Vindmøllerotorblad med reduceret akustisk emission
US20040224331A1 (en) 2003-01-17 2004-11-11 The Trustees Of Boston University Haplotype analysis
WO2004065628A1 (en) 2003-01-21 2004-08-05 Guoliang Fu Quantitative multiplex detection of nucleic acids
US7575865B2 (en) 2003-01-29 2009-08-18 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
EP2159285B1 (de) 2003-01-29 2012-09-26 454 Life Sciences Corporation Verfahren zur Verstärkung und Sequenzierung von Nukleinsäuren
WO2004078999A1 (en) 2003-03-05 2004-09-16 Genetic Technologies Limited Identification of fetal dna and fetal cell markers in maternal plasma or serum
US20040209299A1 (en) 2003-03-07 2004-10-21 Rubicon Genomics, Inc. In vitro DNA immortalization and whole genome amplification using libraries generated from randomly fragmented DNA
US20040197832A1 (en) 2003-04-03 2004-10-07 Mor Research Applications Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
AU2003229256A1 (en) 2003-05-09 2004-11-26 Capital Biochip Company, Ltd. Methods and compositions for optimizing multiplex pcr primers
WO2005000006A2 (en) 2003-05-28 2005-01-06 Pioneer Hi-Bred International, Inc. Plant breeding method
US20040259100A1 (en) 2003-06-20 2004-12-23 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
DK1660680T3 (da) 2003-07-31 2009-06-22 Sequenom Inc Fremgangsmåde til multipleks-polymerasekædereaktioner på höjt niveau og homogene masseforlængelsesreaktioner til genotypebestemmelse af polymorfismer
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
AU2003263660A1 (en) 2003-08-29 2005-03-16 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
WO2005023091A2 (en) 2003-09-05 2005-03-17 The Trustees Of Boston University Method for non-invasive prenatal diagnosis
US20050053950A1 (en) 2003-09-08 2005-03-10 Enrique Zudaire Ubani Protocol and software for multiplex real-time PCR quantification based on the different melting temperatures of amplicons
EP1669447A4 (de) * 2003-09-24 2007-03-14 Kyushu Tlo Co Ltd Snps im 5'-regulatorischen bereich des mdr1-gens
WO2005030999A1 (en) 2003-09-25 2005-04-07 Dana-Farber Cancer Institute, Inc Methods to detect lineage-specific cells
WO2005035725A2 (en) 2003-10-08 2005-04-21 The Trustees Of Boston University Methods for prenatal diagnosis of chromosomal abnormalities
CA2482097C (en) 2003-10-13 2012-02-21 F. Hoffmann-La Roche Ag Methods for isolating nucleic acids
EP1524321B2 (de) 2003-10-16 2014-07-23 Sequenom, Inc. Nicht invasiver Nachweis fötaler genetischer Merkmale
WO2005039389A2 (en) 2003-10-22 2005-05-06 454 Corporation Sequence-based karyotyping
US20070212689A1 (en) 2003-10-30 2007-09-13 Bianchi Diana W Prenatal Diagnosis Using Cell-Free Fetal DNA in Amniotic Fluid
US20050164252A1 (en) 2003-12-04 2005-07-28 Yeung Wah Hin A. Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
US7892732B2 (en) 2004-01-12 2011-02-22 Roche Nimblegen, Inc. Method of performing PCR amplification on a microarray
US20100216151A1 (en) 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US20060046258A1 (en) 2004-02-27 2006-03-02 Lapidus Stanley N Applications of single molecule sequencing
US20100216153A1 (en) 2004-02-27 2010-08-26 Helicos Biosciences Corporation Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities
US7035740B2 (en) 2004-03-24 2006-04-25 Illumina, Inc. Artificial intelligence and global normalization methods for genotyping
JP4437050B2 (ja) 2004-03-26 2010-03-24 株式会社日立製作所 診断支援システム、診断支援方法および診断支援サービスの提供方法
WO2005094363A2 (en) 2004-03-30 2005-10-13 New York University System, method and software arrangement for bi-allele haplotype phasing
JP4756032B2 (ja) 2004-03-31 2011-08-24 アトナーゲン アクチエンゲゼルシャフト 胎児赤血球細胞に対して特異性を有するモノクローナル抗体
US7414118B1 (en) 2004-04-14 2008-08-19 Applied Biosystems Inc. Modified oligonucleotides and applications thereof
US7468249B2 (en) 2004-05-05 2008-12-23 Biocept, Inc. Detection of chromosomal disorders
US7709194B2 (en) 2004-06-04 2010-05-04 The Chinese University Of Hong Kong Marker for prenatal diagnosis and monitoring
JP2008506637A (ja) 2004-06-14 2008-03-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 胎児起源の細胞に対する抗体
WO2006002491A1 (en) 2004-07-06 2006-01-12 Genera Biosystems Pty Ltd Method of detecting aneuploidy
DE102004036285A1 (de) 2004-07-27 2006-02-16 Advalytix Ag Verfahren zum Bestimmen der Häufigkeit von Sequenzen einer Probe
WO2006020617A1 (en) 2004-08-09 2006-02-23 Generation Biotech, Llc Method for nucleic acid isolation and amplification
EP1789786A4 (de) 2004-08-18 2008-02-13 Abbott Molecular Inc Bestimmung der qualität von daten und/oder der segmentalen aneusomie unter verwendung eines computersystems
US7634808B1 (en) 2004-08-20 2009-12-15 Symantec Corporation Method and apparatus to block fast-spreading computer worms that use DNS MX record queries
JP4810164B2 (ja) 2004-09-03 2011-11-09 富士フイルム株式会社 核酸分離精製方法
US8024128B2 (en) 2004-09-07 2011-09-20 Gene Security Network, Inc. System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US20060134662A1 (en) 2004-10-25 2006-06-22 Pratt Mark R Method and system for genotyping samples in a normalized allelic space
CA2585784A1 (en) 2004-11-17 2006-05-26 Mosaic Reproductive Health And Genetics, Llc Methods of determining human egg competency
EP1845968A2 (de) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen
US20070042384A1 (en) 2004-12-01 2007-02-22 Weiwei Li Method for isolating and modifying DNA from blood and body fluids
WO2006091979A2 (en) 2005-02-25 2006-08-31 The Regents Of The University Of California Full karyotype single cell chromosome analysis
US7618777B2 (en) 2005-03-16 2009-11-17 Agilent Technologies, Inc. Composition and method for array hybridization
ES2398233T3 (es) 2005-03-18 2013-03-14 The Chinese University Of Hong Kong Un método para la detección de aneuploidías cromosómicas
EP2161347B1 (de) 2005-03-18 2016-08-24 The Chinese University Of Hong Kong Marker zur prenatalen Diagnose und zum prenatalen Monitoring
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
ES2404311T3 (es) 2005-04-12 2013-05-27 454 Life Sciences Corporation Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda
EP1888786A4 (de) 2005-05-27 2009-12-30 Wayne John Cancer Inst Verwendung freier zirkulierender dna zur diagnose, prognose und behandlung von krebs
WO2007117256A1 (en) 2005-05-31 2007-10-18 Applera Corporation Multiplexed amplification of short nucleic acids
WO2007145612A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
US7709197B2 (en) 2005-06-15 2010-05-04 Callida Genomics, Inc. Nucleic acid analysis by random mixtures of non-overlapping fragments
US7745122B2 (en) 2005-07-15 2010-06-29 Applied Biosystems, Llc Analyzing messenger RNA and micro RNA in the same reaction mixture
US20070020640A1 (en) 2005-07-21 2007-01-25 Mccloskey Megan L Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis
RU2290078C1 (ru) 2005-07-25 2006-12-27 Евгений Владимирович Новичков Способ прогнозирования рецидива серозного рака яичников
US8515679B2 (en) 2005-12-06 2013-08-20 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US20070027636A1 (en) 2005-07-29 2007-02-01 Matthew Rabinowitz System and method for using genetic, phentoypic and clinical data to make predictions for clinical or lifestyle decisions
US8532930B2 (en) * 2005-11-26 2013-09-10 Natera, Inc. Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US20070178501A1 (en) 2005-12-06 2007-08-02 Matthew Rabinowitz System and method for integrating and validating genotypic, phenotypic and medical information into a database according to a standardized ontology
ATE510930T1 (de) 2005-08-02 2011-06-15 Rubicon Genomics Inc Zusammensetzungen und verfahren zur bearbeitung und amplifikation von dna mit verwendung mehrerer enzyme in einer einzigen reaktion
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
GB0522310D0 (en) 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0523276D0 (en) 2005-11-15 2005-12-21 London Bridge Fertility Chromosomal analysis by molecular karyotyping
EP3012760A1 (de) 2005-11-26 2016-04-27 Natera, Inc. System und verfahren zum reinigen von rauschbehafteten genetischen daten und verwendung von daten für prädiktionen
US20070172853A1 (en) 2005-12-02 2007-07-26 The General Hospital Corporation Use of deletion polymorphisms to predict, prevent, and manage histoincompatibility
WO2007070482A2 (en) 2005-12-14 2007-06-21 Xueliang Xia Microarray-based preimplantation genetic diagnosis of chromosomal abnormalities
DK1966394T3 (da) 2005-12-22 2012-10-29 Keygene Nv Forbedrede strategier til transkriptprofilering under anvendelse af high throughput-sekventeringsteknologier
PL3002338T3 (pl) 2006-02-02 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Nieinwazyjne badania przesiewowe płodu poprzez analizę cyfrową
WO2007092538A2 (en) 2006-02-07 2007-08-16 President And Fellows Of Harvard College Methods for making nucleotide probes for sequencing and synthesis
WO2007091064A1 (en) 2006-02-08 2007-08-16 Solexa Limited End modification to prevent over-representation of fragments
DK1996728T3 (da) 2006-02-28 2011-08-15 Univ Louisville Res Found Detektering af føtale chromosomale abnormiteter under anvendelse af tandem-enkeltnukleotid-polymorfismer
US20100184043A1 (en) 2006-02-28 2010-07-22 University Of Louisville Research Foundation Detecting Genetic Abnormalities
EP2007904A4 (de) 2006-03-13 2009-06-10 Veridex Llc Fortpflanzung von primärzellen
US20080038733A1 (en) 2006-03-28 2008-02-14 Baylor College Of Medicine Screening for down syndrome
JP2009072062A (ja) 2006-04-07 2009-04-09 Institute Of Physical & Chemical Research 核酸の５’末端を単離するための方法およびその適用
WO2007121276A2 (en) 2006-04-12 2007-10-25 Biocept, Inc. Enrichment of circulating fetal dna
US7901884B2 (en) 2006-05-03 2011-03-08 The Chinese University Of Hong Kong Markers for prenatal diagnosis and monitoring
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US8679741B2 (en) * 2006-05-31 2014-03-25 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample
US7981609B2 (en) 2006-06-09 2011-07-19 The Brigham And Women's Hospital, Inc. Methods for identifying and using SNP panels
EP2061801A4 (de) 2006-06-14 2009-11-11 Living Microsystems Inc Diagnose fötaler anomalien durch vergleichende genomische hybridisierung
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP3424598B1 (de) 2006-06-14 2022-06-08 Verinata Health, Inc. Analyse seltener zellen mittels probentrennung und dna-etiketten
EP2024512A4 (de) 2006-06-14 2009-12-09 Artemis Health Inc Verfahren zur diagnose fötaler anomalitäten
DK2029778T3 (en) 2006-06-14 2018-08-20 Verinata Health Inc DIAGNOSIS OF Fetal ABNORMITIES
WO2007147074A2 (en) 2006-06-14 2007-12-21 Living Microsystems, Inc. Use of highly parallel snp genotyping for fetal diagnosis
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
WO2007147018A1 (en) 2006-06-14 2007-12-21 Cellpoint Diagnostics, Inc. Analysis of rare cell-enriched samples
WO2007149791A2 (en) 2006-06-15 2007-12-27 Stratagene System for isolating biomolecules from a sample
AU2007260750A1 (en) 2006-06-16 2007-12-21 Sequenom, Inc. Methods and compositions for the amplification, detection and quantification of nucleic acid from a sample
US20080182244A1 (en) 2006-08-04 2008-07-31 Ikonisys, Inc. Pre-Implantation Genetic Diagnosis Test
WO2008024473A2 (en) 2006-08-24 2008-02-28 University Of Massachusetts Medical School Mapping of genomic interactions
US9149473B2 (en) 2006-09-14 2015-10-06 Ibis Biosciences, Inc. Targeted whole genome amplification method for identification of pathogens
US20080085836A1 (en) 2006-09-22 2008-04-10 Kearns William G Method for genetic testing of human embryos for chromosome abnormalities, segregating genetic disorders with or without a known mutation and mitochondrial disorders following in vitro fertilization (IVF), embryo culture and embryo biopsy
WO2008048931A1 (en) 2006-10-16 2008-04-24 Celula Inc. Methods and compositions for differential expansion of fetal cells in maternal blood and their use
WO2008051928A2 (en) 2006-10-23 2008-05-02 The Salk Institute For Biological Studies Target-oriented whole genome amplification of nucliec acids
KR100825367B1 (ko) 2006-11-07 2008-04-28 전남대학교산학협력단 표지자로서 미토콘드리아 유전자 과변이부위를 이용하는조혈모세포이식 후 생착능 평가방법 및 키트
US20110045462A1 (en) 2006-11-14 2011-02-24 The Regents Of The University Of California Digital analysis of gene expression
US20100092965A1 (en) 2006-11-16 2010-04-15 Somasekar Seshagiri Genetic variations associated with tumors
WO2008059578A1 (fr) 2006-11-16 2008-05-22 Olympus Corporation Procédé d'amplification pcr multiplex
WO2008079374A2 (en) 2006-12-21 2008-07-03 Wang Eric T Methods and compositions for selecting and using single nucleotide polymorphisms
WO2008081451A2 (en) 2007-01-03 2008-07-10 Monaliza Medical Ltd. Methods and kits for analyzing genetic material of a fetus
DK2121977T3 (en) 2007-01-11 2017-09-18 Erasmus Univ Medical Center Capture (4C) OF CHROMOSOMES WITH CIRCULAR CONFORMATION
US20100129792A1 (en) 2007-02-06 2010-05-27 Gerassimos Makrigiorgos Direct monitoring and pcr amplification of the dosage and dosage difference between target genetic regions
WO2008098142A2 (en) 2007-02-08 2008-08-14 Sequenom, Inc. Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
CA2679511A1 (en) 2007-03-16 2008-09-25 454 Life Sciences Corporation System and method for detection of hiv drug resistant variants
WO2008115497A2 (en) 2007-03-16 2008-09-25 Gene Security Network System and method for cleaning noisy genetic data and determining chromsome copy number
US8652780B2 (en) 2007-03-26 2014-02-18 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
JP5262230B2 (ja) 2007-03-28 2013-08-14 独立行政法人理化学研究所 新規多型検出法
ITTO20070307A1 (it) 2007-05-04 2008-11-05 Silicon Biosystems Spa Metodo e dispositivo per la diagnosi prenatale non-invasiva
CA2688155C (en) 2007-05-31 2020-02-11 The Regents Of The University Of California High specificity and high sensitivity detection based on steric hindrance & enzyme-related signal amplification
WO2008157264A2 (en) 2007-06-15 2008-12-24 Sequenom, Inc. Combined methods for the detection of chromosomal aneuploidy
US20090023190A1 (en) 2007-06-20 2009-01-22 Kai Qin Lao Sequence amplification with loopable primers
ES2647237T3 (es) 2007-07-03 2017-12-20 Genaphora Ltd. Cebadores quiméricos para reacciones de amplificación de ácidos nucleicos mejoradas
WO2009009769A2 (en) 2007-07-11 2009-01-15 Artemis Health, Inc. Diagnosis of fetal abnormalities using nucleated red blood cells
EP3770275A1 (de) 2007-07-23 2021-01-27 The Chinese University of Hong Kong Bestimmung einer fötalen aneuploidie
US20100112590A1 (en) 2007-07-23 2010-05-06 The Chinese University Of Hong Kong Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment
US8455190B2 (en) 2007-08-01 2013-06-04 Dana-Farber Cancer Institute, Inc. Enrichment of a target sequence
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
WO2009019215A1 (en) 2007-08-03 2009-02-12 Dkfz Deutsches Krebsforschungszentrum Method for prenatal diagnosis using exosomes and cd24 as a marker
US9404150B2 (en) 2007-08-29 2016-08-02 Sequenom, Inc. Methods and compositions for universal size-specific PCR
WO2009032779A2 (en) 2007-08-29 2009-03-12 Sequenom, Inc. Methods and compositions for the size-specific seperation of nucleic acid from a sample
US8748100B2 (en) 2007-08-30 2014-06-10 The Chinese University Of Hong Kong Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences
CA2698545C (en) 2007-09-07 2014-07-08 Fluidigm Corporation Copy number variation determination, methods and systems
US20090081678A1 (en) 2007-09-21 2009-03-26 Streck, Inc. Nucleic acid isolation in preserved whole blood
CA2697640C (en) 2007-09-21 2016-06-21 Katholieke Universiteit Leuven Tools and methods for genetic tests using next generation sequencing
JP2011500041A (ja) 2007-10-16 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー クローナルシークエンシングによる高分解能かつ高効率のｈｌａ遺伝子型決定法
US20100086914A1 (en) 2008-10-03 2010-04-08 Roche Molecular Systems, Inc. High resolution, high throughput hla genotyping by clonal sequencing
WO2009064897A2 (en) 2007-11-14 2009-05-22 Chronix Biomedical Detection of nucleic acid sequence variations in circulating nucleic acid in bovine spongiform encephalopathy
JP5726529B2 (ja) 2007-11-30 2015-06-03 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 単一試料からのゲノムｄｎａ、ｒｎａおよびタンパク質の単離方法
FR2925480B1 (fr) 2007-12-21 2011-07-01 Gervais Danone Sa Procede d'enrichissement d'une eau en oxygene par voie electrolytique, eau ou boisson enrichie en oxygene et utilisations
EP2077337A1 (de) 2007-12-26 2009-07-08 Eppendorf Array Technologies SA Zusammensetzung, Verfahren und Kit zum Nachweis und zur Amplifikation
WO2009091934A1 (en) 2008-01-17 2009-07-23 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
US8852864B2 (en) 2008-01-17 2014-10-07 Sequenom Inc. Methods and compositions for the analysis of nucleic acids
SG10201609507TA (en) 2008-02-01 2017-01-27 Gen Hospital Corp Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
EP2245198A1 (de) 2008-02-04 2010-11-03 Massachusetts Institute of Technology Selektion von nukleinsäuren durch lösungshybridisierung an oligonukleotidköder
US20110033862A1 (en) 2008-02-19 2011-02-10 Gene Security Network, Inc. Methods for cell genotyping
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
AU2009223671B2 (en) 2008-03-11 2014-11-27 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US20090299645A1 (en) 2008-03-19 2009-12-03 Brandon Colby Genetic analysis
CA2718137A1 (en) 2008-03-26 2009-10-01 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
EP2274446B1 (de) 2008-03-31 2015-09-09 Pacific Biosciences of California, Inc. Systeme und verfahren für polymeraseenzymreaktionen in zwei langsamen schritten
PT2271767T (pt) 2008-04-03 2016-08-18 Cb Biotechnologies Inc Reação em cadeia de polimerase para captura de amplicões em multiplexo para amplificação de alvos múltiplos
WO2009146335A1 (en) 2008-05-27 2009-12-03 Gene Security Network, Inc. Methods for embryo characterization and comparison
WO2010017214A1 (en) 2008-08-04 2010-02-11 Gene Security Network, Inc. Methods for allele calling and ploidy calling
EP2128169A1 (de) 2008-05-30 2009-12-02 Qiagen GmbH Verfahren zur Isolierung von kurzkettigen Nukleinsäuren
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP2326732A4 (de) 2008-08-26 2012-11-14 Fluidigm Corp Testverfahren für erhöhten durchsatz von proben und/oder targets
DE102008045705A1 (de) 2008-09-04 2010-04-22 Macherey, Nagel Gmbh & Co. Kg Handelsgesellschaft Verfahren zur Gewinnung von kurzer RNA sowie Kit hierfür
US8586310B2 (en) 2008-09-05 2013-11-19 Washington University Method for multiplexed nucleic acid patch polymerase chain reaction
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
ES2599967T3 (es) 2008-09-16 2017-02-06 Sequenom, Inc. Procedimientos y composiciones para el enriquecimiento basado en metilación de ácido nucleico fetal de una muestra materna útiles para diagnósticos prenatales no invasivos
WO2010033652A1 (en) 2008-09-17 2010-03-25 Ge Healthcare Bio-Sciences Corp. Method for small rna isolation
LT2562268T (lt) 2008-09-20 2017-04-25 The Board Of Trustees Of The Leland Stanford Junior University Neinvazinis fetalinės aneuploidijos diagnozavimas sekvenavimu
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US20110301221A1 (en) 2008-10-10 2011-12-08 Swedish Health Services Diagnosis, prognosis and treatment of glioblastoma multiforme
WO2010045617A2 (en) 2008-10-17 2010-04-22 University Of Louisville Research Foundation Detecting genetic abnormalities
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP4335932A3 (de) 2008-11-07 2024-06-26 Adaptive Biotechnologies Corporation Verfahren zur überwachung von zuständen durch sequenzanalyse
CN104531837A (zh) 2008-12-22 2015-04-22 赛卢拉有限公司 检测等位基因、基因组和转录物组的方法和基因型分析谱
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
US8450063B2 (en) 2009-01-28 2013-05-28 Fluidigm Corporation Determination of copy number differences by amplification
DK3290530T3 (da) 2009-02-18 2020-12-07 Streck Inc Konservering af cellefrie nukleinsyrer
JP5805064B2 (ja) 2009-03-27 2015-11-04 ライフ テクノロジーズ コーポレーション 対立遺伝子変種を検出するための方法、組成物、およびキット
US8691509B2 (en) 2009-04-02 2014-04-08 Fluidigm Corporation Multi-primer amplification method for barcoding of target nucleic acids
US20100285537A1 (en) 2009-04-02 2010-11-11 Fluidigm Corporation Selective tagging of short nucleic acid fragments and selective protection of target sequences from degradation
EP3514244B1 (de) 2009-04-03 2021-07-07 Sequenom, Inc. Verfahren für die herstellung von nukleinsäuren
EP2417270B1 (de) 2009-04-06 2017-09-20 The Johns Hopkins University Digitale quantifizierung von dna-methylierung
US9085798B2 (en) 2009-04-30 2015-07-21 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
US8481699B2 (en) 2009-07-14 2013-07-09 Academia Sinica Multiplex barcoded Paired-End ditag (mbPED) library construction for ultra high throughput sequencing
US20130196862A1 (en) 2009-07-17 2013-08-01 Natera, Inc. Informatics Enhanced Analysis of Fetal Samples Subject to Maternal Contamination
US8563242B2 (en) 2009-08-11 2013-10-22 The Chinese University Of Hong Kong Method for detecting chromosomal aneuploidy
CN101643904B (zh) 2009-08-27 2011-04-27 北京北方微电子基地设备工艺研究中心有限责任公司 深硅刻蚀装置和深硅刻蚀设备的进气系统
WO2011032078A1 (en) 2009-09-11 2011-03-17 Health Reseach Inc. Detection of x4 strains of hiv-1 by heteroduplex tracking assay
US9005894B2 (en) 2009-09-22 2015-04-14 Roche Molecular Systems, Inc. Determination of KIR haplotypes associated with disease
AU2010298620B2 (en) 2009-09-24 2016-08-11 Qiagen Gaithersburg Inc. Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material
ES2640776T3 (es) 2009-09-30 2017-11-06 Natera, Inc. Métodos para denominar de forma no invasiva ploidía prenatal
EP2824191A3 (de) 2009-10-26 2015-02-18 Lifecodexx AG Mittel und Verfahren zur nichtinvasiven Diagnose von chromosomaler Aneuploidie
HUE061110T2 (hu) 2009-11-05 2023-05-28 Univ Hong Kong Chinese Magzati genomelemzés anyai biológiai mintából
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
EP2504448B1 (de) 2009-11-25 2016-10-19 Bio-Rad Laboratories, Inc. Verfahren und zusammensetzung zur erkennung von genetischem material
EP2509418A4 (de) 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc Verfahren und niedrigdosierungspläne zur behandlung von erythrozytendysfunktion
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US9315857B2 (en) 2009-12-15 2016-04-19 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse label-tags
WO2011087760A2 (en) 2009-12-22 2011-07-21 Sequenom, Inc. Processes and kits for identifying aneuploidy
US8574842B2 (en) 2009-12-22 2013-11-05 The Board Of Trustees Of The Leland Stanford Junior University Direct molecular diagnosis of fetal aneuploidy
CA2786916A1 (en) 2010-01-15 2011-07-21 The University Of British Columbia Multiplex amplification for the detection of nucleic acid variations
US20120010085A1 (en) * 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
ES2704701T3 (es) 2010-01-19 2019-03-19 Verinata Health Inc Nuevo protocolo de preparación de bibliotecas de secuenciación
US9323888B2 (en) 2010-01-19 2016-04-26 Verinata Health, Inc. Detecting and classifying copy number variation
US10388403B2 (en) 2010-01-19 2019-08-20 Verinata Health, Inc. Analyzing copy number variation in the detection of cancer
US20120270739A1 (en) 2010-01-19 2012-10-25 Verinata Health, Inc. Method for sample analysis of aneuploidies in maternal samples
US20110312503A1 (en) 2010-01-23 2011-12-22 Artemis Health, Inc. Methods of fetal abnormality detection
US8940487B2 (en) 2010-02-09 2015-01-27 UmiTaq Bio Methods and compositions for universal detection of nucleic acids
EP2539472B1 (de) 2010-02-26 2015-05-20 Life Technologies Corporation Schnelle pcr für str-genotypisierung
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
US9234240B2 (en) 2010-05-07 2016-01-12 The Board Of Trustees Of The Leland Stanford Junior University Measurement and comparison of immune diversity by high-throughput sequencing
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US20130123120A1 (en) 2010-05-18 2013-05-16 Natera, Inc. Highly Multiplex PCR Methods and Compositions
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190284623A1 (en) 2010-05-18 2019-09-19 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2854057B1 (de) 2010-05-18 2018-03-07 Natera, Inc. Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US20190309358A1 (en) 2010-05-18 2019-10-10 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190323076A1 (en) 2010-05-18 2019-10-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
WO2013052557A2 (en) 2011-10-03 2013-04-11 Natera, Inc. Methods for preimplantation genetic diagnosis by sequencing
US20140206552A1 (en) 2010-05-18 2014-07-24 Natera, Inc. Methods for preimplantation genetic diagnosis by sequencing
US20110301854A1 (en) 2010-06-08 2011-12-08 Curry Bo U Method of Determining Allele-Specific Copy Number of a SNP
US20130040375A1 (en) 2011-08-08 2013-02-14 Tandem Diagnotics, Inc. Assay systems for genetic analysis
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US8700338B2 (en) 2011-01-25 2014-04-15 Ariosa Diagnosis, Inc. Risk calculation for evaluation of fetal aneuploidy
US20120190557A1 (en) 2011-01-25 2012-07-26 Aria Diagnostics, Inc. Risk calculation for evaluation of fetal aneuploidy
EP2426217A1 (de) 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytische Verfahren für zellfreie Nucleinsäuren und Anwendungen
WO2012042374A2 (en) 2010-10-01 2012-04-05 Anssi Jussi Nikolai Taipale Method of determining number or concentration of molecules
US9267174B2 (en) 2010-10-26 2016-02-23 Stanford University Method of simultaneously screening for multiple genotypes and/or mutations
WO2012058488A1 (en) 2010-10-27 2012-05-03 President And Fellows Of Harvard College Compositions of toehold primer duplexes and methods of use
MX349568B (es) 2010-11-30 2017-08-03 Univ Hong Kong Chinese Deteccion de aberraciones geneticas o moleculares asociadas con el cancer.
US8877442B2 (en) 2010-12-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive determination of fetal inheritance of parental haplotypes at the genome-wide scale
US20150064695A1 (en) 2010-12-17 2015-03-05 Celula Inc. Methods for screening and diagnosing genetic conditions
CA2821906C (en) 2010-12-22 2020-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
WO2012103031A2 (en) 2011-01-25 2012-08-02 Ariosa Diagnostics, Inc. Detection of genetic abnormalities
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
EP3760730A1 (de) 2011-02-09 2021-01-06 Natera, Inc. Verfahren zur nichtinvasiven pränatalen ploidiezuordnung
GB2488358A (en) 2011-02-25 2012-08-29 Univ Plymouth Enrichment of foetal DNA in maternal plasma
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
DK3567124T3 (da) 2011-04-12 2022-03-07 Verinata Health Inc Opløsning af genomfraktioner ved anvendelse af polymorfisme-optællinger
AU2012242525B2 (en) 2011-04-14 2015-09-17 Complete Genomics, Inc. Processing and analysis of complex nucleic acid sequence data
US9411937B2 (en) 2011-04-15 2016-08-09 Verinata Health, Inc. Detecting and classifying copy number variation
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
CN106912197B (zh) 2011-04-28 2022-01-25 生命技术公司 用于多重pcr的方法和组合物
CA2834218C (en) 2011-04-29 2021-02-16 Sequenom, Inc. Quantification of a minority nucleic acid species using inhibitory oligonucleotides
CN102876660A (zh) 2011-07-11 2013-01-16 三星电子株式会社 扩增靶核酸的方法和测定样品中的靶核酸的相对量的方法
US20130024127A1 (en) 2011-07-19 2013-01-24 John Stuelpnagel Determination of source contributions using binomial probability calculations
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
US8712697B2 (en) 2011-09-07 2014-04-29 Ariosa Diagnostics, Inc. Determination of copy number variations using binomial probability calculations
JP5536729B2 (ja) 2011-09-20 2014-07-02 株式会社ソニー・コンピュータエンタテインメント 情報処理装置、アプリケーション提供システム、アプリケーション提供サーバ、アプリケーション提供方法、および情報処理方法
CN113388606A (zh) 2011-09-26 2021-09-14 凯杰有限公司 用于分离细胞外核酸的快速方法
US9367663B2 (en) 2011-10-06 2016-06-14 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9984198B2 (en) 2011-10-06 2018-05-29 Sequenom, Inc. Reducing sequence read count error in assessment of complex genetic variations
AU2012321053B2 (en) 2011-10-07 2018-04-19 Murdoch Childrens Research Institute Diagnostic assay for tissue transplantation status
WO2013078470A2 (en) 2011-11-22 2013-05-30 MOTIF, Active Multiplex isolation of protein-associated nucleic acids
US20140364439A1 (en) 2011-12-07 2014-12-11 The Broad Institute, Inc. Markers associated with chronic lymphocytic leukemia prognosis and progression
US20130190653A1 (en) 2012-01-25 2013-07-25 Angel Gabriel Alvarez Ramos Device for blood collection from the placenta and the umbilical cord
WO2013123220A1 (en) 2012-02-14 2013-08-22 Cornell University Method for relative quantification of nucleic acid sequence, expression, or copy changes, using combined nuclease, ligation, and polymerase reactions
WO2013128281A1 (en) 2012-02-28 2013-09-06 Population Genetics Technologies Ltd Method for attaching a counter sequence to a nucleic acid sample
WO2013130848A1 (en) 2012-02-29 2013-09-06 Natera, Inc. Informatics enhanced analysis of fetal samples subject to maternal contamination
US9862995B2 (en) 2012-03-13 2018-01-09 Abhijit Ajit Patel Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
CA3209140A1 (en) 2012-04-19 2013-10-24 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
EP4026912A1 (de) 2012-05-10 2022-07-13 The General Hospital Corporation Verfahren zur bestimmung einer nukleotidsequenz
CA2874413A1 (en) 2012-05-21 2013-11-28 The Scripps Research Institute Methods of sample preparation
WO2013181651A1 (en) 2012-06-01 2013-12-05 Omega Bio-Tek, Inc. Selective nucleic acid fragment recovery
WO2014004726A1 (en) 2012-06-26 2014-01-03 Caifu Chen Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer
EP2875149B1 (de) 2012-07-20 2019-12-04 Verinata Health, Inc. Erkennung und klassifizierung von kopienzahlvarianten in einem krebsgenom
KR101890466B1 (ko) 2012-07-24 2018-08-21 내테라, 인코포레이티드 고도의 다중 ｐｃｒ 방법 및 조성물
US10993418B2 (en) 2012-08-13 2021-05-04 Life Genetics Lab, Llc Method for measuring tumor burden in patient derived xenograft (PDX) mice
US10988803B2 (en) 2014-12-29 2021-04-27 Life Genetics Lab, Llc Multiplexed assay for quantitating and assessing integrity of cell-free DNA in biological fluids for cancer diagnosis, prognosis and surveillance
US20140051585A1 (en) 2012-08-15 2014-02-20 Natera, Inc. Methods and compositions for reducing genetic library contamination
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
CN108103057B (zh) 2012-08-28 2021-09-03 阿科尼生物系统公司 用于纯化核酸的方法和试剂盒
WO2014039556A1 (en) 2012-09-04 2014-03-13 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140066317A1 (en) 2012-09-04 2014-03-06 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140065621A1 (en) 2012-09-04 2014-03-06 Natera, Inc. Methods for increasing fetal fraction in maternal blood
EP3026124A1 (de) 2012-10-31 2016-06-01 Genesupport SA Nicht invasives verfahren zum erfassen einer chromosomalen fötusaneuploidie
AU2014205110A1 (en) 2013-01-13 2015-08-27 Unitaq Bio Methods and compositions for PCR using blocked and universal primers
US10745686B2 (en) 2013-02-08 2020-08-18 Qiagen Gmbh Method for separating DNA by size
US9982255B2 (en) 2013-03-11 2018-05-29 Kailos Genetics, Inc. Capture methodologies for circulating cell free DNA
US10385394B2 (en) 2013-03-15 2019-08-20 The Translational Genomics Research Institute Processes of identifying and characterizing X-linked disorders
CN105408496A (zh) 2013-03-15 2016-03-16 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
US20140272956A1 (en) 2013-03-15 2014-09-18 Abbott Molecular Inc. Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
WO2014145078A1 (en) 2013-03-15 2014-09-18 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
BR112015022821A2 (pt) 2013-03-15 2017-11-07 Immucor Gti Diagnostics Inc método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico
CN113337604A (zh) 2013-03-15 2021-09-03 莱兰斯坦福初级大学评议会 循环核酸肿瘤标志物的鉴别和用途
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
ES2704682T5 (es) 2013-05-29 2023-11-10 Chronix Biomedical Detección y cuantificación de ADN extracelular del donante en la circulación de receptores de trasplantes de órganos
EP3049557B1 (de) 2013-09-27 2021-05-05 University of Washington Verfahren und systeme für gross angelegtes scaffolding von genomassemblierungen
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
US9499870B2 (en) 2013-09-27 2016-11-22 Natera, Inc. Cell free DNA diagnostic testing standards
DK3077539T3 (en) 2013-12-02 2018-11-19 Personal Genome Diagnostics Inc Procedure for evaluating minority variations in a sample
EP3087204B1 (de) 2013-12-28 2018-02-14 Guardant Health, Inc. Verfahren und systeme für den nachweis genetischer varianten
WO2015103339A1 (en) 2013-12-30 2015-07-09 Atreca, Inc. Analysis of nucleic acids associated with single cells using nucleic acid barcodes
CA2938080A1 (en) 2014-01-27 2015-07-30 The General Hospital Corporation Methods of preparing nucleic acids for sequencing
CN110819621B (zh) 2014-02-11 2024-03-26 豪夫迈·罗氏有限公司 靶向测序和uid过滤
CN113528645A (zh) 2014-03-14 2021-10-22 凯尔迪克斯公司 用于在移植受体中监测免疫抑制疗法的方法
CA2943636C (en) 2014-03-25 2020-06-09 Quest Diagnostics Investments Incorporated Detection of gene fusions by intragenic differential expression (ide) using average cycle thresholds
CN106460070B (zh) 2014-04-21 2021-10-08 纳特拉公司 检测染色体片段中的突变和倍性
WO2015164432A1 (en) 2014-04-21 2015-10-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
ES2815349T3 (es) 2014-06-27 2021-03-29 Inst Nat Sante Rech Med Métodos que emplean ADN y miARN circulantes como biomarcadores para la infertilidad femenina
DK3164489T3 (da) 2014-07-03 2020-08-10 Rhodx Inc Mærkning og vurdering af en målsekvens
CN106574265B (zh) 2014-07-17 2020-07-28 凯杰有限公司 高产量分离rna的方法
EP3940703A1 (de) 2014-07-18 2022-01-19 Illumina, Inc. Nichtinvasive pränatale diagnose fötaler genetischer leiden mittels zellulärer dna und zellfreier dna
PT3690060T (pt) 2014-10-08 2022-01-27 Univ Cornell Método de identificação e quantificação relativa da expressão de sequências de ácidos nucleicos, variantes de splicing, translocação, número de cópias ou alterações de metilação utilizando reações combinadas de nuclease, ligação e polimerase com prevenção de arraste
WO2016063122A1 (en) 2014-10-20 2016-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
EP3209403A4 (de) 2014-10-24 2018-09-12 Abbott Molecular Inc. Anreicherung von kleinen nukleinsäuren
US10626455B2 (en) 2014-11-11 2020-04-21 Bgi Shenzhen Multi-pass sequencing
WO2016089920A1 (en) 2014-12-01 2016-06-09 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
GB201501907D0 (en) 2015-02-05 2015-03-25 Technion Res & Dev Foundation System and method for single cell genetic analysis
WO2016123698A1 (en) 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
US10557134B2 (en) 2015-02-24 2020-02-11 Trustees Of Boston University Protection of barcodes during DNA amplification using molecular hairpins
WO2016138500A1 (en) 2015-02-27 2016-09-01 Cellular Research, Inc. Methods and compositions for barcoding nucleic acids for sequencing
JP7508191B2 (ja) 2015-03-30 2024-07-01 ベクトン・ディキンソン・アンド・カンパニー コンビナトリアルバーコーディングのための方法および組成物
KR101850437B1 (ko) 2015-04-14 2018-04-20 이원다이애그노믹스(주) 차세대 염기서열 분석기법을 이용한 장기 이식 거부 반응 예측 방법
US11390914B2 (en) 2015-04-23 2022-07-19 Becton, Dickinson And Company Methods and compositions for whole transcriptome amplification
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
CA2984352A1 (en) 2015-04-30 2016-11-03 Aoy Tomita Mitchell Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna
EP4428863A2 (de) 2015-05-11 2024-09-11 Natera, Inc. Verfahren und zusammensetzungen zur bestimmung der ploidie
US20180291365A1 (en) 2015-06-05 2018-10-11 Qiagen Gmbh Method for separating dna by size
US20160371428A1 (en) 2015-06-19 2016-12-22 Natera, Inc. Systems and methods for determining aneuploidy risk using sample fetal fraction
US12018314B2 (en) 2015-07-02 2024-06-25 Arima Genomics, Inc. Accurate molecular deconvolution of mixture samples
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3356559A4 (de) 2015-09-29 2019-03-06 Ludwig Institute for Cancer Research Ltd Typisierung und zusammenstellung diskontinuierlicher genomischer elemente
KR20180096586A (ko) 2015-10-19 2018-08-29 더브테일 제노믹스 엘엘씨 게놈 어셈블리, 하플로타입 페이징 및 표적 독립적 핵산 검출을 위한 방법
CN105986030A (zh) 2016-02-03 2016-10-05 广州市基准医疗有限责任公司 甲基化dna检测方法
EP3433373B1 (de) 2016-03-22 2022-01-12 Myriad Women's Health, Inc. Kombinatorisches dna-screening
US10781439B2 (en) 2016-03-30 2020-09-22 Covaris, Inc. Extraction of cfDNA from biological samples
EP3443066B1 (de) 2016-04-14 2024-10-02 Guardant Health, Inc. Verfahren zum frühen nachweis von krebs
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
EA201892489A1 (ru) 2016-04-29 2019-05-31 Дзе Медикал Колледж Оф Висконсин, Инк. Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EP3464634B1 (de) 2016-05-24 2021-02-17 The Translational Genomics Research Institute Molekulare markierungsverfahren und sequenzierungsbibliotheken
WO2017205826A1 (en) 2016-05-27 2017-11-30 Sequenom, Inc. Methods for detecting genetic variations
AU2017290809A1 (en) 2016-07-01 2018-12-13 Natera, Inc. Compositions and methods for detection of nucleic acid mutations
SG11201811556RA (en) 2016-07-06 2019-01-30 Guardant Health Inc Methods for fragmentome profiling of cell-free nucleic acids
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
EP3535413A1 (de) 2016-11-02 2019-09-11 The Medical College of Wisconsin, Inc. Verfahren zur risikobeurteilung unter verwendung von gesamter und spezifischer zellfreier dna
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
KR20190077061A (ko) 2016-11-08 2019-07-02 셀룰러 리서치, 인크. 세포 표지 분류 방법
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
EP4050113A1 (de) 2017-01-17 2022-08-31 Life Technologies Corporation Zusammensetzungen und verfahren zur sequenzierung des immunrepertoires
AU2018225348A1 (en) 2017-02-21 2019-07-18 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
AU2018288835A1 (en) 2017-06-20 2020-01-16 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free DNA
CA3067635A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
WO2019067092A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
EP3676399B1 (de) 2017-09-01 2022-05-11 Life Technologies Corporation Zusammensetzungen und verfahren zur sequenzierung des immunrepertoires
US11091800B2 (en) 2017-09-20 2021-08-17 University Of Utah Research Foundation Size-selection of cell-free DNA for increasing family size during next-generation sequencing
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
WO2019140298A1 (en) 2018-01-12 2019-07-18 Natera, Inc. Novel primers and uses thereof
WO2019161244A1 (en) 2018-02-15 2019-08-22 Natera, Inc. Methods for isolating nucleic acids with size selection
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
WO2019241349A1 (en) 2018-06-12 2019-12-19 Natera, Inc. Methods and systems for calling mutations
WO2020010255A1 (en) 2018-07-03 2020-01-09 Natera, Inc. Methods for detection of donor-derived cell-free dna
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN112639982A (zh) 2018-07-17 2021-04-09 纳特拉公司 使用神经网络调用倍性状态的方法和系统
WO2020041449A1 (en) 2018-08-21 2020-02-27 Zymo Research Corporation Methods and compositions for tracking sample quality
WO2020076957A1 (en) 2018-10-09 2020-04-16 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
EP3884087A4 (de) 2018-11-21 2022-09-07 Karius Inc. Nachweis und vorhersage von infektionskrankheiten
EP3899030A2 (de) 2018-12-17 2021-10-27 Natera, Inc. Verfahren zur analyse von zirkulierenden zellen
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2020214547A1 (en) 2019-04-15 2020-10-22 Natera, Inc. Improved liquid biopsy using size selection
WO2020247263A1 (en) 2019-06-06 2020-12-10 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
WO2021055968A1 (en) 2019-09-20 2021-03-25 Natera Inc. Methods for assessing graft suitability for transplantation
CN115917001A (zh) 2020-05-29 2023-04-04 纳特拉公司 用于检测供体源性游离dna的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. CHRISTINA FAN ET AL: "Sensitivity of Noninvasive Prenatal Detection of Fetal Aneuploidy from Maternal Plasma Using Shotgun Sequencing Is Limited Only by Counting Statistics", PLOS ONE, vol. 5, no. 5, 1 January 2010 (2010-01-01), pages e10439, XP055026436, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0010439 *

Also Published As

Publication number Publication date
CA3037126C (en) 2023-09-12
US8949036B2 (en) 2015-02-03
HK1208941A1 (en) 2016-03-18
HK1208940A1 (en) 2016-03-18
EP2854057A3 (de) 2015-08-26
US20180073080A1 (en) 2018-03-15
US20140162269A1 (en) 2014-06-12
US20150072872A1 (en) 2015-03-12
US20140336060A1 (en) 2014-11-13
US8825412B2 (en) 2014-09-02
EP2572003A1 (de) 2013-03-27
US11306357B2 (en) 2022-04-19
CA2798758C (en) 2019-05-07
US20140100134A1 (en) 2014-04-10
CA3037126A1 (en) 2011-11-24
WO2011146632A1 (en) 2011-11-24
EP2854058A2 (de) 2015-04-01
US20110288780A1 (en) 2011-11-24
CA2798758A1 (en) 2011-11-24
EP2854058A3 (de) 2015-10-28
US9334541B2 (en) 2016-05-10
US20220042103A1 (en) 2022-02-10
CA3207599A1 (en) 2011-11-24
EP2572003A4 (de) 2016-01-13
AU2011255641A1 (en) 2012-12-06
US20180057885A1 (en) 2018-03-01
EP2854057A2 (de) 2015-04-01

Similar Documents

Publication Publication Date Title
US20220042103A1 (en) Methods for non-invasive prenatal ploidy calling
US20240331799A1 (en) Methods for non-invasive prenatal ploidy calling
US12020778B2 (en) Methods for non-invasive prenatal ploidy calling
US20190309358A1 (en) Methods for non-invasive prenatal ploidy calling
EP2902500B1 (de) Verfahren zur nichtinvasiven pränatalen Ploidiezuordnung
AU2015252046B2 (en) Methods for Non-Invasive Prenatal Ploidy Calling

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141217

AC Divisional application: reference to earlier application

Ref document number: 2572003

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G06F 19/18 20110101AFI20150722BHEP

Ipc: C12Q 1/68 20060101ALI20150722BHEP

Ipc: G06F 19/22 20110101ALI20150722BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208940

Country of ref document: HK

R17P Request for examination filed (corrected)

Effective date: 20160225

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

17Q First examination report despatched

Effective date: 20160531

17Q First examination report despatched

Effective date: 20160608

17Q First examination report despatched

Effective date: 20160617

17Q First examination report despatched

Effective date: 20160617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170914

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2572003

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 977303

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VENI GMBH, CH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011046417

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180307

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180607

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208940

Country of ref document: HK

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 977303

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180607

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011046417

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G06F0019180000

Ipc: G16B0020000000

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011046417

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180709

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

26N No opposition filed

Effective date: 20181210

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180707

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240529

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240522

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240524

Year of fee payment: 14